

NOTEN

Explaining “Unexplained Illnesses” *Disease Paradigm for Chronic Fatigue Syndrome, Multiple Chemical Sensitivity, Fibromyalgia, Post-Traumatic Stress Disorder, Gulf War Syndrome, and Others*

Martin L. Pall



Harrington Park Press®
The Trade Division of The Haworth Press, Inc.
New York • London

INHOUD-LIJST

	Opgehaalde noten (samenvatting)	Boek blz.	Noten blz.
Hfd-01	De NO/ONOO-cyclus	[001]	[327]
Hfd-02	Belangrijke bestanddelen en hun eigenschappen	[027]	[339]
Hfd-03	Symptomen en klachten van Multisysteem Ziekten 03-109 /	[049]	[343]
Hfd-04	De aard van het NO/ONOO-cyclusmechanisme	[069]	[358]
Hfd-05	Chronisch vermoeidheidssyndroom	[077]	[359]
Hfd-06	Multisysteemziekten: Hydroxocobalamine B12 en Siroxat	[105]	[369]
Hfd-07	Meervoudige chemische overgevoeligheid	[111]	[372]
Hfd-08	Posttraumatische stress	[139]	[377]
Hfd-09	Fibromyalgie	[149]	[382]
Hfd-10	Golfoorlog Syndroom: Een combinatie van alle vier (CVS, MCS, FM en PTSS)	[159]	[387]
Hfd-11	De tol van meervoudige systeemziekten	[171]	[390]
Hfd-12	Algemeen bewijs en wat is er nog nodig	[179]	[394]
Hfd-13	Of zit alles tussen de oren? 13-006 / 13-077 /	[189]	[394]
Hfd-14	Een nieuw paradigma voor menselijke ziekten?	[231]	[399]
Hfd-15	Therapie	[265]	[417]
Hfd-16	Overzicht	[317]	[437]

REFERENTIES

[327] - [339]

HOOFDSTUK – 01

De NO/ONOO-cyclus

▲ 01-001	Miller CS. Are we on the threshold of a new theory of disease? Toxicant-induced loss of tolerance and its relationship in addiction and abidction. Toxicol Ind Health 1999 ;15:284-294. Samenvatting-01-001
▲ 01-002	Buchwald D, Garrity D. Comparison of patients with chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities. Arch Int Med 1994 ;154: 2049-2053. https://pubmed.ncbi.nlm.nih.gov/8092909/
3.	Ziem G, Donnay A. Chronic fatigue, fibromyalgia, and chemical sensitivity: overlapping disorders. Arch Intern Med 1995 ;155:1913. Korte samenvatting bezwaar tegen keuze's
4.	Donnay A, Ziem G. Prevalence and overlap of chronic fatigue syndrome and fibromyalgia syndrome among 100 new patients. J Chronic Fatigue Syndr 1999; 5(3/4):71-80. Niets gevonden
5.	Clauw DJ, Crousos GE Chronic pain and fatigue syndromes: overlapping clinical and neuroendocrine features. Neuroimmunomodulation 1997 ;4:134-153. https://pubmed.ncbi.nlm.nih.gov/9500148/
6.	Yunus MB. Central sensitivity syndromes: a unified concept for fibromyalgia and other similar maladies. J Indian

	Rheumatism Assoc 2001;8(1):27-33. https://pubmed.ncbi.nlm.nih.gov/17350675/
7.	White KP, Speechley M, Harth M, Ostbye T. Co-existence of chronic fatigue syndrome with fibromyalgia in the general population - A controlled study. Scand J Rheum 2000;29:44-51. https://pubmed.ncbi.nlm.nih.gov/10722257/
8.	Rowat SC. Integrated defense system overlaps as a disease model: with examples for multiple chemical sensitivity. Env Health Perspect 1998;106(Suppl 1): 85-109. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1533268/
9.	Clauw D. Fibromyalgia associated syndromes. J Musculoskeletal Pain 2002; 10(1/2):201-214. Niets gevonden
10.	Wessely S, Nimnuan C, Sharpe M. Functional somatic syndromes: one or many? Lancet 1999;354:936-939. https://pubmed.ncbi.nlm.nih.gov/10489969/
11.	Aaron LA, Buchwald D. A review of the evidence for overlap among unexplained clinical conditions. Ann Intern Med 2001;134:868-881. https://pubmed.ncbi.nlm.nih.gov/11346323/
12.	Lipschitz EL. Chronic fatigue syndrome and posttraumatic stress disorder. JAMA 2001;286:916-917. Geen samenvatting
13.	Cohen H, Neumann L, Haiman Y, Matar MA, Press J, Buskila D. Prevalence of post-traumatic stress disorder in fibromyalgia patients: overlapping syndromes of post-traumatic fibromyalgia syndrome? Semin Arthritis Rheum 2002;32: 38-50. https://pubmed.ncbi.nlm.nih.gov/12219319/

14.	Friedman MJ. Neurobiological sensitization models of post-traumatic stress disorder: their possible relevance to multiple chemical sensitivity syndrome. <i>Toxicol Ind Health</i> 1994;10:449-462. https://pubmed.ncbi.nlm.nih.gov/7778107/
15.	Pall ML. Common etiology of posttraumatic stress disorder, fibromyalgia, chronic fatigue syndrome and multiple chemical sensitivity via elevated nitric oxide/peroxynitrite. <i>Med Hypoth</i> 2001;57:139-145. https://pubmed.ncbi.nlm.nih.gov/11461161/
16.	The Iowa Persian Gulf Study Group. Self-reported illness and health status among Gulf War veterans-a population-based study. <i>JAMA</i> 1997;277:238-245. https://pubmed.ncbi.nlm.nih.gov/9005274/
17.	Kipen MH, Hallman W, Kang H, Fiedler N, Natelson BH. Prevalence of chronic fatigue and chemical sensitivities in Gulf War Registry Veterans. <i>Arch Environ Health</i> 1999;54:313-318. https://pubmed.ncbi.nlm.nih.gov/10501146/
18.	Nicolson GL, Nicolson NL. Gulf War illnesses: complex medical, scientific paradox. <i>Med Confl Surviv</i> 1998;14:156-165. Niet gevonden
19.	Hodgson MJ, Kipen HM. Gulf War illnesses: causation and treatment. <i>J Occup Environ Med</i> 1999;41:443-452. https://pubmed.ncbi.nlm.nih.gov/10390695/
20.	Baker DG, Mendenhall CL, Simbartl LA, Magan LK, Steinberg JL. Relationship between posttraumatic stress

	disorder and self-reported symptoms of Persian Gulf War veterans. Arch Intern Med 1997; 157:2076-2078. https://pubmed.ncbi.nlm.nih.gov/9382663/
21.	Pall ML. Elevated, sustained peroxynitrite levels as the cause of chronic fatigue syndrome. Med Hypoth 2000;54:115-125.
22.	Behan PO, Goldberg DP, Mowbray JF, eds. Postviral Fatigue Syndrome, Br Med J, vol 47. Edinburgh: Churchill Livingstone; 1991.
23.	Bell, DS. The Doctor's Guide to Chronic Fatigue Syndrome. Reading, MA: Addison-Wesley; 1995.
24.	Komaroff AL. Clinical presentation of chronic fatigue syndrome. Ciba Foundation Syntp 1993; 173:43-54.
25.	Mowbray JF, Yousef GE. Immunology of postviral fatigue syndrome. Br Med Bull 1991;47:886-894.
26.	Behan PO, Bakheit AMO. Clinical spectrum of postviral fatigue syndrome. Br Med Bull 1991;47:793-808.
27.	Natelson BH, Lange G. A status report on chronic fatigue syndrome. Environ Health Perspect 2002;110(suppl4):673-677.
28.	Englebienne P, DeMeirleir K, eds. Chronic Fatigue Syndrome: A Biological Approach. Boca Raton: CRC Press;2002.
29.	Rea T, Russo J, Katon W, Ashley RL, Buchwald D. A prospective study of tender points and fibromyalgia during and after an acute viral infection. Arch Intern Med 1499;159:865-870.
30.	30. Massarotti EM. Lyme arthritis. Med Clin North Am

	2002;86:297-309.
31.	Daoud KF, Barkhuizen A. Rheumatic mimics and selected triggers of fibromyalgia. Curr Pain Headache Rep 2002;6:284-288.
32.	Vassilopoulos D, Calabrese LH. Rheumatic manifestations of hepatitis C infection. Curr Rheumntol Rep 2003;5:200-204.
33.	Buskila D, Gladman DD, Langevitz P, Urowitz S, Smythe HA. Fibromyalgia in human immunodeficiency virus infection. J Rheumntol 1990; 17:1202-1206. 34. Wolfe F Fibromyalgia. Rheum Dis Clin North Am 1990;16:681-698.
35.	Waylonis GW, Perkins RH. Post-traumatic fibromyalgia. A long term follow-up. Am J Phys Med Rehabil 1994;73:403-412.
36.	Greenfield S, Fitzcharled MA, Esdaille JM. Reactive fibromyalgia syndrome. Arthritis Rheum 1992;35:678-681.
37.	Aaron LA, Bradley LA, Alacon GS, et al. Perceived physical and emotional trauma as precipitating events in fibromyalgia. Associations with health care seeking and disability status but not pain severity. Arthritis Rheum 1997;40:453-460.
38.	Al-Allaf AW, Dunbar KL, Hallum NS, Nosratzadeh B, Templeton KD, Pullar T. A case-control study examining the role of physical trauma in the onset of fibromyalgia syndrome. Rheumatology 2002;41:450-453.
39.	Buskila D, Neumann L, Vaisberg G, Alakalay D, Wolfe F. Increased rates of fibromyalgia following cervical spine injury. A controlled study of 161 cases of traumatic injury. Arthritis Rheum. 1997;40:446-452.

40.	40. Neumann L, Zeldets V, Bolotin A, Buskila D. Outcome of posttraumatic fibromyalgia: a 3-year followup of 78 cases of cervical spine injuries. Semin Arthritis Rheum 2003;32:320-325.
01-041	Ashford NA, Miller C. Chemical Exposures: Low Levels and High Stakes. New York: John Wiley and Sons, Inc; 1998. Is een boek / Amazon.com 2024-04-30
42.	Sorg BA. Multiple chemical sensitivity: Potential role for neural sensitization. Crit Rev Neurobiol 1999;13:283-316. https://pubmed.ncbi.nlm.nih.gov/10803638/
01-043	Johnson A, ed. Casualties of Progress. MCS Information Exchange, Brunswick, ME; 2000. Is boek Amazon 2024-04-29 *****
01-044	Miller CS, Mitzel HC. Chemical sensitivity attributed to pesticide exposure versus remodeling. Arch Environ Health 1995;50:119-129. https://pubmed.ncbi.nlm.nih.gov/7786048/
45.	Rea WJ. Chemical Sensitivity. Vol. 1, Boca Raton: Lewis Publishers;1992. 46. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 4th ed. DSM-IV. Washington, DC: American Psychiatric Press; 1994. Staat op 'C' site
47.	Pall ML. Elevated peroxynitrite as the cause of chronic fatigue syndrome: Other inducers and mechanisms of symptom generation. J Chronic Fatigue Syndr 2000;7(4):45-58.
48.	Pall ML. Common etiology of posttraumatic stress disorder, fibromyalgia, chronic fatigue syndrome and multiple chemical sensitivity. Medical Hypoth 2001; 57:139-145.
49.	Pall ML, Satterlee JD. Elevated nitric oxide/peroxynitrite

	mechanism for the common etiology of multiple chemical sensitivity, chronic fatigue syndrome and posttraumatic stress disorder. Ann NYAcad Sci 2001;933:323-329.
50.	Pall ML. NMDA sensitization and stimulation by peroxynitrite, nitric oxide and organic FASEB J 2002;16:1407-1417.
51.	Pall ML. Elevated nitric oxide/peroxynitrite theory of multiple chemical sensitivity: central role of N-methyl-D-aspartate receptors in the sensitivity mechanism. Environ Health Perspect 2003; 11461-1464.
52.	Pall ML, Anderson JH. The vanilloid receptor as a putative target of diverse chemicals in multiple chemical sensitivity. Arch Environ Health 2004;59: 363-375.
53.	Wallis RA, Panizzon KL, Girard JM. Traumatic neuroprotection with inhibitors of nitric oxide and ADP-ribosylation. Brain Res 1996;710:169-177.
54.	Stoll G, Jander S, Schroeter M. Detrimental and beneficial effects of injuryinduced inflammation and cytokine expression in the nervous system. Adv Exp Med Biol 2002;513:87-113.
55.	55. Wada K, Chatzipanteli K, Busto R, Dietrich WD. Role of nitric oxide in traumatic brain injury in the rat. JNeurosurg 1998;89:807-818.
56.	Lewen A, Matz P, Chan PH. Free radical pathways in CNS injury. J Neurotrauma 2000;17:871-890.
57.	Khalidi A, Chiueh CC, Bullock MR, Woodward JJ. The significance of nitric oxide production in the brain after injury. Anti NY Acad Sci 2002;962:53-59.
58.	Obrenovitch TP, Urenjak J. Is extracellular glutamate the

	key to excitotoxicity after brain injury? J Neurotrauma 1997; 14:677-698.
59.	Khalidi A, Chiueh CC, Bullock MR, Woodward JJ. The significance of nitric oxide production in the brain after injury. Ann NYAcad Sci 2002;962:53-59.
60.	Lynch DR, Dawson TM. Secondary mechanisms in neuronal trauma. Curr Opin Neurol 7:1994;510-516.
61.	Palmer GC. Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies. Curr Drug Targets 2001;2:241-271.
62.	Gebhardt F, Nussler AK, Rosch M, Pfetsch H, Kinzl L, Bruckner UB. Early posttraumatic increase in production of nitric oxide in humans. Shock 1998; 10:237-242.
63.	Wotta DR, El-Fakahany E. Muscarinic receptor-mediated activation of nitric oxide synthase. Drug Dev Res 1997;40:205-214.
64.	McKinney M. Muscarinic receptor subtype-specific coupling to second messengers in neuronal systems. Prog Brain Res 1993;98:333-340.
65.	van Zwieten PA, Doods HN. Muscarinic receptors and drugs in cardiovascular medicine. Cardiovasc Drugs Ther 1995;9:159-167.
66.	Okere CO, Kaba H, Higuchi T. Importance of endogenous nitric oxide synthase in the rat hypothalamus and amygdala in mediating the response to capsaicin. J Comp Neurol 2000;423: 670-686.
67.	Wu J, Lin Q, McAdoo DJ, Willis WD. Nitric oxide contributes to central sensitization following intradermal injection of capsaicin. Neuroreport 1998;9:589-92.

68.	Rinder J. Sensory neuropeptides and nitric oxide in nasal vascular regulation. <i>Acta Physiol Scand</i> 1996;(Suppl1632):1-45.
69.	Akiba Y, Guth PH, Engel E, Nastaskin I, Kaunitz JD. Acid-sensing pathways of rat duodenum. <i>Am J Physiol</i> 1999;277:G268-74.
70.	Suzuki T, Wada S, Tomizawa N, et al. A possible role of nitric oxide formation in the vasodilation of rabbit ear artery induced by topically applied capsaicin analogue. <i>J Vet Med Sci.</i> 1998;60:691-697.
71.	Hou M, Uddman R, Tajti J, Kanje M, Edvinsson L. Capsaicin receptor immunoreactivity in the human trigeminal ganglion. <i>Neurosci Lett.</i> 2002;330:223-226.
72.	Kamei J, Tanihara H, Igarashi H, Kasuya Y. The effects of N-methyl-Daspartate antagonists on the cough reflex. <i>Ear JPharmacol</i> 1989;168:153-158.
73.	Coderre TJ, Melzack R. Central neural mediators of secondary hyperalgesia following heat injury in rats: neuropeptides and excitatory amino acids. <i>Neurosci Lett</i> 1991;131:71-74.
74.	Dougherty PM, Willis WD. Enhanced responses of spinothalamic tract neurons to excitatory amino acids accompany capsaicin-induced sensitization in monkey. <i>J Neurosci</i> 1992;12:883-894.
75.	Dray A. Neuropharmacological mechanisms of capsaicin and related substances. <i>Biochem Pharmacol</i> 1992;44:611-615.
76.	Andersen OK, Felsby S, Nicolaisen L, Bjerring P, Jensen TS, Arendt-Nielsen L. The effect of Ketamine on stimulation of primary and secondary hyperalgesia area induced by

	capsaicin-a double blind, placebo-controlled, human experimental study. Pain 1996;66:51-62.
77.	Sethna NF, Liu M, Gracely R, Bennett GJ, Max MB. Analgesic and cognitive effects of intravenous ketamine-alfentanil combinations versus either drug alone after intradermal capsaicin in normal subjects. Anesth Analg 1998;86:1250-1256.
78.	Mitsikostas DD, Sanchez del Rio M, Waeber C, Moskowitz MA, Cutrer FM. The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalis. Pain 1998;76:239-248.
79.	Kawamata T, Omote K, Toriyabe M, Kawamata M, Namiki A. Involvement of capsaicin-sensitive fibers in spinal NMDA-induced glutamate release. Neuroreport 2001;12:3447-3450.
80.	Palazzo E, de Novellis V, Marabese I, et al. Interaction between vanilloid and glutamate receptors in the central modulation of nociception. Eur J Pharmacol 2002;439:69-75.
81.	Heresco-Levy U, Javitt DC. The role of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes. Neuropharmacology 1998;37:141-152.
82.	McEwen BS. Possible mechanisms for atrophy of the human hippocampus. Mol Psychiatry 1997;2:255-262.
83.	Chambers RA, Bremner JD, Moghaddam B, Southwick SM, Charney DS, Krystal JH. Glutamate and post-traumatic stress disorder: toward a psychobiology of dissociation. Semin Clin Neuropsychiatry 1999;4:274-281.

84.	Miserendino MJ, Sananes CB, Melia KR, Davis M. Blocking of acquisition but not expression of conditioned fear-potentiated startle by NMDA antagonists in the amygdala. <i>Nature</i> 1990;345:716-718.
85.	Goldstein LE, Rasmussen AM, Bunney BS, Roth RH. Role of the amygdala in the coordination of behavioral, neuroendocrine and prefrontal cortical monoamine responses to psychological stress in the rat. <i>JNeurosci</i> 1996;16:4787-4798.
86.	Goldstein LE, Rasmussen AM, Bunney BS, Roth RH. The NMDA glycine site antagonist (+)-HA-966 selectively regulates conditioned stress-induced metabolic activation of the mesofrontal cortical dopamine but not serotonin systems: a behavioral, neuroendocrine and neurochemical study. <i>JNeurosci</i> 1994;14:4937-4950.
87.	Adamec RE, Burton P, Shallow T, Budgell J. NMDA receptors mediate lasting increases in anxiety-like behavior produced by the stress of predator exposure implications for anxiety associated with posttraumatic stress disorder. <i>Physiol Behav</i> 1999;65:723-737.
88.	Gould E, Cameron HA. Early NMDA blockade impairs defensive behavior and increases cell proliferation in the dentate gyrus of developing rats. <i>Behav Neurosci</i> 1997;111:49-56.
89.	Shots TJ, Elkabes S, Selcher JC, Black IB. Stress persistently increases NMDA receptor-mediated binding of [3H]PDBu (a marker for protein kinase C) in the amygdala and re-exposure to the stressful context reactivates the increase. <i>Brain Res</i> 1997;750:293-300.
90.	Laudanno OM, Cesolari JA, San Miguel P, Bedini OA. A

	role of inducible nitric oxide synthase in acute gastric mucosal damage in stress in rats. <i>Acta Gastroenterol Latinoam</i> 1996;26:221-224.
91.	Behan PO. Chronic fatigue syndrome as a delayed reaction to chronic lowdose organophosphate exposure. <i>J Nutr Environ Med</i> 1996;6:341.
92.	Kennedy G, Abbot NC, Spence V, Underwood C, Belch JJ. The specificity of the CDC-1994 criteria for chronic fatigue syndrome: comparison of health status in three groups of patients who fulfill the criteria. <i>Ann Epidemiol</i> 2004;14:95-100.
93.	Wood GC, Bentall RP, Gopfert M, Edwards RH. A comparative psychiatric assessment of patients with chronic fatigue syndrome and muscle diseases. <i>Psychol Med</i> 1991;21:619-628.
94.	Dobbins JG, Natelson BH, Brassloff I, Drastal S, Sisto S-A. Physical, behavioral, and psychological risk factors for chronic fatigue syndrome: a central role for stress? <i>J Chronic Fatigue Syndr</i> 1995;1:43-58.
95.	Taylor RR, Jason LA. Chronic fatigue, abuse-related traumatization, and psychiatric disorders in a community-based sample. <i>Social Sci Med</i> 2002;55: 247-256.
96.	Klimas NG, Morgan R, Salvato F, et al. Chronic fatigue syndrome and psychoneuroimmunology. In: Schneiderman N, McCabe P, Baum A, eds. <i>Stress and Disease Progression: Perspectives in Behavioral Medicine</i> . Hillsdale, NJ: Lawrence Erlbaum, Assoc.; 1992:121-137.
01-097	Sorg BA, Prasad BM. Potential role of stress and sensitization in the development and expression of multiple chemical sensitivity. <i>Environ Health- Perspect</i> 1997; 1

	05(Suppl)2:467-471. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1469803/ Ook als PDF ophalen Volledig in Samenvatting
98.	Bell IR, Baldwin CM, Russek LGS, Schwartz GER, Hardin EE. Early life stress, negative paternal relationships, and chemical intolerance in middleage women: support for a neural sensitization model. J Women's Health 1998;7: 1135-1147. https://pubmed.ncbi.nlm.nih.gov/9861591/
99.	Harvey AG, Brewin CR, Jones C, Kopelman MD. Coexistence of posttraumatic stress disorder and traumatic brain injury: Towards a resolution of the paradox. J Int Neuropsychological Soc 2003;9:663-676.
100	Shalev AY Acute stress reactions in adults. Biol Ps vchántry 2002;51: 532-543.
101.	Boisset-Pioro MH, Esdaile JM, Fitzcharles MA. Sexual and physical abuse in women with fibromyalgia syndrome. Arthritis Rheum 1995;38:235-241.
102.	Racciatti D, Vecchiet J, Ceccomancini A, Ricci F, Pizzigallo E. Chronic fatigue syndrome following a toxic exposure. Sci Total Environ 2001;270:27-31
103.	Chester AC, Levine PH. Concurrent sick building syndrome and chronic fatigue syndrome. Clin Infect Dis 1994; 18(suppl 1):S43-S48.
104.	Abdel-Rahman A, Shetty AK, Abou-Donia MB. Disruption of the bloodbrain barrier and neuronal death in cingulated cortex, dentate gyrus, thalamus and hypothalamus in a rat model of Gulf-War syndrome. Neurobiol Dis 2002; 10:306-326.

105.	Abdel-Rahman A, Abou-Donia SM, El-Masry EM, et al. Stresss and combined exposure to low doses of pyridostigmine bromide, DEET and permethrin produce neurochemical and neuropathological alterations in cerebral cortex, hippocampus and cerebellum. J Toxicol Env Health 2004;676:163-192.
106.	Piette J, Piret B, Bonizzi G, et al. Multiple redox regulation in NF-KB transcription factor activation. Biol Chem 1997;378:1237-1245.
107.	Baeuerle PA, Henkel T. Function and activation of NF-KB in the immune system. Ann Rev Immunol 1994; 12:141-179.
108.	Janssen-Heininger YM, Poynter ME, Baeuerle PA. Recent advances towards understanding redox mechanisms in the activation of nuclear factor kappa B. Free Radic Biol Med 2000;28:1317-1327.
109.	Cooke CL, Davidge ST. Peroxynitrite increases iNOS through NF-KB and decreases prostacyclin synthase in endothelial cells. Am J Physiol Cell Physiol 2002;282:C395-C402.
110.	Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV- 1. EMBO J 1991;10:2247-2258.
111.	Akira S, Kishimoto T. NF-IL6 and NF-KB in cytokine gene regulation. Adv Immunol 1997;65:1-46.
112.	Baeuerle PA, Baichal VR. NF-KB as a frequent target for immunosuppressive and anti-inflammatory molecules. Advlmmuool 1997;65:111-137.
113.	Roebuck KA. Regulation of interleukin-8 gene expression. J

	Interferon Cytokine Res 1999;19:429-438.
114.	Palanki MS. Inhibitors of AP-1 and NF-KB mediated transcriptional activation: therapeutic potential in autoimmune diseases and structural diversity. Curr Med Chem 2002;9:219-227.
115.	Xie QW, Kashiwabara Y, Nathan C. Role of transcription factor NF-kappa B B/Rel in induction of nitric oxide synthase. J Biol Chem 1994;269:4705-4708.
116.	Asehoune K, Strassheim D, Mitra S, Kim JY, Abraham E. Involvement of reactive oxygen species in Toll-like receptor 4-dependent activation of NF-KB. J Immunol 2004;172:2522-2529.
117.	Bai Y, Onuma H, Bai X, et al. Persistent nuclear factor-kappa B activation in Ucp2 ^{-/-} mice leads to enhanced nitric oxide and inflammatory cytokine production. J Biol Chem 2005;280:19062-19069.
118.	Snyder AR, Morgan WF. Differential induction and activation of NF-kappa B transcription complexes in radiation-induced chromosomally unstable cell lines. Environ Mol Mutagen 2005;45:177-187.
119.	Zheng X, Zhang Y, Chen YQ, et al. Inhibition of NF-KB stabilizes gadd45alpha mRNA. Biochem Biophys Res Commun 2005;329:95-99.
120.	Goldhaber JI, Qayum MS. Oxygen free radicals and excitation-contraction coupling. Antioxid Redox Signal 2000;2:55-64.
121.	Chakraborti T, Das S, Mondal M, Roychoudhury S. Chakraborti S. Oxidant, mitochondria and calcium: an overview. Cell Signal 1999; 1L77-85.

122.	Lounsbury KM, Hu Q. Ziegelstein RC. Calcium signaling and oxidant stress in the vasculature. Free Rad Biol Med 2000;28:1362-1369.
123.	Zaidi A, Michaelis ML. Effects of reactive oxygen species on brain synaptic plasma membrane Ca(2+)-ATPase. Free Radic Biol Med 1999;27:810-821.
124.	Schoneich C, Viner RI, Ferrington DA, Bigelow DJ. Age-related chemical modification of the skeletal muscle sarcoplasmic reticulum Ca-ATPase of the rat. Mech Ageing Dev 1999;107:221-231.
125.	Muriel P, Sandoval G. Hepatic basolateral plasma high-affinity Ca ²⁺ -ATPase is inhibited by nitric oxide and peroxynitrite anion. J Appl Toxicol 2000; 20:435-439.
126.	Gutierrez-Martin Y, Martin-Romero FJ, Henao F, Gutierrez-Merino C. Synaptosomal plasma membrane Ca(2+) pump activity inhibition by repetitive micromolar ONOO ⁻ pulses. Free Radic Biol Med 2002;32:46-55.
127.	Choudhary G, Dudley SC Jr. Heart failure, oxidative stress, and ion channel modulation. Congest Heart Fail 2002;8(3):148-155.
128.	Grover AK, Kwan CY, Samson SE. Effects of peroxynitrite on sarco/endoplasmic reticulum Ca ²⁺ pump isoforms SERCA2b and SERCA3A. Am J Physiol Cell Physiol 2003;285:C 1537-C 1543.
129.	Mattson MP. Free radicals, calcium, and the synaptic plasticity-cell death continuum: emerging roles of the transcription factor NF kappa B. Int Rev Neurobiol 1998;42:103-168.
130.	Lewis RS. Calcium oscillations in T-cells: mechanisms and

	consequences for gene expression. Biochem Soc Trans 2003;31:925-929.
131.	MacMillan-Crow LA, Crow JP, Kerby JP, Beckman J, Thompson JA. Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts. Proc Natl Acad Sci USA 1996;93:11853-11858.
132.	MacMillan-Crow LA, Crow JP, Thompson JA. Peroxynitrite-mediated inactivation of manganese superoxide dismutase involves nitration and oxidation of critical tyrosine residues. Biochemistry 1998;37:1613-1622.
133.	McCord JM, Roy RS. The pathophysiology of superoxide: roles of inflammation and ischemia. Can J Ph* vsiol Pharmacol 1982;60:1346-1352.
134.	McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Eiigl J Med 1985;312:159-163.
135.	Atlante A, Gagliardi S, Minervini GM, et al. Glutamate neurotoxicity in rat cerebellar granule cells: a major role for xanthine oxidase in oxygen radical formation. J Neurochem 1997;68:2038-2045.
136.	Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Pfysiol 2003;555: 589-606.
137.	Meneshian A, Bulkley GB. The physiology of endothelial xanthine oxidase: from urate metabolism to reperfusion injury in inflammatory signal transduction. Microcirculation 2002;9:161-175.
138.	Kosenko E, Venediktova N, Kaminsky Y, Montoliu C, Felipe V. Sources of oxygen radicals in brain in acute

	ammonia intoxication in vivo. Brain Res 2003; 981:193-200.
139.	Amaya F, Oh-hashi K, Naruse Y, et al. Local inflammation increases vanilloid receptor 1 expression within distinct subgroups of DRG neurons. Brain Res 2003;963:190-196.
140.	140. Ganju P, O'Bryan JP, Der C, Winter J, James IF. Differential regulation of SHC proteins by nerve growth factor in sensory neuronse and PC] 2 cells. Eur J Neurosci 1998;10:1995-2008.
141.	Dai Y, Iwata K, Fukuoka T, et al. Phosphorylation of extracellular signalregulated kinase in primary afferent neurons by noxious stimuli and its involvement in peripheral sensitization. J Neurosci 2002;22:7737-7745.
142.	Zhou Y, Li GD, Zhao ZQ. State-dependent phosphorylation of epsilonisozyme of protein kinase C in adult rat dorsal root ganglia after inflammation and nerve injury. JNeurochem 2003;85:571-580.
143.	Distler C, Rathee PK, Lips KS, Obreja 0, Neuhuber W, Kress M. Fast Ca' induced potentiation of heat-activated ionic currents requires camp/PKA signaling and functional AKAP anchoring. J Neurophys 2003;89:2499-2505.
144.	Vellani V, Mapplebeck S, Moriondo A, Davis JB, McNaughton PA. Protein kinase C activation potentiates gating of the vanilloid receptor VR I by capsaicin, protons, heat and anadamide. J Physiol 2001;534:813-825.
145.	Ustinova EE, Schultz HD. Activation of cardiac vagal afferents by oxygenderived free radicals in rats. Circ Res 1994;74:895-903.
146.	Schultz HD, Ustinova EE. Capsaicin receptors mediate free radical-induced activation of cardiac afferent endings.

	Cardiovascular Res 1998;38:348-355.
147.	Chen J, Daggett H, De Waard M, Heinemann SH, Hoshi T. Nitric oxide augments voltage-gated P/Q-type Ca(2+) channels constituting a putative positive feedback loop. Free Radic Biol Med 2002;32:638-649.
148.	Canossa M, Giordano E, Capello S, Guanieri C, Ferri S. Nitric oxide downregulates brain-derived neurotrophii factor secretion in cultured hippocampal cells. Proc Natl Acad Sci USA 2002;99:3282-3287.
149.	Banan A, Fields JZ, Zhang Y, Keshavarzian A. iNOS upregulation mediates oxidant-induced disruption of F-actin and barrier intestinal monolayers. Am J Physiol Gastrointest Liver Physiol 2001;280:G 1234-G 1246.
150.	Hallen K, Olgart C, Gustafsson LE, Wiklund NE. Modulation of neuronal nitric oxide release by soluble guanylate cyclase in guinea pig colon. Biochem Biophys Res Canmun 2001;280:1130-1134.
151.	Chen JX, Berry LC, Tanner M, et al. Nitric oxide donors regulate nitric oxide synthase in bovine pulmonary artery endothelium. J Cell Physiol 2001;186:116-123.
152.	Yuhanna IS, MacRitchie AN, Lantin-Hermoso RL, Wells LB, Shaul PW. Nitric oxide (NO) upregulates NO synthase expression in fetal intrapulmonary artery endothelial cells. Am J Respir Cell Mol Biol 1999;21:629-636.
153.	McVeigh GE, Hamilton P, Wilson M, et al. Platelet nitric oxide and superoxide release during development of nitrate tolerance: effect of supplemental ascorbate. Circulation 2002;106:208-213.
154.	Reuter U, Chiarugi A, Bolay H, Moskowitz MA. Nuclear

	factor-kappa B as a molecular target for migraine therapy. Ann Neurol 2002;51:507-516.
155.	Reuter U, Bolay H, Jansen-Olesen I, et al. Delayed inflammation in rat meninges: implications for migraine pathophysiology. Brain 2001; 124:2490-2502.
156.	Kaesemeyer WH, Ogonowski AA, Jin L, Caldwell RB, Caldwell RW. Endothelial nitric oxide synthase is a site of superoxide synthesis in endothelial cells treated with glyceryl nitrate. Br J Pharmacol 2000; 131:1019-1023.
157.	Pardutz A, Krizbai I, Multon S, Vecsie L, Scoenen J. Systemic nitroglycerine increases nNOS levels in rat trigeminal nucleus caudalis. Neuroreport 2000; 28:3071-3075.
158.	Abou-Mohamed G, Kaesemeyer WH, Caldwell RB, Caldwell RW. Role of L-arginine in the vascular actions and development of tolerance to nitroglycerin. Br J Pharmacol 2000;130:211-218.
159.	Rachmilewitz D, Stamler JS, Karmeli F, et al. Peroxynitrite-induced rat colitis-a new model of colonic inflammation. Gastroenterol 1993; 105:1681-1688.
160.	Rachmilewitz D, Karmeli F, Okon E, et al. Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. Gut 1995;37:247-255.
161.	Chao CC, De La Hunt M, Hu S, Close K, Peterson PK. Immunologically mediated fatigue: a murine model. Clin Immunol Immunopathol 1992;64:161-165.
162.	Sheng WS, Hu S, Lamkin A, Peterson PK, Chao CC. Susceptibility to immunologically mediated fatigue in C57BL/6 versus Balb/C mice. Clin Immunol Immunopathol

	1996;81:161-167.
163.	Sheng WS, Lin JC, Apple F, Hu S, Peterson PK, Chao CC. Brain energy stores in C57BL/6 mice after <i>C. parvum</i> injection. Neuroreport 1999;10:177-81.
164.	Sheng WS, Hu S, Ding JM, Chao CC, Peterson PK. Cytokine expression in the mouse brain in response to immune activation by <i>Corynebacterium parvum</i> . Clin Diagn Lab Immunol 2001;8:446-448.
165.	Ambs S, Ogunfusika MO, Merriam WG, Bennett WP, Billiar TR, Harris CC. Up-regulation of inducible nitric oxide synthase expression in cancer-prone p53 knockout mice. Proc Natl Acad Sci USA 1998;95:8823-8828.
166.	Urban MO, Gebhart GF. Supraspinal contributions to hyperalgesia. Proc Natl Acad Sci USA 1999;96:7687-7692.
167.	Willis WD. Role of neurotransmitters and sensitization of pain responses. Ann N Y Acad Sci 2001;933:142-156.
168.	Ferreira SH. The role of interleukins and nitric oxide in the mediation of inflammatory pain and its control by peripheral analgesics. Drugs 1993;46(suppl 1):1-9.
169.	Liu L, Simon SA. Modulation of IA currents by capsaicin in rat trigeminal ganglion neurons. J Neurophysiol 2003;89:1387-1401.
170.	170. Sung CS, Wen ZH, Chang WK, et al. Intrathecal interleukin-1 β administration induces thermal hyperalgesia by activating inducible nitric oxide synthase expression in the rat spinal cord. Brain Res 2004;1015:145-153.
171.	Tegeder I, Niederberger E, Schmidt R, et al. Specific inhibition of I-kappa B kinase reduces hyperalgesia and neuropathic pain models in rats. J Neurosci 2004; 24:1637-

	1645.
172.	Sakaue G, Shimaoka M, Fukuoka T, et al. NF-kappa B decoy suppresses cytokine expression and thermal hyperalgesia in a rat neuropathic pain model. <i>Neuroreport</i> 2001; 12:2079-2084.
173.	Chan CF, Sun WZ, Lin JK, Lin-Shiau SY. Activation of transcription factors nuclear factor kappa B, activator protein-1 and octamer factors in hyperalgesia. <i>Eur J Pharmacol</i> 2000;402:61-68.
174.	Nicholson B. Gabapentin use in neuropathic pain. <i>Acta Neurol Scand</i> 2000; 101:359-371.
175.	Saegusa H, Kurihara T, Zong S, et al. Suppression of inflammatory and neuropathic pain symptoms in mice lacking N-type Ca ²⁺ channel. <i>EMBO J</i> 2001; 20:2349-2356.
176.	Distler C, Rathee PK, Lips KS, et al. Fast Ca ²⁺ -induced potentiation of heat-activated ionic currents requires camp/PKA signaling and functional AKAP anchoring. <i>J Neurophysiol</i> 2003;89:2499-2505.
177.	Isaev D, Gerber G, Park SK, Chung JM, Randik M. Facilitation of NMDA-induced currents and Ca ²⁺ transients in the rat substantia gelatinosa neurons after ligation of L5-L6 spinal nerves. <i>Neuroreport</i> 2000;11:4055-4061.
178.	McRoberts JA, Coutinho SV, Marvizon JC, et al. Role of peripheral N-methyl-D-aspartate (NMDA) receptors in visceral nociception in rats. <i>Gastroenterology</i> 2001;120:1737-1748.
179.	Caterina MJ, Leffler A, Malmberg AB, et al. Impaired nociception and pain sensation in mice lacking the capsaicin

	receptor. Science 2000;288:306-313.
180.	180. Di Marzo V, Blumberg PM, Szallasi A. Endovanilloid signaling in pain. Curr Opin Neurobiol 2002;12:372-379.
181.	Sachs D, Cunha FQ, Poole S, Ferreira SH. Tumor necrosis factor- α , interleukin-1 β , and interleukin-8 induce persistent mechanical nociceptor hypersensitivity. Pain 2002;96:89-97.
182.	Schafers M, Sorkin LS, Sommer C. Intramuscular injection of tumor necrosis factor- α induces muscle hyperalgesia in rats. Pain 2003;104:579-588.
183.	Obreja O, Rathee PK, Lips KS, Distler C, Kress M. IL-1 β potentiates head activated currents in rat sensory neurons: involvement of IL-1R1, tyrosine kinase and protein kinase C. FASEB J 2002;16:1497-1503.
184.	Wang ZQ, Porreca F, Cuzzocrea S, et al. A newly identified role for superoxide in inflammatory pain. J Pharmacol Exp Ther 2004;309:869-878.
185.	Tal M. A novel antioxidant alleviates heat hyperalgesia in rats with experimental painful peripheral neuropathy. Neuroreport 1996;7:1382-1384.
186.	Liu T, Knight KR, Tracey DJ. Hyperalgesia due to nerve injury-role of peroxynitrite. Neuroscience 2000;97:125-131.
187.	Ridger VC, Greenacre SA, Handy RL, et al. Effect of peroxynitrite on plasma extravasation, microvascular blood flow and nociception in the rat. Br J Pharmacol 1997;122:1083-1088.
188.	Donnay A. On the recognition of multiple chemical sensitivity in medical literature and government policy. Int J Toxicol 1999;18:383-392.

189.	Donnay A. Carbon monoxide as an unrecognized cause of neurasthenia: a history. In Penney D, ed. Carbon Monoxide Toxicity. Boca Raton, Florida: CRC; 2000:231-260.
190.	Keller RH, Lane JL, Klimas N, et al. Association between HLA class II antigens and the chronic fatigue immune dysfunction syndrome. Clin Infect Dis 1994; 18(Suppl):S154-S156.
191.	Rowe PC, Barron DF, Calkins H, Maumenee IH, Tong PY, Geraghty MT. Orthostatic intolerance and chronic fatigue associated with Ehlers-Danlos syndrome. J Pediatr 1999;135:494-499.
192.	Buchwald D, Herrell R, Ashton S, et al. A twin study of chronic fatigue. Psychosom Med 2001;63:936-943.
193.	Torpy DJ, Bachmann AW, Grice JE, et al. Familial corticosteroid-binding globulin deficiency due to a novel null mutation: association with fatigue and relative hypotension. J Clin Endocrinol Metab 2001;86:3692-3700.
194.	Aaron LA, Herrell R, Ashton S, et al. Comorbid clinical conditions in chronic fatigue: a co-twin study. J Gen Intern Med 2001;16:24-31.
195.	Pellegrino MJ, Waylonis GW, Sommer A. Familial occurrence of primary fibromyalgia. Arch Phys Med Rehabil 1989;70:61-63,
196.	Buskila D, Neumann L, Hazanof I, Carmi R. Familial aggregation in the fibromyalgia syndrome. Semin Arthritis Rheum 1996;26:605-611.
197.	Buskila D, Neumann L. Fibromyalgia syndrome (FM) and nonarticular tenderness in relatives of patients with FM. J Rheumatol 1997;24:941-944.

198.	Burda CD, Cox FR, Osborne P. Histocompatibility antigens in fibrositis (fibromyalgia) syndrome. Clin Exp Rheumntol 1986;4:355-358.
199.	Bondy B, Spaeth M, Offenbaecher M, et al. The T102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia. Neurobiol Dis 1999;6:433-439.
200.	Yunus MB, Kahn MA, Rawlings KK, Green JR, Olson JM, Shah S. Genetic linkage analysis of multicase families with fibromyalgia syndrome. J Rheumatol 1999;26:408-412.
201.	Gursoy S, Erdal E, Herken H, Madenci E, Alashirli B, Erdai N. Significance of catechol-O-methyltransferase gene polymorphism in fibromylgia syndrome. Rheumatol Int 2003;23:104-107.
202.	Gursoy S, Erdal E, Herken H, Madenci E, Alasehirli B, Erdal N. Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome. Rheuniatol Int 2002;23:104-107.
203.	Karaaslan Y, Haznedaroglu S, Ozturk M. Joint hypermobility and primary fibromyalgia: a clinical enigma. J Rheumatol 2000;27:1774-1776.
204.	Haley RW, Billecke S, La Du BN. Association of low PON I type Q (type A) aryl esterase activity with neurologic symptom complexes in Gulf War veterans. Toxicol Appl Pharmacol 1999;157:227-233.
205.	Binkley K, King N, Poonai N, Seeman P, Ulpian C, Kennedy J. Idiopathic environmental intolerance: increased prevalence of panic disorder associated with cholecystokin B receptor allele. J Allergy Clin Immunol 2001;107:887-890.

206.	McKeown-Eyssen G, Baines C, Cole DE, et al. Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2, MTHFR. <i>Int J Epidemiol</i> in press 2004.
207.	Koenen KC, Lyons MJ, Goldberg J, et al. A high risk twin study of combatrelated PTSD. <i>Twin Res</i> 2003;6:218-226.
208.	Stein MB, Jang KL, Taylor S, Vernon PA, Livesley WJ. Genetic and environmental influences on trauma exposure and posttraumatic stress disorder symptoms. <i>Am J Psychiatry</i> 2002;159:1675-1681.
209.	Segman RH, Cooper-Kazaz R, Macciardi F, et al. Association between the dopamine transporter gene and posttraumatic stress disorder. <i>Mol Psychiatry</i> 2002; 7:903-907.
210.	Radant A, Tsuang D, Peskind ER, McFall M, Raskind W. Biological markers and diagnostic accuracy in the genetics of posttraumatic stress disorder. <i>Psychiatry Res</i> 2001;102:203-215.
211.	Hukkanen V, Broberg E, Salmi A, Eralinna JE Cytokines in experimental herpes simplex virus infection. <i>Int Rev Immunol</i> 2002;21:355-371.
212.	Imanishi J. Expression of cytokines in bacterial and viral infections and their biochemical targets. <i>J Biochem</i> 2000; 127:525-530.
213.	Skoldenberg B. Herpes simplex encephalitis. <i>Scand J Infect Dis Suppl</i> 1996;100:8-13.
214.	Cals-Grierson MM, Ormerod AD. Nitric oxide function in the skin. <i>Nitric Oxide</i> 2004;10:179-193.
215.	Novick A, Weiner M. Enzyme induction as an all-or-none

	phenomenon. Proc Natl Acad Sci USA 1957;43:553-566.
216.	Guilherme L, Kalil J. Rheumatic fever: the T cell response leading to autoimmune aggression in the heart. Autoimmun Rev 2002;L261-266.
217.	Quinn A, Kosanke S, Fischetti VA, Factor SM, Cunningham MW. Induction of autoimmune valvular heart disease by recombinant streptococcal M protein. Infect Immun 2001;69:4072-4078.
218.	Veasy LG, Hill HR. Immunologic and clinical correlations in rheumatic fever and rheumatic heart disease. Pediatr Infect Dis 1997; 16:400-407.
219.	Anonymous. Sydney Brenner to keynote digital biology symposium. ASBMB Today. Aug 2003:16.
220.	Pilgeram L. A crisis developing in biology. ASBMB Today. Nov 2003:2.

[339] - [343]

HOOFDSTUK – 02

1.	Nathan C, Xie QW. Nitric oxide synthases: roles, tolls and controls. Cell 1994; 78:915-918.
2.	Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J 1994;298:249-258.
3.	Bredt DS, Snyder SH, Nitric oxide: a physiologic messenger molecule. Ann Rev Biochem 1994;63:175-195.
4.	Murad E Regulation of cytosolic guanylyl cyclase by nitric oxide: the NOcyclic GMP signal transduction system. Adv Pharmacol 1994;26:19-33
5.	Beckman JS, Koppenol WH. Nitric oxide, superoxide and peroxynitrite: the good, the bad and the ugly. Am J Physiol 1996;271:C]424-C]437.
6.	Pryor WA, Squadrito GL. The chemistry of peroxynitrite: a product from thereaction of nitric oxide and superoxide. Afr J Physiol 1995;268:L699-L722.
7.	Szabo C. Multiple pathways of peroxynitrite cytotoxicity. Toxicol Lett 2003; 140-141:105-112.
8.	Hogg N. The biochemistry and physiology of S-nitrosothiols. Ann Rev Phcrrmacol Toxicol 2002;42:585-600.
9.	Aleryani S, Milo E, Rose Y. Kostka P. Superoxide-mediated decomposition of biological S-nitrosothiols. JBiol Chem 1998;273:6041-6045.

10.	Rauhala P, Lin AM, Chiueh CC. Neuroprotection by S-nitrosoglutathione on the brain dopamine neurons from oxidative stress. <i>FASEB J</i> 1998; 12:165-173.
11.	Fridovich L Superoxide radical and superoxide dismutases. <i>Ann Rev Biochem</i> 1995;64:97-112.
12.	Lebovitz RM, Zhang H, Vogel H, et al. Neurodegeneration, myocardial injury and perinatal death in mitochondrial superoxide dismutase-deficient mice. <i>Proc Natl Acczd Sci USA</i> 1996;93:9782-9787.
13.	Pall ML. Elevated, sustained peroxynitrite levels as the cause of chronic fatigue syndrome. <i>Med H- vpoth</i> 2000;54:115-125.
14.	Radi R, Cassina A, Hodara R, Quijano C, Castro L. Peroxynitrite reactions and formation in mitochondria. <i>Free Radic Biol Med</i> 2002;33:1451-1464.
15.	Szabo C, Dawson VL. Role of poly (ADP-ribose) synthetase inflammation and ischaemia-reperfusion. <i>Trends in Pharmacol Sci</i> 1998;19:287-298:
16.	Pieper AA, Verma A, Zhang J, Snyder SH. Poly (ADP-ribose) polymerase, nitric oxide and cell death. <i>Trends in Phnrniacol Sci</i> 1999;20:171-181.
17.	Ellithorpe RR, Settinery RA, Nicolson GL. Pilot study: reduction of fatigue by use of a supplement containing dietary glycopospholipids. <i>JAm Neutrnceuticnl Assoc</i> 2003;6:23-28.
18.	Nathan C. Nitric oxide as a secretory product of mammalian cells. <i>FASEB J</i> 1992;6:3051-3064.
19.	Moncada S, Higgs A. The L-arginine-nitric oxide pathway. <i>New Eng J Med</i> 1993;329:2002-2012.

20.	Brunori M, Giuffre A, Forte E, Mastronicola D, Barone MC, Sarti P. Control of cytochrome C oxidase activity by nitric oxide. <i>Biochim Biophys Acta</i> 2004; 1655:365-371.
21.	Gardner PR, Costantino G, Szabo C, Salzman AL. Nitric oxide sensitivity of the aconitases. <i>J Biol Chem</i> 1997;272:25071-25076.
22.	Gardner PR. Superoxide-driven aconitase FE-S center cycling. <i>Biosci Rep</i> 1997;17:33-42.
23.	Castro L, Rodriguez M, Radi M. Aconitase is readily inactivated by peroxynitrite, but not its precursor nitric oxide. <i>J Biol Chem</i> 1994;269:29409-29415.
24.	Keller JN, Kindy MS, Holtsberg FW. Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction. <i>J Neurosci</i> 1998;18:687-697.
25.	Kim PK, Zamora R, Petrosko P, Billiar TR. The regulatory role of nitric oxide in apoptosis. <i>Int J Immunopharmacol</i> 2001;1:1421-1441.
26.	Vojdani A, Ghoneum M, Choppa PC, Magtoto L, Lapp CW. Elevated apoptotic cell populations in patients with chronic fatigue syndrome: the pivotal role of protein kinase RNA. <i>J Intern Med</i> 1997;242:409-410.
27.	Krueger GR, Koch B, Hoffman A, et al. Dynamics of chronic active herpesvirus-6 infection in patients with chronic fatigue syndrome: data acquisition for computer modeling. <i>In Vivo</i> 2001 Nov-Dec. 2001;461-465.
28.	Kennedy G, Spence V, Underwood C, Belch JJ. Increased neutrophil apoptosis in chronic fatigue syndrome. <i>J Clin</i>

	Pathol 2004;57:891-893.
29.	Baschetti R. Cortisol deficiency may account for elevated apoptotic cell population in patients with chronic fatigue syndrome. Jnt Med 1999;245:409-410.
30.	Vojdani A, Mordechai E, Brautbar N. Abnormal apoptosis and cell cycle progression in humans exposed to methyl tertiary-butyl ether and benzene contaminated water. Human Expt Toxicol 1997;16:485-494.
31.	Fremont M, D' Haese AD, Roelens S, et al. In Englebienne P. de Meirlier K, eds. Chronic Fatigue Syndrome: A Biological Approach. Boca Raton: CRC Press; 2002:131-174.
32.	Vojdani A, Ghoneum M, Choppa PC, Magtoto K, Lapp CW. Elevated apoptotic cell population in patients with chronic fatigue syndrome: the pivotal role of protein kinase RNA. J Intern Med 1997;242:465-478.
33.	Hassan IS, Bannister BA, Akbar A, Weir W, Bofill M. A study of immunology of the chronic fatigue syndrome: correlation of immunological parameters to health dysfunction. Clin Immunol Immunopathol 1998;87:60-67.
34.	Swanink CM, Vercoulen JH, Galama JM, et al. Lymphocyte subsets, apoptosis and cytokines in patients with chronic fatigue syndrome. J Infect Dis 1996; 173:460-463.
35.	Kozikowski AP, ed. Neurobiology of the NMDA Receptor: From Chemistry to the Clinic. New York: VCH Publishers;1991.
36.	Mori H, Mishina M. Structure and function of the NMDA receptor channel. Neuropharmacology 1995;34:1219-1237.
37.	Mody I, MacDonald JF. NMDA receptor-dependent

	excitotoxicity: the role of intracellular Ca ²⁺ release. Trends Pharmacol Sci 1995;16:356-359.
38.	Kosenko E, Montoliu C, Giordano G, et al. Acute ammonia intoxication induces an NMDA receptor-mediated increase in poly(ADP-ribose) polymerase level and NAD metabolism in nuclei of rat brain cells. J Neurochem 2004;89:1101-1110.
39.	Pall ML. NMDA sensitization and stimulation by peroxynitrite, nitric oxide and organic solvents as the mechanism of chemical sensitivity in multiple chemical sensitivity. FASEB J 2002;16:1407-1417.
40.	Iravani MM, Liu L, Rose S, Jenner P. Role of inducible nitric oxide synthase in N-methyl-D-aspartic acid-induced strio-nigral degeneration. Brain Res 2004; 1029:103-113.
41.	Acarin L, Peluffo H, Gonzalez B, Castellano B. Expression of inducible nitric oxide synthase and cyclooxygenase-2 after excitotoxic damage to the immature rat brain. J Neurosci Res 2002;68:745-754.
42.	Cardenas A, Moro MA, Hurtado O, et al. Implication of glutamate in the expression of inducible nitric oxide synthase after oxygen and glucose deprivation in rat forebrain slices. J Neurochem 2000;74:2041-2048.
43.	Yoneda K, Yamamoto T, Ueta E, Osaka T. Suppression by azelastine hydrochloride of NF-kappa B activation involved in generation of cytokines and nitric oxide. Jpn J Pharmacol 1997;73:145-153.
44.	McInnis J, Wang C, Anastasio N, et al. The role of superoxide and nuclear factor-kappa B signaling in N-methyl-D-aspartate-induced necrosis and apoptosis. J Pharmacol Exp Ther 2002;301:478-487.

45.	Lafon-Cazal M, Pietri S, Culcasi M, Bockaert J. NMDA-dependent superoxide production and neurotoxicity. <i>Nature</i> 1993;364:535-537.
	46. Borg J, London J. Copper/zinc superoxide dismutase overexpression promotes survival of cortical neurons exposed to neurotoxins in vitro. <i>J Neurosci Res</i> 2002;70:180-189.
	Hongpaisan J, Winters CA, Andrews SB. Calcium-dependent mitochondrial superoxide modulates nuclear CREB phosphorylation in hippocampal neurons. <i>Mol Cell Neurosci</i> 2003;24:1103-1115.
48.	Radenovic L, Selakovic V, Kartelija G, Todorovid N, Nedeljkovic M. Differential effects of NMDA and AMPA/kainite receptor antagonists on superoxide production and MnSOD activity in rat brain following intrahippocampal injection. <i>Brain Res Bull</i> 2004;64:85-93.
49.	Muscoli C, Mollace V, Wheatley J, et al. Superoxide-mediated nitration of spinal manganese superoxide dismutase: a novel pathway in N-methyl-D-aspartatemediated hyperalgesia. <i>Pain</i> 2004;111:96-103.
50.	Atlante A, Gagliardi S, Minervini GM, et al. Glutamate neurotoxicity in rat cerebellar granule cells: a major role for xanthine oxidase. <i>J Neurochem</i> 1997; 68:2038-2045.
51.	Atlante A, Valenti D, Gagliardi S, Passarella S. A sensitive method to assay the xanthine oxidase activity in primary cultures of cerebellar granule cells. <i>Brain Res Brain Res Protoc</i> 2000;6:1-5.
52.	Pall ML, Anderson JH. The Vanilloid Receptor as a Putative Target of Diverse Chemicals in Multiple Chemical Sensitivity. <i>Arch Environ Health</i> 2004;59:363-375.

53.	Nielsen GD. Mechanisms of activation of the sensory irritant receptor by airborne chemicals. CRC Crit Revs Toxicol 1991;2L 183-208.
54.	Szallasi A, Blumberg PM. Vanilloid (capsaicin) receptors and mechanisms. Pharmacol Rev 1999;51:159-211.
55.	Cortright DN, Szallasi A. Biochemical pharmacology of the vanilloid receptor TRPV 1: an update. Eur J Biochem 2004;271:1814-1819.
56.	FerrerMontiel A, Garcia-Martinez C, Morenilla-Palao C, et al. Molecular architecture of the vanilloid receptor: insights for drug design. Eur J Biochem 2004; 217:1820-1826.
57.	Mery PF, Abi-Gerges N, Vandecasteele G, Jurevicius J, Eschenhagen T, Fischmeister R. Muscarinic regulation of the L-type calcium current in isolated cardiac myocytes. Life Sci 1997;60:1113-1120.
02-058	Ashford NA, Miller CS. Chemical Exposures: Low Levels and High Stakes. 2nd ed. New York: John Wiley and Sons;1998. Boek zie 01-041
59.	Sorg BA. Multiple chemical sensitivity: potential role for neural sensitization. Crit Rev Neurobiol 1999; 13:283-316.
60.	Patarca-Montero, R. The Concise Encyclopedia of Fibromyalgia and Myofascial Pain. Binghamton, NY: Haworth Medical Press;2002.
61.	Bell DS. The Doctor's Guide to Chronic Fatigue Syndrome. Reading, MA: Addison-Wesley; 1995.
62.	Yunus MB. Central sensitivity syndromes: a unified concept for fibromyalgia and other maladies. J Indian Rheumatism Assoc 2001;8:27-33.

63.	Neumann I, Buskila D. Epidemiology of fibromyalgia. Curr Pain Headache Rep 2003;7:362-368.
64.	Nicolodi M, Sicuteri R Fibromyalgia and migraine, two faces of the same mechanism. Adv Exp Med Biol 1996;398:373-379.

[343] -[358]

HOOFDSTUK – 03

1.	Pall, ML. Elevated, sustained peroxynitrite levels as the cause of chronic fatigue syndrome. Med Hypoth 2000;54:115-125.
2.	Farquhar WB, Hunt BE, Taylor JA, Darling SE, Freeman R. Blood volume and its relation to peak O ₂ consumption and physical activity in patients with chronic fatigue syndrome. Am J Physiol Heart Circ Physiol 2002;282:H66-H71.
3.	McCully KK, Smith S, Rajaei S, Leigh Jr JS, Natelson BH. Blood flow and muscle metabolism in chronic fatigue syndrome. Clin Sci (Lond). 2003;104:641-647.
4.	Chazotte B. Mitochondrial dysfunction in chronic fatigue syndrome. In Lemasters, Niemenen, eds. Mitochondria in Pathogenesis. New York: Kluwer Academic/Plenum Publishers, 2001:393-410.
5.	Park JH, Niermann KJ, Olsen N. Evidence for metabolic abnormalities in the muscles of patients with fibromyalgia. Curr Rheumatol Rep 2000;2:131-140.
6.	Yunus MB, Kalyan Raman UP, Kalyan Raman K. Primary fibromyalgia syndrome and myofascial pain syndrome: clinical features and muscle pathology. Arch Phys Med Rehabil 1988;69:451-454.
7.	Yunus MB, Kalyan-Raman UP, Kalyan-Raman K, Masi AT. Pathologic changes in muscle in primary fibromyalgia. Am J Med 1986;81(3A):38-42.

8.	Pongratz DE, Späth M. Morphologic aspects of tibromyalgia. Z Rheumatol 1998;57:47-51.
9.	Kalyan Raman UP, Kalyan Raman K, Yunus MB, Masi AT. Muscle pathology in primary fibromyalgia syndrome: a light microscopic, histochemical and ultrastructural study. J Rheumatol 1984; 11:808-813.
10.	Lindman R, Hagberg M, Bengtsson A, et al. Capillary structure and mitochondrial volume density in the trapezius muscle of chronic trapezius myalgia, fibromyalgia and healthy subjects. J Musculoskeletal Pain 1995;3:5-22.
11.	Drewes AM, Andreasen A, Schroder HD, Hogsaa B, Jennum P. Pathology of skeletal muscle fibromyalgia: a histo-immuno-chemical and ultrastructural study. Br J Rheurnatol 1993;32:479-483.
12.	Fassbender HG, Wegner K. Morphologie und Pathogenese des Weichteilrheumatismus. ZRheurnaforsch 1973;33:355-374.
13.	Park JH, Phothimat P, Oates CT, Hernanz Schulman M, Olsen NJ. Use of P-31 magnetic resonanace spectroscopy to detect metabolic abnormalities in muscles in patients with fibromylagia. Arthritis Rheum 1998;41;406-413.
14.	Sprott H, Salemi S, Gay RE, et al. Increased DNA fragmentation and ultrastructural changes in fibromyalgia muscle fibers. Ann Rheum Dis 2004;63:245-251.
15.	Sheng WS, Lin JC, Apple F, Hu S, Peterson PK, Chao CC. Brain energy stores in C57BL/6 mice after C. parvum injection. Neuroreport 1999;10:177-181.
16.	Fulle S, Mecocci P, Fano G, et al. Specific oxidative alterations in vastus lateralis muscle in patients with the

	diagnosis of chronic fatigue syndrome. Free Radic Biol Med 2000;29:1252-1259.
17.	Richards RS, Roberts TK, McGregor NR, Butt HL. Blood parameters indicative of oxidative stress are associated with symptom expression in chronic fatigue syndrome. Redox Rep 2000;5:35-41.
18.	Richards RS, Roberts TK, Dunstan RH, McGregor NR, Butt HL. Free radicals in chronic fatigue syndrome: cause or effect? Redox Rep 2000;5:146-147.
19.	Keenoy BM, Moorkens G, Vertommen J, DeLeeuw I. Antioxidant status and lipoprotein oxidation in chronic fatigue syndrome. Life Sci 2001;68:2037-2049.
20.	Logan AC, Wong C. Chronic fatigue syndrome: oxidative stress and dietary modifications. Altern Med Rev 2001;6:450-459.
21.	Smimova IV, Pall ML. Elevated levels of protein carbonyls in sera of chronic fatigue syndrome patients. Mol Cell Biochem 2003;248:93-95.
22.	Kurup RK, Kurup PA. Hypothalamic digoxin, cerebral chemical dominance and myalgic encephalomyelitis. Intern J Neuroscience 2003; 113:445-457.
23.	Vecchiet J, Cipollone F, Falasca K, et al. Relationship between musculoskeletal symptoms and blood markers of oxidative stress in patients with chronic fatigue syndrome. Neurosci Lett 2003;335:151-154.
24.	Ionescu G, Merck M, Bradford R. Simple chemiluminescence assays for free radicals in venous blood and serum samples: results in atopic dermatitis, psoriasis, MCS and cancer patients. Forsch Komplementarmed

	1999;6:294-300.
25.	Eisinger J, Gandolfo C, Zakarian H, Ayavou T. Reactive oxygen species, antioxidant status and fibromyalgia. J Musculoskeletal Pain 5(4):5-15.
26.	Eisinger J, Zakarian H, Pouly F, Plantamura A, Ayavou T. Protein peroxidation, magnesium deficiency and fibromyalgia. Magnes Res 1996;9:313-316.
27.	Hein G, Franke S. Are advanced glycation end-product-modified proteins of pathogenetic importance in fibromyalgia? Rheumatology 2002;41:1163-1176.
28.	Bagis S, Tamer L, Sahin G, et al. Free radicals and antioxidants in primary fibromyalgia: an oxidative stress disorder? Rheumatol Int 2005;25:188-190.
29.	Tezcan E, Atmaca M, Kuloglu M, Ustundag B. Free radicals in patients with post-traumatic stress disorder. Neuroreport 2003;23:913-916.
30.	Alptekin N, Seckin S, Dogru Abbasoglu S, et al. Lipid peroxides, glutathione, y-glutamylcysteine synthetase and y-glutamyltranspeptidase activities in several tissues of rats following water-immersion stress. eliminary findings. Int J Biosocial Res 1996;3:44-47.
31.	Seckin S, Alptekin N, Dogru Abbasoglu S, et al. The effect of chronic stress on hepatic and gastric peroxidation in long-term depletion of glutathione in rats. Pharmacol Res 1997;36:55-57.
32.	Martinez-Augustin O, de Medina FS. Effect of psychogenic stress on gastrointestinal function. J Physiol Biochem 2000;56:259-273.
33.	Singh A, Garg V, Gupta S, Kulkarni SK. Role of

	antioxidants in chronic fatigue syndrome in mice. Indian J Exp Biol 2002;40:1240-1244.
34.	Tirelli U, Chierichetti F, Tavio M, et al. Brain positron emission tomography (PET) in chronic fatigue syndrome: preliminary data. Am J Med 1998;105(3A): 54S-58S.
35.	MacHale SM, Lawrie SM, Cavanagh JT, et al. Cerebral perfusion in chronic fatigue syndrome and depression. Br J Psychiatry 2000;176:550-556.
36.	Seissmeier T, Nix WA, Hardt J, et al. Observer independent analysis of cerebral glucose metabolism in patients with chronic fatigue syndrome. J Neurol Neurosurg Psychiatry 2003;74:922-928.
37.	Lekander M, Frederikson M, Wik G. Neuroimmune relations in patients with fibromyalgia: a positron emission tomography study. Neurosci Lett 2000;282:193-196.
38.	Heuser G, Wu JC. Deep subcortical (including limbic) hypermetabolism in patients with chemical intolerance: human PET studies. Ann NY Acad Sci 2001; 933:319-322.
39.	Bell IR, Miller CS, Schwartz GE, Peterson JM, Amend D. Neuropsychiatric and somatic characteristics of young adults with and without self-reported chemical odor intolerance and chemical sensitivity. Arch Environ Health 1996;51:9-21.
40.	Lekander M, Frederikson M, Wik G. Neuroimmune relations in patients with fibromyalgia: a positron emission tomography study. Neurosci Lett 2000;282:193-196.
41.	Yunus MB, Young CS, Saeed SA, Mountz JM, Aldag JC. Positron emission tomography in patients with fibromyalgia syndrome and healthy controls. Arthritis Rheum. 2004;51:513-518.

42.	Bremner JD, Vythilingam M, Vermetten E, et al. MRI and PET study of deficits in hippocampal structure and function in women with childhood sexual abuse and posttraumatic stress disorder. <i>Am J Psychiatry</i> 2003; 160:924-932.
43.	Shin LM, Orr SP, Carson MA, et al. Regional blood flow in the amygdala and medial prefrontal cortex during traumatic imagery in male and female Vietnam veterans with PTSD. <i>Arch Gen Psychiatry</i> 2004;61:168-176.
44.	Bonne O, Gilboa A, Louzoun Y, et al. Resting regional perfusion in recent posttraumatic stress disorder. <i>Biol Psychiatry</i> 54:1077-1086.
45.	Bremner JD, Vythilingam M, Vermetten E, et al. MRI and PET study of deficits in hippocampal structure and function in women with childhood sexual abuse and posttraumatic stress disorder. <i>Am J Psychiatry</i> 2003;160:924-932.
46.	Ichise M, Salit IE, Abbey SE, et al. Assessment of regional cerebral perfusion by 99Tcm-HMPAO SPECT in chronic fatigue syndrome. <i>Nucl Med Commun</i> 1992;13:767-772.
47.	Schwartz RB, Komaroff AL, Garada BM, et al. SPECT imaging of the brain: comparison of findings in patients with chronic fatigue syndrome, AIDS dementia complex and major unipolar depression. <i>Am J Roentgenol</i> 1994;162:943-951.
48.	Dickinson CJ. Chronic fatigue syndrome-aetiological aspects. <i>Eur J Clin Invest</i> 1997;27:257-267.
49.	Fischler B, D'Haenen H, Cluydts R, et al. Comparison of 99m Tc HMPAO SPECT scan between chronic fatigue syndrome, major depression and healthy controls: an exploratory study of clinical correlates of regional cerebral blood flow. <i>Neuropsychobiology</i> 1996;34:175-183.

50.	Simon T, Hickey D, Fincher C, Johnson A, Ross G, Rea W. Single photon emission computed tomography of the brain in patients with chemical sensitivities. Toxicol Ind Health 1994;10:573-577.
51.	Heuser G, Mena I, Alamos F. Neurospect findings in patients exposed to neurotoxic chemicals. Toxicol Ind Health 1994; 10:561-572.
52.	Ross GH, Rea WJ, Johnson AR, Hickey DC, Simon TR. Neurotoxicity in single photon emission computed tomography brain scans of patients reporting chemical sensitivities. Toxicol Ind Health 1999; 15:415-420.
53.	Kwiatk R, Barnden L, Tedman R, et al. Regional blood flow in fibromyalgia: single-photon-emission computed tomography evidence of reduction of the pontine tegmentum and thalami. Arthritis Rheum 2000;43:2823-2833.
54.	Pitman RK, Shin LM, Rauch SL. Investigating the pathogenesis of posttraumatic stress disorder with neuroimaging. J Clin Psychiatry 2001;62(Suppl) 17:47-54.
55.	Villarreal G, King CY. Brain imaging in posttraumatic stress disorder. Semin Clin Neuropsychiatry 2001;6:131-145.
56.	Van Der Kolk BA. The psychobiology and psychopharmacology of PTSD. Hain Ps'ychopharmacol 2001;16(S 1):S49-S64.
57.	Mirzaei S, Knoll P, Keck A, et al. Regional cerebral blood flow in patients suffering from post-traumatic stress disorder. Neuropsychobiology 2001;43:260-264,
58.	Zubieta JK, Chinitz JA, Lombardi U, et al. Medial frontal cortex involvement in PTSD symptoms: a SPECT study. J Psychiatr Res 1999;33:259-264.

59.	Aoki T, Miyakoshi H, Usuda Y, Heberman RB. Low NK syndrome and its relationship to chronic fatigue syndrome. Clin Immunol Immunopath 1993;69:253-265.
60.	Natelson BH, Haghighi MH, Ponzio NM. Evidence for the presence of immune dysfunction in chronic fatigue syndrome. Clin Diagnostic Lab Immunol 2002;9:747-752.
61.	Komarolif AL, Buchwald DS. Chronic fatigue syndrome: an update. Ann Rev Med 1998;49:1-13.
62.	Pall ML. Elevated peroxynitrite as the cause of chronic fatigue syndrome. Medical Hypoth 2000;54:115-125.
63.	Patarca R. Cytokines and chronic fatigue syndrome. Ann NY Acad Sci 2001; 933:185-200.
03-064	Ashford NA, Miller C. Chemical Exposures: Low Levels and High Stakes. New York: John Wiley and Sons;1998. Boek zie 01-041
65.	Sorg BA. Multiple chemical sensitivity: potential role for neural sensitization. Crit Rev Neurobiol 1999; 13:283-316.
66.	Landis CA, Lentz MJ, Tsuji J, Buchwald D, Shaver JL. Pain, psychological variables, sleep quality, and natural killer cell activity in midlife women with and without fibromyalgia. Brain Behav Immun 2004;18:304-313.
67.	Patarca-Montero R. The Concise Encyclopedia of Fibromyalgia and Myofascial Pain. Binghamton, NY: Haworth Medical Press;2002.
68.	Mosnaim AD, Wolf ME, Maturana P, et al. In vitro studies of natural killer cell activity in posttraumatic stress disorder patients. Immunopharmacology 1993; 25:107-116.
69.	Ironson G, Wynings C, Schneiderman N, et al. Posttraumatic

	stress symptoms, intrusive thoughts, loss and immune function after Hurricane Andrew. <i>Psychsom Med</i> 1997;59:142-243.
70.	Inoue-Sakurai C, Maruyama S, Morimoto K. Posttraumatic stress and lifestyles are associated with natural killer cell activity in victims of the Hanshin-Awaji earthquake in Japan. <i>Prev Med</i> 2000;31:467-473.
71.	Kawamura N, Kim Y, Asukai N. Suppression of cellular immunity in men with a past history of posttraumatic stress disorder. <i>Am JPsychiatry</i> 2001;158: 484-486.
72.	Skowera A, Cleare A, Blair D, Bevis L, Wessely SC, Peakman M. High levels of type 2 cytokine-producing cells in chronic fatigue syndrome. <i>Clin Exp Immunol</i> . 2004;135:294-302.
73.	Pall ML. The nitric oxide synthase product, citrulline is elevated in the sera of chronic fatigue syndrome patients. <i>J Chronic Fatigue Syndr</i> 2002; 10(3/4):37-42.
74.	Patarca-Montero R. <i>Chronic Fatigue Syndrome and the Body's Immune Defense System</i> . Binghamton, NY: Haworth Medical Press;2002.
75.	Gur A, Karakoc M, Erdogan S, Nas K, Cevik R, Sarac AJ. Regional cerebral blood flow and cytokines in young females with fibromyalgia. <i>Clin Exp Rheumatol</i> 2002;20:753-760.
76.	Salemi S, Rethage J, Wollina U, et al. Detection of interleukin β (IL β), IL-6, and tumor necrosis factor- α in skin of patients with fibromyalgia. <i>J Rheumatol</i> 2003;30:146-150.
77.	Maes M, Lin AH, Delmeire L, et al. Elevated serum

	interleukin-6 (IL-6) and IL-6 receptor concentrations in posttraumatic stress disorder following accidental man-made traumatic events. Biol Psychiatry 1999;45:833-839.
78.	Spivak B, Shohat B, Mester R, et al. Elevated levels of serum interleukin-1 β in combat related posttraumatic stress disorder. Biol Psychiatry 1997;42:345-348.
79.	Baker DG, Ekhtator NN, Kasckow JW, et al. Plasma and cerebrospinal fluid interleukin-6 concentrations in posttraumatic stress disorder. Neuroimmunomodulation 2001;9:209-217.
80.	Aurer A, Aurer-Kozelj J, Stavljenic-Rukavina A, Kalenic S, Ivic-Kardum M, Haban V. Inflammatory mediators in saliva of patients with rapidly progressive periodontitis during war stress induced incidence increase. Coll Antropol 1999; 23:117-124.
81.	Ushio H, Nohara K, Fujimaki H. Effects of environmental pollutants on the production of inflammatory cytokines by normal human dermal keratinocytes. Toxicol Lett 1999;105:17-24.
82.	Watkins LR, Martin D, Ulrich P, Tracey KJ, Maier SF. Evidence for involvement of spinal cord glia in subcutaneous formalin induced hyperalgesia in the rat. Pain 1997;71:225-235.
83.	Demitrack MA, Dale JK, Straus SE, et al. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 1991;73:1224-1234.
84.	Demitrack MA. Neuroendocrine correlates of chronic fatigue syndrome: a brief review. J Psychiat Res 1997;31:69-82.

85.	Appels A. Exhausted subjects, exhausted systems. <i>Acta Physiol Scand Suppl</i> 1997;640:153-154.
86.	Cleare AJ. The HPA axis and the genesis of chronic fatigue syndrome. <i>Trends Endocrinol Metab</i> 2004;15:55-59.
87.	Thompson D, Lettich L, Takeshita J. Fibromyalgia: an overview. <i>Curr Psychiatry</i> 2003;5:211-217.
88.	Okifuji A, Turk DC. Stress and psychophysiology dysregulation in patients with fibromyalgia syndrome. <i>Appl Psychophysiol Biofeedback</i> 2002;27:129-141.
89.	Adler GK, Manfredsdottir VF, Creskoff KW. Neuroendocrine abnormalities in fibromyalgia. <i>Curr Pain Headache Rep</i> 2002;6:289-298.
90.	Crofford LJ. The hypothalamic-pituitary-adrenal axis in pathogenesis of rheumatic diseases. <i>Endocrinol Metab Clin North Am</i> 2002;31:1-13.
91.	Clauw DJ. Potential mechanisms in chemical intolerance and related conditions. <i>Ann NY Acad Sci</i> 2001;933:235-253.
92.	Nawab SS, Miller CS, Dale JK, et al. Self-reported sensitivity to chemical exposures in five clinical populations and healthy controls. <i>Psychiatry Res</i> 2000; 95:67-74.
93.	Yehuda R, Giller EL, Southwick SM, Lowy MT, Mason JW. Hypothalamic-pituitary-adrenal dysfunction in post-traumatic stress disorder. <i>Biol Psych</i> 1991; 30:1031-1048.
94.	Yehuda R, Boisoneau D, Lowy MT, Giller EL, Jr. Dose-response changes in plasma cortisol and lymphocyte glucocorticoid receptors following dexamethasone administration in combat veterans with and without posttraumatic stress disorder. <i>Arch Gen Psych</i> 1996;52:583-593.

95.	Grossman R, Yehuda R, New A, et al. Dexamethasone suppression of test findings in subjects with personality disorders: association with posttraumatic stress disorder and major depression. <i>Am J Psychiatry</i> 2003; 160:1291-1298.
96.	Thaller V, Vrkljan M, Hotujac L, Thakore J. The potential role of hypercortisolism in the pathophysiology of PTSD and psoriasis. <i>Collegium Anthropologicum</i> 1999;23:611-619.
97.	Kellner M, Yassouridis A, Hubner R, Baker DG, Wiedemann K. Endocrine and cardiovascular responses to corticotropin-releasing hormone in patients with posttraumatic stress disorder: a role for atrial natriuretic peptide? <i>Neuropsychobiology</i> 2003;47:102-108.
98.	Yehuda R, Golier JA, Kaufman S. Circadian rhythm of salivary cortisol in holocaust survivors with and without PTSD. <i>Am J Psychiatry</i> 2005;162:998-1000.
99.	Sorg BA, Bailie TM, Tschirigi ML, Li N, Wu WR. Exposure to repeated lowlevel-formaldehyde in rats increases basal corticosterone levels and enhances the corticosterone response to subsequent formaldehyde. <i>Brain Res</i> 2001;898:314-320.
100.	Bell DS. <i>The Doctor's Guide to Chronic Fatigue Syndrome</i> . Reading, MA: Addison-Wesley; 1995.
101.	Fukuda K, Strauss SE, Hickie I, Sharpe MC, Dobbin JG, Komaroff A. The chronic fatigue syndrome: A comprehensive approach to definition and study. International Chronic Fatigue Syndrome Group. <i>Ann Intern Med</i> 1994;121:953-959.
102.	Goldenberg DL. Fibromyalgia syndrome a decade later: What have we learned? <i>Arch Intern Med</i> 1999; 159:777-

	785.
103.	Larson AA, Kovacs KJ. Nociceptive aspects of fibromyalgia. Curr Pain Headache Rep 2001;5338-346.
104.	Adamec R. Modelling anxiety disorders following chemical exposures. ToxicolIndHealth 1994;10:391-420.
105.	Bell IR, Peterson JM, Schwartz GE. Medical histories and psychological profiles of middle-aged women with and without self-reported illness from environmental chemicals. J Clin Psychiatry 1995;56:151-160. https://pubmed.ncbi.nlm.nih.gov/7713854/
106.	Moore LJ, Boehnlein JK. Posttraumatic stress disorder, depression and somatic symptoms in U.S. Mein patients. J Nerv Ment Dis 1991;179:728-733.
107.	Jones F, Vermaas RH, McCartney H, et al. Flashbacks and post-traumatic stress disorder: the genesis of a 20th century diagnosis. Br J Psychiatry 2003; 182:158-163.
108.	Bennett A. A view of violence contained in chronic fatigue syndrome. J Anal Psychol 1997;42:237-251.
▲ 03-109	Bell IR, Baldwin CM, Fenandez M, Schwartz GE. Neural sensitization model of multiple chemical sensitivity. Toxicol Indust Health 1999. https://pubmed.ncbi.nlm.nih.gov/10416281/ Samenvatting
110.	Chemtob CM, Novaco RW, Hamada RS, Gross DM, Smith G. Anger regulation deficits in combat-related posttraumatic stress disorder. J Trauma Stress 1998;10:17-36.
111.	Sandman CA, Barron JL, Nackoul K, Goldstein J, Fidler F. Memory deficits associated with chronic fatigue immune dysfunction syndrome. Biol Psychiatry 1993;33:618-123.

112.	Michiels V, Cluydts R, Fischler B. Attention and verbal learning in patients with chronic fatigue syndrome. J Int Neuropsychol Soc 1998;4:456-466.
113.	Servatius RJ, Tapp WN, Bergen MT, et al. Impaired associative learning in chronic fatigue syndrome. Neuroreport 1998;9:1153-1157.
114.	Busichio K, Tiersky LA, DeLuca J, Natelson BH. Neuropsychological deficits in patients with chronic fatigue syndrome. J Int Neuropsych Soc 2004; 10:278-285.
115.	Pall, ML. Elevated peroxynitrite as the cause of chronic fatigue syndrome: Other inducers and mechanisms of symptom generation. J Chronic Fatigue Syndr 2000;7(4):39-44.
116.	Okifuji A, Ashburn MA. Fibromyalgia syndrome: toward an integration of the literature. Crit Revs Physical Rehab Med 2001;13:27-54.
117.	Lipschitz EL. Chronic fatigue syndrome and posttraumatic stress disorder. JAMA 2001;286:916-917.
118.	Brandes D, Ben-Schachar G, Gilboa A, Bonne O, Freedman S, Shalev AY. PTSD symptoms and cognitive performance in recent trauma survivors. Psychiatry Res 2002;110:102-110.
119.	Homer MD, Hamner MB. Neurocognitive functioning in posttraumatic stress disorder. Neuropsychol Rev 2002;12:15-30.
120.	Burloux G, Forestier P, Dalery J, Guyotat J. Chronic pain and posttraumatic stress disorders. Psychother Psychosom 1989;52:119-124.
121.	Beckham JC, Crawford AL, Feldman ME, et al. Chronic

	posttraumatic stress disorder and chronic pain in Vietnam combat veterans. J Psychosom Res 1997;43:379-389.
122.	Dagan Y, Zinger Y, Lavic P. Actigraphic sleep monitoring in posttraumatic stress disorder (PTSD) patients. J Psychosom Res 1997;42:577-581.
123.	Mellman TA, Bustamante V, Fins AI, Pigeon WR, Nolan B. REM sleep and the early development of posttraumatic stress disorder. Am J Psychiatry 2002; 159:1696-1701.
124.	Rowe PC, Bou Holoigah I, Kan J, Calkins H. Is neurally mediated hypotension an unrecognized cause of chronic fatigue? Lancet 1995;345:623-624.
125.	Stewart JM, Gewitz MH, Weldon A, et al. Patterns of delayed orthostatic intolerance: the orthostatic tachycardia syndrome and adolescent chronic fatigue syndrome. J Pediatr 1999;135:218-225.
126.	Bell IR, Baldwin CM, Russek LG, Schwartz GE, Hardin EE. Early life stress, negative paternal relationships, and chemical intolerance in middle-aged women: support for a neural sensitization model. J Women's Health 1998;7:1135-1147. https://pubmed.ncbi.nlm.nih.gov/9861591/ ook 01-098 *oooo
127.	Orr SP, Meyerhoff JL, Edwards JV, Pitman RK. Heart rate and blood pressure resting levels and responses to generic stressors in Vietnam veterans with posttraumatic stress disorder. J Trauma Stress 1998;11: 155-164.
128.	Hinton D, Ba P, Peou S, Um K. Panic disorder among Cambodian refugees attending a psychiatric clinic. Prevalence and subtypes. Gen Hosp Psychiatry 2000; 22:437-444.

129.	Pietrini P, Teipel SJ, Bartenstein P, et al. PET and the effects of aging and neurodegeneration on brain function: basic principles. <i>Drug News Perspect</i> 1998; 11: 161-165.
130.	Holthoff VA, Beuthien-Baumann B, Zundorf G, et al. Changes in brain metabolism associated with remission in unipolar major depression. <i>Acta Psychiatr Scand</i> 2004;110:184-194.
131.	Silverman DH, Small KA, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. <i>JAMA</i> 2001;286:2120-2127.
132.	Jacquier-Sarlin MR, Polla BS, Slosman DO. Oxidoreductive state: the major determinant for cellular retention of technetium-99m-HMPAO. <i>J Nucl Med</i> 1996;37:1413-1416.
133.	Suess E, Malessa K, Ungersbock K, et al. Technetium-99m-D,L-hexamethylpropyleneamine oxime (HMPAO) uptake and glutathione content of brain tumors.
134.	Meydani SN, Wu D, Santos MS, Hayek MG. Antioxidants and immune response in aged persons: overview of present evidence. <i>Am J Clin Nutr</i> 1995; 62(Suppl): 1462S- 1476S.
135.	Nakamura K, Matsunaga K. Susceptibility of natural killer (NK) cells to reactive oxygen species (ROS) and their restoration by the mimics of superoxide dismutase (SOD). <i>Cancer Biothe Radiopharm</i> 1998; 13:275-2090.
136.	Hansson M, Asea A, Ersson U, Hermodsson S, Hellstrand K. Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. <i>J Immunol</i> 1996; 156:42-47.
137.	Takeuchi M, Nagai S, Nakajima A, et al. Inhibition of lung

	natural killer cell activity by smoking: the role of alveolar macrophages. <i>Respiration</i> 2001; 168:262-267.
138.	Heuser G, Vojdani A. Enhancement of natural killer cell activity and T and B cell function by buffered vitamin C in patients exposed to toxic chemicals: the role of protein kinase C. <i>Immunopharmacol Immunotoxicol</i> 1997;19:291-312.
139.	Ogawa M, Nishiura T, Yoshimura M, et al. Decreased nitric oxide-mediated natural killer cell activation in chronic fatigue syndrome. <i>Ear J Clin Invest</i> 1998; 28:937-943.
140.	Riedel WS. Role of nitric oxide in the control of the hypothalamic-pituitary-adrenal axis. <i>Z Rheumatol</i> 2000;59(Suppl 2):36-42.
141.	Chikanza IC. Neuroendocrine immune features of pediatric inflammatory rheumatic diseases. <i>Ann NYAcad Sci</i> 1999;876:71-80.
142.	Bomholt SF, Harbuz MS, Blackburn-Munro G, Blackburn-Munro RE. Involvement and role of the hypothalamo-pituitary-adrenal (HPA) stress axis in animal models of chronic pain and inflammation. <i>Stress</i> 2004;7:1-14.
143.	Buske-Kirschbaum A, Hellhammer DH. Endocrine and immune responses to stress in chronic inflammatory skin disorders. <i>Ann NYAcad Sci</i> 2003;992:231-240.
144.	Huitinga I, Erkut ZA, van Beurden D, Swaab DF. The hypothalamo-pituitary-adrenal axis in multiple sclerosis. <i>Ann NYAcad Sci</i> . 2003;992:118-128.
145.	Bornstein SR, Rutkowski H. The adrenal hormone metabolism in the immune/inflammatory reaction. <i>Endocr Res</i> 2002;28:719-728.

146.	Adamec RE. Evidence that NMDA-dependent limbic neural plasticity in the right hemisphere mediated pharmacological stressor (FG-7142)-induced lasting increased in anxiety-like behavior. <i>J Psychopharmacol</i> 1998;12:122-128.
147.	Davis M. Neurobiology of fear responses: the role of the amygdala. <i>J Neuropsychiatry Clin Neurosci</i> 1997;9:382-402.
148.	Adamec RE, Burton P, Shallow T, Budgell J. Unilateral block of NMDA receptors in the amygdala prevents predator stress-induced lasting increases in anxietylike behavior and unconditioned startle-effective hemisphere depends on behavior. <i>Physiol Behav</i> 1999;65:739-751.
149.	Shekhar A, Sajdyk TJ, Gehlert DR, Rainnie DG. The amygdala, panic disorder, and cardiovascular responses. <i>Ann NY Acad Sci</i> 2003;985:308-325.
150.	Volke V, Koks S, Vasar E, et al. Inhibition of nitric oxide synthase causes anxiolytic-like behavior in an elevated plus-maze. <i>Neuroreport</i> 6:1413-1416.
151	L Faria MS, Muscara MN, Moreno Junior H, et al. Acute inhibition of nitric oxide synthesis induces anxiolysis in the plus maze test. <i>Eur J Pharmacol</i> 1997; 323:37-43.
152.	Monzon ME, Varas MM, De Barioglio SR. Anxiogenesis induced by nitric oxide synthase inhibition and anxiolytic effect of melanin-concentrating hormone (MCH) in rat brain. <i>Peptides</i> 200122:1043-1047.
153.	Werner C, Raivich G, Cowen M, et al. Importance of NO/cGMP signaling via cGMP-dependent protein kinase II for controlling emotionality and neurobehavioural effects of alcohol. <i>Eur J Neurosci</i> 2004;20:3498-3506.

154.	Volke V, Wegener G, Vasar E. Augmentation of the NO-cGMP cascade induces anxiolytic-like effect in mice. <i>J Physiol Pharmacol</i> 2003;54:653-660.
155.	Kurt M, Bilge SS, Aksoz E, et al. Effect of sildenafil on anxiety in the plusmaze test in mice. <i>Pol J Pharmacol</i> 2004;56:55-59.
156.	Papageorgiou C, Grapsab NG, Chritodoulouc NG, et al. Association of serum nitric oxide with depressive symptoms: a study with end-stage renal failure patients. <i>Psychother Psychosomatics</i> 2001;70:216-220.
157.	Suzuki E, Yagi G, Nakaki T, Kanba S, Asai M. Elevated plasma nitrate levels in depressive states. <i>J Affect Disord</i> 2001;63:221-224.
158.	McLeod TM, Lopez-Figueroa AL, Lopez-Figueroa MO. Nitric oxide, stress and depression. <i>Psychopharmacol Bull</i> 2001;35:24-41.
159.	Paul IA, Skolnik P. Glutamate and depression: clinical and preclinical studies. <i>Ann N Y Acad Sci</i> 2003;1003:250-272.
160.	Finkel MS, Laghrissi-Thode F, Pollock BG, Rong J. Paroxetine is a novel nitric oxide synthase inhibitor. <i>Psychopharmacol Bull</i> 1996;32:653-658. Seroxat
161.	Angulo J, Peiro C, Sanchez-Ferrer CF, et al. Differential effects of serotonin reuptake inhibitors on erectile responses, NO-production, and neuronal NO synthase expression in rat corpus cavernosum tissue. <i>Br J Pharmacol</i> 2001;134:1190-1194.
162.	Capuron L, Dantzer R. Cytokines and depression: the need for a new paradigm. <i>Brain Behav Immun</i> 2003; 17(Suppl

	1):S119-S124.
163.	Anisman H, Merali Z. Cytokines, stress and depressive illness: brain-immune interactions. <i>Ann Med</i> 2003;35:2-11.
	164. O'Brien SM, Scott LV, Dinan TG. Cytokines: abnormalities in major depression and implications for pharmacological treatment. <i>Hum Psychopharmacol</i> 2003; 19:397-403.
165.	Bandler R. Induction of 'rage' following microinjections of glutamate into midbrain but not hypothalamus of cats. <i>Neurosci Lett</i> 1982;30:183-188.
166.	Schubert K, Shaik MB, Siegel A. NMDA receptors in the midbrain of periaqueductal gray mediate hypothalamically evoked hissing behavior in cat. <i>Brain Res</i> 1996;726:80-90.
167.	Greg TR, Siegel A. Brain structures and neurotransmitters regulating aggression in cats: implications for human aggression. <i>Prog Neuropsychopharmacol Biol Psychiatry</i> 2001;25:91-140.
168.	Gammie SC, Nelson RJ. Maternal aggression is reduced in neuronal nitric oxide synthase-deficient mice. <i>J Neurosci</i> 1999; 19:8027-8035.
169.	Albensi BC. Models of brain injury and alterations and alterations in synaptic plasticity. <i>J Neurosci Res</i> 2001;65:279-283.
170.	Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. <i>Nature</i> 1993;361:31-39.
171.	Bennett MR. The concept of long term potentiation of transmission at synapses. <i>Prog Neurobiol</i> 2000;60:109-137.

172.	Platenik J, Kuramoto N, Yoneda Y. Molecular mechanisms associated with long-term consolidation of the NMDA signals. <i>Life Sci</i> 2000;67:231-253.
173.	Prast H, Philippu A. Nitric oxide as a modulator of neuronal function. <i>Prog Neurobiol</i> 2001;64:51-68.
174.	Cotman CW, Monaghan DT, Ganong AH. Excitatory amino acid neurotransmission: NMDA receptors and Hebb-type synaptic plasticity. <i>Ann Rev Neurosci</i> 1988;11:61-80.
175.	Bliss TV, Douglas RM, Errington ML, Lynch MA. Correlation between long-term potentiation and release of endogenous amino acids from dentate gyrus of anesthetized rats. <i>J Physiol</i> 1986;377:391-408.
176.	Kuriyama K, Ohkuma S. Role of nitric oxide in central synaptic transmission: effects on neurotransmitter release. <i>Jpn J Pharmacol</i> 1995;34:347-350.
177.	Zhang J, Snyder SH. Nitric oxide in the nervous system. <i>Annu Rev Pharmacol Toxicol</i> 1995;35:213-233.
178.	Williams JH. Retrograde messengers and long-term potentiation: a progress report. <i>J Lipid Mediat Cell Signal</i> 1996;14:331-339.
179.	Hawkins RD, Son H, Arancio O. Nitric oxide as a retrograde messenger during long-term potentiation in hippocampus. <i>Prog Brain Res</i> 1998;118:155-172.
180.	Tegeder I, Del Turco D, Schmidtke A, et al. Reduced inflammatory hyperalgesia with preservation of acute thermal nociception in mice lacking cGMPdependent protein kinase I. <i>Proc Natl Acad Sci USA</i> 2004; 101:3253-3257.
181.	Brune Kay, Handwerker Hermann, eds. <i>Hyperalgesin</i> :

	Molecular Mechanisms and Clinical Implications. Seattle: IASP Press;2004.
182.	Turkoski BB. Tired blood. Part I. Orthop Nurs 2003;22:222-227; Sobrero A, Puglisi F, Guglielmi A, et al. Fatigue: a main component of anemia symptomatology. Sefnin Oncol 2001;28(Supp18):15-18.
183.	Annibele B, Marignani M, Monarca B, et al. Reversal of iron deficiency anemia after Helicobacter pylori eradication in patients with asymptomatic gastritis. Ann Intern Med 1999;131:668-672.
184.	Kaltwasser JP, Kessler U, Gottschalk R, Stucki G, Moller B. Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis. JRheurnato12001;28:2430-2436.
185.	Littlewood TJ, Bajetta E, Nortier JWR, et al. Effects of Epoetin Alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
186.	Nybo L. CNS fatigue and prolonged exercise: effect of glucose supplementation. Med Sci Sports Exerc 2003;35:589-594.
187.	Brouns F. Nutritional aspects of health and performance at lowland and altitude. Int J Sports Med 1993; 13(suppl 1):S 100-S 106.
188.	Costill DL, Hargreaves M. Carbohydrate nutrition and fatigue. Sports Med 1992; 13:86-92.
189.	Griggs RC, Karpati G. Muscle pain, fatigue and mitochondriopathies. New Eng J Med 1999;34L1077-1078.

190.	Kabbouche MA, Powers SW, Vockell AL, LeCates SL, Hershey AD. Carnitine palmityltransferase II(CPT2) deficiency and migraine headaches: two case reports. Headache 2003;43:490-495.
191.	Hooper RG, Thomas AR, Kearl RA. Mitochondrial enzyme deficiency causing exercise limitation in normal-appearing adults. Chest 1995;107:317-322.
192.	Wouters BG, Delahoussaye YM, Evans JW, et al. Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine. Cancer Res 2001;61:145-152.
193.	Neri S, Pistone GF, Saraceno B, et al. L-carnitine decreases severity and type of fatigue induced by interferon-(x in the treatment of patients with hepatitis C. Neuropsychobiology 2003;47:94-97.
194.	Brass EP, Adler S, Sietsema KE, Hiatt WR, Orlando AM, Amato A. Intravenous L-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients. Am J Kidney Dis 2001;37:1018-1028.
195.	Plioplys AV, Plioplys S. Amantadine and L-carnitine treatment of chronic fatigue. Neuropsychobiology 1997;35:16-23.
196.	Ellithorpe RR, Settineri RA, Nicolson GL. Pilot study: reduction of fatigue by use of a supplement containing dietary glycopospholipids. JAm Nutraceutical Assoc 2003;6:23-28.
197.	Agadjanyan M, Vasilevko V, Ghochikyan A, et al. Nutritional supplement (NT Factor) restores mitochondrial function and reduces moderately severe fatigue in aged

	subjects. J Chronic Fatigue Syndr 2003;11(4):1-12.
198.	Singh RB, Neki NS, Kartikey K, et al. Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction. Mol Cell Biochem 2003;246:75-82.
199.	Sahlin K. Metabolic factors in fatigue. Sports Med 1992;13:99-107; Green HJ. Mechanisms of muscle fatigue in intense exercise. J Sports Sci 1997; 15:247-256.
200.	McLester JR, Jr. Muscle contraction and fatigue. The role of adenosine 5'diphosphate and inorganic phosphate. Sports Med 1997;23:287-305.
201.	Dengler R, Wohlfarth K, Zierz S, Jobges M, Schubert M. Muscle fatigue, lactate and pyruvate in mitochondrial myopathy with progressive external ophthalmoplegia. Muscle Nerve 1996;19:456-462.
202.	Roussel M, Bendahan D, Mattei JP, Le Fur Y, Cozzone PJ. P-31 magnetic resonance spectroscopy study of phosphocreatine recovery kinetics by skeletal muscle: the issue of intersubject variability. Biochim Biophys Acta 2000;1457:18-26.
203.	Benington JH, Heller HC. Restoration of brain energy metabolism as the function of sleep. Prog Neurobiol 1995;45:347-360.
204.	Kreuger JM, Obal FJ, Fang J, Kubota T, Taishi P. The role of cytokines in physiological sleep regulation. Ann NYAcad Sci 2001;933:211-221.
205.	Liew FY. Interactions between cytokines and nitric oxide. Adv Neuroimmunol 1995;5:201-209.
206.	Burlet S, Leger L, Cespeglio R. Nitric oxide and sleep in the rat: a puzzling relationship. Neuroscience 1999;92:627-639.

207.	Nijs J, De Meirleir K, Meeus M, McGregor NR, Englebienne P. Chronic fatigue syndrome: intracellular immune deregulations as a possible etiology for abnormal exercise response. <i>Med Hypoth</i> 2004;62:759-765.
208.	Garland EM, Winker R, Williams SM, et al. Endothelial NO synthase polymorphisms and postural tachycardia syndrome. <i>Hypertension</i> 2005;46:1103-1110.
209.	Krukoff TL. Central control of autonomic function: no brakes? <i>Clin Exp Pharmacol Physiol</i> 1998;25:474-478.
210.	Chowdhary S, Townsend JN. Nitric oxide and hypertension: not just an endothelium derived relaxing factor. <i>J Hum Hypertens</i> 2001; 15:219-227.
211.	Hirooka Y, Kishi T, Sakai K, Shimokawa H, Takeshita A. Effect of overproduction of nitric oxide in the brain stem on the cardiovascular response in conscious rats. <i>J Cardiovasc Pharmacol</i> 2003;41(Suppl 1):S 119-5 126.
212.	Akaike T, Suga M, Maeda, H. Free radicals in viral pathogenesis: molecular mechanisms involving superoxide and NO. <i>Proc Soc Exp Biol Med</i> 1998;217:64-73.
213.	Kawashima H, Watanabe Y, Ichiyama T, et al. High concentrations of serum nitrite/nitrate obtained from patients with influenza-associated encephalopathy. <i>Pediatr Int</i> 2002;44:705-707.
214.	Akaike T, Maeda H. Nitric oxide and virus infection. <i>Immunology</i> 2000; 101:300-308.
215.	Suliman HB, Ryan LK, Bishop L, Folz RJ. Prevention of influenza-induced lung injury in mice overexpressing extracellular superoxide dismutase. <i>Am J Physiol Lung Cell Mol Physiol</i> 2001;280:L69-L78.

216.	Mori I, Liu B, Hossain MJ, et al. Successful protection by amantadine hydrochloride against lethal encephalitis caused by highly virulent recombinant influenza A virus in mice. <i>Virology</i> 2002;303:287-296.
217.	Rigden S, Barrager E, Bland JS. Evaluation of the effect of a modified enteropathic resuscitation program in chronic fatigue syndrome patients. <i>J Adv Med</i> 1998; 11:247-262.
218.	Logan AC, Rao AV, Irani D. Chronic fatigue syndrome: lactic acid bacteria may be of therapeutic value. <i>Med Hypoth</i> 2003;60:915-923,
219.	Gomborone JE, Gorard DA, Dewsnap PA, et al. Prevalence of irritable bowel syndrome in chronic fatigue syndrome. <i>J R Coll Physicians Lond</i> 1996;30:512-513.
220.	Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia and temporomandibular disorder. <i>Arch Intern Med</i> 2000;160:221-227.
221.	Chang L. The association of functional gastrointestinal disorders and fibromyalgia. <i>Eur J Surg</i> 1998;(Suppl 583):32-36.
222.	Barton A, Pal B, Whorwell PJ, Marshall D. Increased prevalence of sicca complex and fibromyalgia in patients with irritable bowel syndrome. <i>Am J Gastroenterol</i> 1999;94:1898-1901.
223.	Sperber AD, Carmel S, Neumann L, et al. Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications. <i>Am J Gastroenterol</i> 1999;94:3541-3546.
224.	Irwin C, Falsetti SA, Lydiard RB, et al. Comorbidity of

	posttraumatic stress disorder and irritable bowel syndrome. J Clin Psychiatry 1996;57:576-578.
225.	Kendall-Tackett KA. Physiological correlates of childhood abuse: chronic hyperarousal in PTSD, depression and irritable bowel syndrome. Child Abuse Negl 2000;24:799-810.
226.	Mayer EA, Craske M, Naliboff BD. Depression, anxiety and the gastrointestinal system. J Clin Psychiatry 2001;62(Suppl 8):28-36.
227.	Azpiroz F, Dapoigny M, Pace F, et al. Nongastrointestinal disorders in irritable bowel syndrome. Digestion 2000;62:66-72.
228.	Crissinger KD, Kvietys PR, Granger DN. Pathophysiology of gastrointestinal mucosal permeability. J Intern Med Suppl 1990;732:145-154.
229.	Peters TJ, Bjarnason L. Uses and abuses of intestinal permeability measurements. Can J Gastroenterol 1988;2:127-132.
230.	Rooney PJ, Jenkins RT, Buchanan WW. A short review of the relationship between intestinal permeability and inflammatory joint disease. Clin Exp Rheumatol 1990;8:75-83.
231.	Walker WA. Antigen absorption from the small intestine and gastrointestinal disease. Pediatr Clin North Am 1975;22:731-746.
232.	Jacobson P, Baker R, Lessof M. Intestinal permeability in patients with eczema and food allergy. Lancet 1981;1(8233):1285-1286.
233.	Vojdani A. A single blood test for the detection of food

	allergy, candidiasis, microflora imbalance, intestinal barrier dysfunction, and humoral immunodeficiencies. Biomed Ther 1999;XVII:129-135.
234.	Mann P, Matthews DA, Lane TJ. Food intolerances in patients with chronic fatigue syndrome. In J Eat Disord 1993; 13:203-209,
235.	Miller CS, Prihoda TJ. A controlled comparison of symptoms and chemical intolerances reported in Gulf War veterans, implant recipients and persons with multiple chemical sensitivity. Toxicol Indust Health 1999; 15:386-397.
236.	Ross GH. Clinical characteristics of chemical sensitivity: an illustrative case history of asthma and MCS. Environ Health Perspect 1997; 1 OS(Supp12):437-441.
03-237	Bell IR. Multiple chemical sensitivities. Psychiatric Times 2003;XX(1): January. https://www.psychiatrictimes.com/view/multiple-chemical-sensitivities Volledig in Samenvattingen *****
238.	Becherel PA, Chosidow O, Le Goff L, et al. Inducible nitric oxide synthase and proinflammatory cytokine expression by human keratinocytes during acute urticaria. Mol Med 1997;3:686-694.
239.	Bayou Y, Alonso A, Sanchez Crespo M. Immunoglobulin-E/dinitrophenyl complexes induce nitric oxide synthesis in rat peritoneal macrophages by a mechanism involving CD23 and NF-kappa B activation. Biochem Biophys Res Commun 242:570-574.
240.	van Straaten EA, Koster-Kamphuis L, Bovee-Oudenhoven IM, van der Meer R, Forget PP. Increase urinary nitric oxidation products in children with active coeliac disease.

	Acta Paediatr 1999;88:528-531.
241.	Fargeas MJ, Theodorou V, Weirich B, Fioramonte J, Bueno L. Decrease in sensitization rate and intestinal anaphylactic response after nitric oxide synthase inhibition in a food hypersensitivity model. Gut 1996;38:598-602.
242.	Barau E, Dupont C. Modifications of intestinal permeability during food provocation procedures in pediatric irritable bowel syndrome. J Pediatr Gastroenterol Nutr 1990;11:72-77.
243.	Goyal RK, Hirano L The enteric nervous system. N Engl J Med 1996; 334:1106-1115.
244.	Dawson TM, Brecht DS, Fotuhi PM, Hwang PM, Snyder SH. Nitric oxide synthase and neuronal NADPH diaphorase are identical in brain and peripheral tissues. Proc Natl Acad Sci USA 1991;88:7797-7801.
245.	Xue L, Farrugia G, Miller SM, et al. Carbon monoxide and nitric oxide as neurotransmitters in the enteric nervous system: evidence from genomic deletion of biosynthetic enzymes. Proc Natl Acad Sci USA 2000;97:1851-1855.
246.	Burns GA, Stephens KE. Expression of mRNA for the N-methyl-D-aspartate (NMDAR) receptor and vasoactive intestinal polypeptide (VIP) co-exist in enteric neurons of the rat. J Auton Nerv Syst 1995;55:207-210.
247.	Izzo AA, Capasso R, Pinto L, et al. Effect of vanilloid drugs on gastrointestinal transit in mice. Br J Pharmacol 2001;132:1411-1416.
248.	Fiocchi C. Intestinal inflammation: a complex interplay of immune and nonimmune cell interactions. Am J Physiol 1997;273:G769-G775.

249.	Holzer P. Sensory neurone responses to mucosal noxae in the upper gut: relevance to mucosal integrity and gastrointestinal pain. <i>Neurogastroenterol Motil</i> 2002;14:459-475.
250.	Cortright DN, Szallasi A. Biochemical pharmacology of the vanilloid receptor TRPV 1. An update. <i>Eur J Biochem</i> 2004;271:1814-1819.
251.	Robinson DR, McNaughton PA, Evans ML, Hicks GA. 2004 Characterization of the primary afferent innervation of the mouse colon using retrograde labeling.
252.	Stanghellini V, De Ponti F, De Georgio R, et al. New developments in the treatment of functional dyspepsia. <i>Drugs</i> 2003;63:869-892.
253.	Fritz E, Hammer J, Schmidt B, Eherer AJ, Hammer HF. Stimulation of the nitric oxide-guanosine 3',5'-cyclic monophosphate pathway by sildenafil: effect on rectal muscle tone, distensibility, and perception of health and irritable bowel syndrome. <i>Am J Gastroenterol</i> 2003;98:2253-2260.
254.	Evans R. Nitric oxide and IBD. <i>Inflammation 2003-Sixth World Congress, Canada: Vancouver;2003:August 2-6.</i>
255.	Casellas F, Mourelle M, Papo M, et al. Bile acid induced colonic irritation stimulates intracolonic nitric oxide release in humans. <i>Gut</i> 1996;38:719-723.
256.	Ritchie J. Mechanisms of pain in the irritable bowel syndrome. In: Read N Ed. <i>Irritable Bowel Syndrome</i> . Philadelphia: Grune and Stratton;1985:163-170.
257.	Kolhekar R, Gebhart GE Modulation of spinal visceral nociceptive transmission by NMDA receptor activation in

	the rat. Brain Res 1996;651:215-226.
258.	Rice AS, McMahon SB. Pre-emptive intrathecal administration of an NMDA receptor antagonist (AP-5) prevents hyper-reflexia in a model of persistent visceral pain. Pain 1994;57:335-340.
259.	Robinson DR, McNaughton PA, Evans ML, Hicks GA. Characterization of the primary spinal afferent innervation of the mouse colon using retrograde labelling. Neurogastroenterol Motil 2004; 16:113-124.
260.	Verne GN, Price DD. Irritable bowel syndrome as a common precipitant of central sensitization. Curr Rheumatol Rep 2002;4:322-328.
261.	Xu DZ, Lu Q, Deitch EA. Nitric oxide directly impairs intestinal barrier function. Shock 2002;17:139-145.
262.	Fink MP. Intestinal epithelial hyperpermeability: update on the pathogenesis of gut mucosal barrier dysfunction in critical illness. Curr Opin Crit Care 2003;9:143-151.
263.	Chavez AM, Menconi MJ, Hodin RA, Fink MP. Cytokine-induced intestinal hyperpermeability: role of nitric oxide. Crit Care Med 1999;27:2246-2251.
264.	Han X, Uchiyama I, Sappington PL, et al. NAD ⁺ ameliorates inflammation-induced epithelial barrier dysfunction in cultured enterocytes and mouse ileal mucosa. J Pharmacol Exp Ther 2003;307:443-449.
265.	Chavez AM, Menconi MJ, Hodin RA, Fink MP. Cytokine-induced intestinal hyperpermeability: role of nitric oxide. Crit Care Med 1999;27:2246-2251.
266.	Banan A, Fields JZ, Zhang Y, Keshavarzian A. iNOS upregulation mediates oxidant-induced disruption of F-actin

	and barrier of intestinal monolayers. Am J Phvsiol Gastrointest Liver Physiol 2001;280:G1234-1246.
267.	Jagtap P, Soriano FG, Virag L, et al. Novel phenanthridinone inhibitors of poly (adenosine 5'-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents. Crit Care Med 2002;30:1071-1082.
268.	Kennedy M, Denenberg AG, Szabo C, Salzman AL. Poly(ADP-ribose) synthetase activation mediates increased permeability induced by peroxynitrite in Caco-2BBE cells. Gastroenterology 1998;114:510-518.
269.	Cuzzocrea S, Mazzon E, De Sarro A, Caputi AP. Role of free radicals and poly(ADP-ribose) synthetase in intestinal tight junction permeability. Mol Med 2000;6:766-778.
270.	Sappington PL, Yang R, Yang H, et al. HMGB 1 box increases permeability of Caco-2 enterocyte monolayers and impairs intestinal barrier function in mice. Gastroenterology 2002; 123:790-802.
271.	Banan A, Fields JZ, Zhang Y, Keshavarzian A. iNOS upregulation mediates oxidant-induced disruption of F-actin and barrier intestinal monolayers. Am J Physiol Gastrointest Liver Physiol 2001;280:G 1234-G 1246.

[358] - [359]

HOOFDSTUK – 04

1.	Chen B, Deen WM. Analysis of the effects of cell spacing and liquid depth on nitric oxide and its oxidation products in cell culture. Chem Res Toxicol 2001; 14:135-147.
2.	Lancaster JR. Simulation of the diffusion and reaction of endogenously produced nitric oxide. Proc Natl Acad Sci USA 1994;91:8137-814 1.
3.	Wood J, Garthwaite J. Models of diffusional spread of nitric oxide: implications for neural signaling and its pharmacological properties. Neuropharmacology 1994;33:1235-1244.
4.	Lebovitz RM, Zhang H, Vogel H, et al. Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. Proc Natl Acad Sci USA 1996;93:9782-9787.
5.	Copin S, Gasche Y, Chan PH. Overexpression of copper/zinc superoxide dismutase does not prevent neonatal lethality in mutant mice that lack manganese superoxide dismutase. Free Radic Biol Med 2000;28:1571-1576.
6.	Taylor RR, Friedberg F, Jason LA. A Clinician's Guide to Controversial Illness: Chronic Fatigue Syndrome, Fibromyalgia, Multiple Chemical Sensitivities. Sarasota, FL: Professional Resource Press;2001.
7.	Sorg BA. Multiple chemical sensitivity: potential role for neural sensitization. Crit Rev Neurobiol 1999; 13:283-316.
8.	Fukuda K, Stauss SE, Hickie I, et al. The chronic fatigue

	syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Group. Ann Intern Med 1994;121:953-959.
9.	Pawloski JR, Hess DT, Stamler JS. Export by red blood cells of nitric oxide bioactivity. Nature 2001;409:622-626.
10.	Pall ML. Elevated peroxynitrite as the caused of chronic fatigue syndrome. Medical Hypoth 2000;54:115-125.
11.	American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders. 4th ed. DSM-IV. Washington, DC: American Psychiatric Press; 1994. Reprinted with permission from APA.

[359] - [369]

HOOFDSTUK – 05

1.	Mowbray JF, Yousef GE. Immunology of postviral fatigue syndrome. Br Med Bull 1991;47:886-894.
2.	Behan PO, Bakheit AMO. Clinical spectrum of postviral fatigue syndrome. Br Med Bull 1991;47:793-808.
3.	White PD, Thomas JM, Amess J, et al. The existence of a fatigue syndrome after glandular fever. Ps ychol Med 1995;25:907-916.
4.	Gow JW, Behan WM, Simpsom K, et al. Studies of enterovirus in patients with chronic fatigue syndrome. Clin Infect Dis 1994;18(Suppl 1):S126-S129.
5.	Lloyd A. Postinfectious fatigue. In: Jason LA, Fennell PA, Taylor RR, eds. Handbook of Chronic Fatigue Syndrome. New Jersey: John Wiley and Sons;2003: 108-123.
6.	Kerr JR, Bracewell J, Laing I, et al. Chronic fatigue syndrome and arthralgia following parvovirus B 19 infection. J Rheumatol 2002;29:595-602.
7.	Selden SM, Cameron AS. Changing epidemiology of Ross River virus disease in South Australia. Med J Aust 1996;165:313-317.
8.	Richardson J. Myalgic encephalomyelitis. J Chron Fatigue Syndr 2002; 10(1):65-80.
9.	Shadick NA, Phillips CB, Sangha 0, et al. Musculoskeletal and neurologic outcomes in patients with previously treated

	Lyme disease. Ann Intern Med 1999; 131:919-926.
10.	Sigal LH. Summary of the first 100 patients seen at a Lyme disease referral center. Arn J Med 1990;88:577-581.
11.	Wildman MJ, Smith EG, Groves J, et al. Chronic fatigue following infection by Coxiella burnetii (Q fever): ten-year follow-up of the 1989 UK outbreak cohort. QJM 2002;95:527-538.
12.	Natelson BH, Lange G. A status report on chronic fatigue syndrome. Environ Health Perspect 2002;110(Supp14):673-677.
13.	Pall ML. Elevated, sustained peroxynitrite levels as the cause of chronic fatigue syndrome. Med Hypoth 2000;54:115-125.
14.	Donnay A. On the recognition of multiple chemical sensitivity in medical literature and government policy. Int J Toxicol 1999; 18:383-392.
15.	Donnay A. Carbon monoxide as an unrecognized cause of neurasthenia: a history. In: Penney D, ed. Carbon Monoxide Toxicity. Boca Raton, Florida: CRC; 2000:231-260.
16.	Pall ML. Common etiology of posttraumatic stress disorder, fibromyalgia, chronic fatigue syndrome and multiple chemical sensitivity via elevated nitric oxide/ peroxynitrite. Med Hypoth 2001;57:139-145.
17.	Thom SR, Fisher D, Zhang J, et al. Neuronal nitric oxide synthase and N-methyl-D-aspartate neurons in experimental carbon monoxide poisoning. Toxicol Appl Pharmacol 2004; 194:280-295.
18.	Tahmaz N, Soutar A, Cherrie JW. Chronic fatigue and organophosphate pesticides in sheep farming: a

	retrospective study amongst people reporting to a UK pharmacovigilance scheme. <i>Ann Occup Hyg</i> 2003;47:261-267.
19.	Kennedy G, Abbot NC, Spence V, Underwood C, Belch JJ. The specificity of the CDC- 1994 criteria for chronic fatigue syndrome: comparison of health status in three groups of patients who fulfill the criteria. <i>Ann Epidemiol</i> 2004;14:95-100.
20.	Pall ML, Satterlee Elevated nitric oxide/peroxynitrite mechanism for the common etiology of multiple chemical sensitivity, chronic fatigue syndrome and posttraumatic stress disorder. <i>Ann NYAcad Sci</i> 2001;933:323-329.
21.	Pearn JH. Chronic fatigue syndrome: chronic ciguatera toxin poisoning as a differential diagnosis. <i>Med J Aust</i> 1979;166:309-310.
22.	Racciatti D, Vecchiet J, Ceccomancini A. Ricci F, Pizzigallo E. Chronic fatigue syndrome following toxic exposure. <i>Sci Total Environ</i> 2001;270:27-31.
23.	Lewis RJ. Ion channels and therapeutics: from cone snail venoms to ciguatera. <i>Ther Drug Monit</i> 2000;22:61-64.
24.	Yu XM, Salter MW. Gain control of NMDA-receptor currents by intracellular sodium. <i>Nature</i> 1998;396:469-474.
25.	Li WI, Berman FW, Okino T, et al. Antillatoxin is a marine cyanobacterial toxin that potently activates voltage-gated sodium channels. <i>Proc Nntl Acad Sci USA</i> 2001;98:7599-7604.
26.	Parada CA, Vivancos GG, Tambeli CH, et al. Activation of presynaptic NMDA receptors coupled to NaV 1.8-resistant sodium channel C-fibers causes retrograde mechanical

	nociceptor sensitization. Proc Natl Acad Sci USA 2003;100:2923-2928.
27.	Verleye M, Andre N, Heulard I, Gillardin JM. Nefopam blocks voltage-sensitive sodium channels and modulates glutamatergic transmission in rodents. Brain Res 2004;1013:249-255.
28.	Dravid SM, Baden DG, Murray Tft Brevetoxin augments NMDA receptor signaling in murine neocortical neurons. Brain Res 2005;1031:30-38.
29.	Berman FW, Murray TE Brevetoxins cause acute excitotoxicity in primary cultures of rat cerebellar granule neurons. JPharmacol Exp Ther 1999;290:439-444.
30.	De Meirleir K, De Becker P, Nijs J, et al. CFS etiology, the immune system, and infection. In: Englebienne P. De Meirleir K, eds, Chronic Fatigue Syndrome, A Biological Approach. Boca Raton: CRC Press;2002.
31.	Brunet LR. Nitric oxide and parasitic infections. Int Immunopharmacol 2001;1:1457-1467.
32.	Khan IA, Schwartzman JD, Matsuura T, Kasper LH. Dichotomous role for nitric oxide during acute Toxoplasma gondii infection in mice. Proc Natl Acad Sci USA 1997;94:13955-13960.
33.	Scharton-Kersten TM, Yap G, Magram J, Sher A. Inducible nitric oxide is essential for host control of persistent but not acute infection with the intracellular pathogen Toxoplasma gondii. J Exp Med 1997;185:1261-1273.
34.	Bell DS. The Doctor's Guide to Chronic Fatigue SYndrome. Addison Wesley Reading, Massachusetts: Publishing Co.; 1995.

35.	Fukuda K, Strauss SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. <i>Ann Intern Med</i> 1994; 121:953-959.
36.	Carruthers BM, Jain AK, De Meirleir KL, et al. Myalgic encephalomyelitis/ chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. <i>J Chronic Fatigue Syndr</i> 2003; 11(1):7-115.
37.	Sharpe M, Archard LC, Banatvala JE, et al. A report-chronic fatigue syndrome: guidelines for research. <i>J R Soc Med</i> 1991;84:118-121.
38.	Komaroff AL, Buchwald DS. Chronic fatigue syndrome: an update. <i>Ann Rev Med</i> 1998;49:1-13.
39.	Jason LA, Richman JA, Rademaker AW, et al. A community based study of chronic fatigue syndrome. <i>Arch Intern Med</i> 1999; 159:2129-2137.
40.	Pall ML. Elevated peroxynitrite as the cause of chronic fatigue syndrome: other inducers and mechanisms of symptom generation. <i>J Chronic Fatigue Syndr</i> 2000;7(4):45-58.
41.	Pall ML. Levels of nitric oxide synthase product citrulline are elevated in sera of chronic fatigue syndrome patients. <i>J Chronic Fatigue Syndr</i> 2002; 10(3/4): 37-41.
42.	Pall ML. Cobalamin used in chronic fatigue syndrome therapy is a nitric oxide scavenger. <i>J Chronic Fatigue Syndr</i> 2001;8(2):39-44.
43.	Smirnova IV, Pall ML. Elevated levels of protein carbonyls in sera of chronic fatigue syndrome patients. <i>Mol Cell Biochem</i> 2003;248:93-95.
44.	Pall ML. Nitric oxide and the etiology of chronic fatigue

	syndrome: Giving credit where credit is due. Med Hypotheses 2005;Jun2.
45.	Chao CC, De La Hunt M, Hu S, Close K, Peterson PK. Immunologically mediated fatigue: a murine model. Clin Immunol Immunopathol 1992;64:161-165.
46.	Sheng WS, Hu S, Lamkin A, Peterson PK, Chao CC. Susceptibility to immunologically mediated fatigue in C57BL/6 versus Balb/C mice. Clin Immunol Immunopathol 1996;81:161-167.
47.	Sheng WS, Lin JC, Apple F, Hu S, Peterson PK, Chao CC. Brain energy stores in C57BL/6 mice after C. parvum injection. Neuroreport 1999;10:177-81.
48.	Sheng WS, Hu S, Ding JM, Chao CC, Peterson PK. Cytokine expression in the mouse brain in response to immune activation by Corynebacterium parvum. Clin Diagn Lab Immunol 2001;8:446-448.
49.	Ambs S, Ogunfusika MO, Merriam WG, Bennett WP, Billiar TR, Harris CC. Up-regulation of inducible nitric oxide synthase expression in cancer-prone p53 knockout mice. Proc Natl Acad Sci USA 1998;95:8823-8828.
50.	Cook HT, Bune AJ, Jansen AS, Taylor GM, Loi RK, Cattell V. Cellular localization of inducible nitric oxide synthase in experimental endotoxic shock in the rat. Clin Sci (Lond). 1994;87:179-186.
51.	Kurup RK, Kurup PA. Hypothalamic digoxin, cerebral chemical dominance and myalgic encephalomyelitis. Int J Neurosci 2003;113:445-457.
52.	Patarca R. Cytokines and chronic fatigue syndrome. Ann NY Acad Sci USA 2001;933:185-200.

53.	Vernon SD, Unger ER, Dimulescu IM, Rajeevan M, Reeves WC. Utility of the blood for gene expression profiling and biomarker discovery in chronic fatigue. Dis Markers 2002;18:193-199.
54.	Buskila D. Fibromyalgia, chronic fatigue syndrome and myofascial pain syndrome. Curr Opin Rheumatol 2001;13:117-127.
55.	Cannon JG, Angel JB, Ball RW, et al. Acute phase responses and cytokine secretion in chronic fatigue syndrome. J Clin /nanuunol 1999;19:414-421.
56.	Droge W, Holm E. Role of cysteine and glutathione in HIV infection and other diseases associated with muscle wasting and immunological dysfunction. FASEB J 1997;11:1077-1089.
57.	Bounos G, Molson J. Competition for glutathione precursors between the immune system and the skeletal muscle: pathogenesis of chronic fatigue syndrome. Med Nypot{i 1999;53:347-349.
58.	McGregor NR, Dunstan RH, Zerbies M, et al. Preliminary determination of the association between symptom expression with urinary metabolites in subjects with chronic fatigue syndrome. Biochem Mol Med 1996;58:85-92.
59.	Young A. 1999 Hypercitricemia in chronic fatigue syndrome. Presentation at the 1999 Sydney ME/CFS Conference.
60.	Carpman V. CFIDS treatment: the Cheney clinic's strategic approach. CFIDS Chronicle Spring 1995:38-45.
61.	Hoh D. Treatment at the Cheney clinic. CFIDS Chronicle 1998;11(4):13-14.

62.	Goldstein JA. Tuning the Brain: Principles and Practice of Neurosomatic Medicine. Binghamton, NY: Haworth Medical Press; 2004.
63.	Manuel y Keenoy B, Moorkens G et al. Magnesium status and parameters of the oxidant-antioxidant balance in patients with chronic fatigue: effects of supplementation with magnesium. J Am Coll Nutr 2000;19:374-382.
64.	Werbach MR. Nutritional strategies for treating chronic fatigue syndrome. Altern Med Rev 2000;5:93-108.
65.	Tarello W. Chronic Fatigue Syndrome (CFS) in 15 dogs and cats with specific biochemical and microbiological. Comp Immunol Microbiol Infect Dis 2001; 24:165-185.
66.	Tarello W. Chronic fatigue and immune dysfunction syndrome associated with Staphylococcus spp. bacteraemia responsive to thiacetarsamide sodium in eight birds of prey. J Vet Med B Infect Dis Vet Public Health 2001;48:267-281.
67.	Fulle S, Mecocci P, Fano G, et al. Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. Free Radic Biol Med 2000;15:1252-1259.
68.	Richards RS, Roberts TK, Mathers MB, Dunstan RH, McGregor NR, Butt HL. Investigation of erythrocyte oxidative damage in rheumatoid arthritis and chronic fatigue syndrome. J Chronic Fatigue Syndr 2000;6(1):37-46.
69.	Richards RS, Roberts TK, McGregor NR, Dunstan RH, Butt HL. Blood parameters indicative of oxidative stress are associated with symptom expression in chronic fatigue syndrome. Redox Rep 2000;5:35-41.
70.	Richards RS, Roberts TK, Dunstan RH, McGregor NR, Butt

	HL. Free radicals in chronic fatigue syndrome: cause or effect? Redox Rep 2000;5:146-147.
71.	Keenoy BM, Moorkens G, Vertommen J, DeLeeuw I. Antioxidant status and lipoprotein oxidation in chronic fatigue syndrome. Life Sciences 2001;68: 2037-2049.
72.	Manuel y Keenoy B, Moorkens G, Vertommen J, et al. Magnesium status and parameters of the oxidant-antioxidant balance in patients with chronic fatigue: effects of supplementation with magnesium. JAm Coll Nutr 19:374-382.
73.	Vecchiet J, Cipollone F, Falasca K, et al. Relationship between musculoskeletal symptoms and blood markers of oxidative stress in patients with chronic fatigue syndrome. Neurosci Lett 2003;335:151-154.
74.	Jammes Y, Steinberg JG, Mambrini O, et al. Chronic fatigue syndrome: assessment of increased oxidative stress and altered muscle excitability in response to incremental exercise. J Intern Med 2005;257:299-310.
75.	Kennedy G, Spence VA, McLaren M, et al. Oxidative stress levels are raised in chronic fatigue syndrome and are associated with clinical symptoms. Free Radic Biol Med 2005;39:584-589.
76.	Singh A, Garg V, Gupta S, Kulkarni SK. Role of antioxidants in chronic fatigue syndrome in mice. Indian J Exp Biol 2002;40:1240-1244.
77.	Logan AC, Wong C. Chronic fatigue syndrome: oxidative stress and dietary modifications. Altern Med Rev 2001;6:450-459,
78.	Rigden S, Barrager E, Bland JS. Evaluation of the effect of

	a modified entero-hepatic resuscitation program in chronic fatigue syndrome patients. J Adv Med 1998; 11:247-262.
79.	Majib A. Ascorbic acid reverses abnormal erythrocyte morphology in chronic fatigue syndrome. Am J Clin Pathol 1991;94:515.
80.	Behan WM, More IA, Behan PO. Mitochondrial abnormalities in the postviral fatigue syndrome. Acta Neuropathol 1991;83:61-65.
81.	Plioplys AV, Plioplys S. Serum levels of carnitine in chronic fatigue syndrome: clinical correlates. Neuropsychobiology 1995;32:132-138.
82.	Kuratsune H, Yamaguti K, Lindh G, et al. Low levels of serum acylcarnitine in chronic fatigue syndrome and chronic hepatitis type C but not seen in other diseases. Int JMol Med 1998;2:51-56.
83.	Wong R, Lopaschuk G, Zhu G, et al. Skeletal muscle metabolism in the chronic fatigue syndrome. In vivo assessment by ³¹ P nuclear magnetic resonance. Chest 1992;102:1716-1722.
84.	Barnes PR, Taylor DJ, Kemp GJ, Radda GK. Skeletal muscle bioenergetics in the chronic fatigue syndrome. JNeurol Neurosurg Psychiatry 1993;56:679-683.
85.	McCully KK, Natelson BH, Iotti S, Sisto S, Leigh JS Jr. Reduced oxidative muscle metabolism in chronic fatigue syndrome. Muscle Nerve 1997;19:621-625.
86.	Vecchiet L, Monanari G, Pizzigally E, et al. Sensory characterization of somatic parietal tissues in humans with chronic fatigue syndrome. Neurosci Lett 1996; 208:117-120.

87.	Hayakawa M, Hattori K, Sugiyama S, Ozawa T. Age-related oxygen damage and mutations in mitochondrial DNA in human hearts. <i>Biochem Biophys Res Commun</i> 1992;189:979-985.
88.	Farquhar WB, Hunt BE, Tayler JA, Darling SE, Freeman R. Blood volume and its relation to peak O ₂ consumption and physical activity in patients with chronic fatigue. <i>Am J Physiol Heart Circ Physiol</i> 2002;282:H66-H71.
89.	McCully KK, Smith S, Rajaei S, Leigh JS, Natelson BH. Muscle metabolism with blood flow restriction in chronic fatigue syndrome. <i>J Appl Physiol</i> 2004; 96:871-878.
90.	Kaushik N, Fear D, Richards SC, et al. Gene expression in peripheral blood mononuclear cells from patients with chronic fatigue syndrome. <i>J Clin-Pathol</i> 2005; 58:826-832.
91.	Plioplys AV, Plioplys S. Amantadine and L-carnitine treatment of chronic fatigue. <i>Neuropsychobiology</i> 1997;35:16-23.
92.	Vermeulen RC, Scholte HR. Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome. <i>Psychosom Med</i> 2004; 66:276-282.
93.	Ellithorpe RR, Settineri RA, Nicolson GL. Pilot study: reduction of fatigue by use of a supplement containing dietary glycerophospholipids. <i>J Am Nutraceutical Assoc</i> 2003;6:23-28.
94.	Agadjanyan M, Vasilevko V, Ghochikyan A, et al. Nutritional supplement (NT Factor'M) restores mitochondrial function and reduces moderately severe fatigue in aged subjects. <i>J Chronic Fatigue Syntl</i> 2003;11(4):1-12.

95.	Aaron LA, Herrell R, Ashton S, et al. Comorbid clinical conditions in chronic fatigue: a co-twin study. J Gen Intern Med 2001;16:24-31.
96.	Buchwald D, Herrell R, Ashton S, et al. A twin study of chronic fatigue. Psychosom Med 2001;63:936-943.
97.	Keller RH, Lane JL, Klimas N, et al. Association between HLA class II antigens and the chronic fatigue immune dysfunction syndrome. Clin Infect Dis 1994; 18(Suppl 1):S154-S156.
98.	Torpy DJ, Bachmann AW, Grice JE, et al, Familial corticosteroid-binding globulin deficiency due to a novel null mutation: association with fatigue and relative hypotension. J Clin Endocrinol Metab 2001;86:3692-3700.
99.	Torpy DJ, Bachmann AW, Gartside M, et al. Association between chronic fatigue syndrome and the corticosteroid-binding globulin gene ALA SER224 polymorphism. Endocrine Res 2004;30:417-429.
100.	Narita M, Nishigami N, Narita N, et al. Association between serotonin transporter gene polymorphism and chronic fatigue syndrome. Biochem Biophys Res Commun 2003;311:264-266.
101.	Vladutiu GD, Natelson BH. Association of medically unexplained fatigue with ACE insertion/deletion polymorphism in Gulf War veterans. Muscle Nerve 2004;30:38-43,
102.	Das UN. Long-chain polyunsaturated fatty acids interact with nitric oxide, superoxide anion, and transforming growth factor-beta to prevent essential human hypertension. Eur J Clin Nutr 2004;58:195-203.

103.	Wolf G. Free radical production and angiotensin. <i>Curr Hypertens Rep</i> 2000;2:167-173.
104.	Rowe PC, Barron DF, Calkins H, Maumenee IH, Tong PY, Geraghty MT. Orthostatic intolerance and chronic fatigue associated with Ehlers-Danlos syndrome. <i>J Pediatr</i> 1999; 135:494-499.
105.	Yeowell HN, Pinnell SR. The Ehlers-Danlos syndromes. <i>Seinin Derinatol</i> 1993;12:229-240.
106.	de Paepe A. The Ehlers-Danlos syndrome: a heritable collagen disorder as a cause of bleeding. <i>Thromb Haemost</i> 1996;75:379-386.
107.	Kuivaniemi H, Tromp G, Prockop DJ. Mutations in fibrillar collagens (types I, II, II, and XI) fibril-associated collagen (type IX), and network-forming collagen (type X) cause a spectrum of diseases of bone, cartilage, and blood vessels. <i>Hum. Mutat</i> 1997;9:300-315.
108.	McGregor NR, Dunstan RH, Butt HL, et al. A preliminary assessment of the association of SCL-90-R psychological inventory responses with changes in urinary metabolites in patients with chronic fatigue syndrome. <i>J Chronic Fatigue Syndr</i> 1997;3(1):17-37.
109.	Jones MG, Cooper E, Amjad S, Goodwin SC, Barron JL, Chambers RA. Urinary and plasma organic acids and amino acids in chronic fatigue syndrome. <i>Clin Chim Acta</i> 2005;361:150-158.
110.	Hokama Y, Uto GA, Palafox NA, et al. Chronic phase lipids in sera of chronic fatigue syndrome (CFS), chronic ciguatera fish poisoning (CCFP), hepatitis B, and cancer with antigenic epitope resembling ciguatoxin, as assessed with MAbCTX. <i>J Cl in Lab Anal</i> 2003;17:132-139.

111.	Buchwald D, Wener MH, Pearlman T, Kith P. Markers of inflammation and immune activation in chronic fatigue and chronic fatigue syndrome. J Rheumatol 1997;24:372-376.
112.	Fehsel K, Plewe D, Kolb-Bachofen. Nitric oxide induced expression of Creactive protein islet cells is a very early marker for islet stress in the rat pancreas. Nitric Oxide 1997;1:254-262.
113.	Ford ES, Liu S, Mannino DM, et al. C-reactive protein concentrations and concentrations of blood vitamins, carotenoids and selenium among United State adults. Eur J Clin Nutr 2003;57:1157-1163.
114.	Horrobin DE Post-viral fatigue syndrome, viral infections in atopic eczema, and essential fatty acids. Med Hypoth 1990;32:211-217.
115.	Liu Z, Wang D, Xue Q, et al. Determination of fatty acid levels in erythrocyte membranes in patients with chronic fatigue syndrome. Nutr Neurosci 2004; 6:389-392.
116.	Berg D, Berg LH, Couvaras J, Harrison H. Chronic fatigue syndrome and/or fibromyalgia as a variation of antiphospholipid antibody syndrome: an explanatory model and approach to laboratory diagnosis. Blood Coagul Fibrinolysis 2004; 10: 435-438.
117.	Hannan KL, Berg DE, Baumzweiger W, et al. Activation of the coagulation system in Gulf War Illness: a potential pathophysiologic link with chronic fatigue syndrome. A laboratory approach to diagnosis. Blood Coagul Fibrinolysis 2000; 11:673-678.
118.	Horkko S, Miller E, Dudl E, et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal

	antibodies to epitopes of oxidized low density lipoproteins. J Clin Invest 1996;98:815-825.
119.	Iuliano L, Practico D, Ferro D, et al. Enhanced lipid peroxidation in patients positive for antiphospholipid antibodies. Blood 1997;90:3931-3935.
120.	Pawlak K, Borawski J, Naumnik B, Mysliwiec M. Relationship between oxidative stress and extrinsic coagulation pathway in haemodialized patients. Throm Res 2003;109:247-251.
121.	Tomiyama K, Kushiro T, Okazaki R, et al. Influences of increased oxidative stress on endothelial function, and fibrinolysis in hypertension associated with glucose intolerance. Hypertens Res 2003;26:295-300.
122.	Chaudhuri A, Watson WS, Pearn J, Behan PO. The symptoms of chronic fatigue syndrome are related to abnormal ion channel function. Med Hypoth 2000; 54:59-63.
123.	Zhang C, Imam SZ, Ali SF, Mayeux PR. Peroxynitrite and the regulation of Na ⁺ , K ⁺ -ATPase activity by angiotensin II in the rat proximal tubule. Nitric Oxide 2002;7:30-35.
124.	Muriel P, Casteneda G, Ortega M, Noel F. Insights into the mechanism of erythrocyte Na ⁺ /K ⁺ -ATPase inhibition by nitric oxide and peroxynitrite anion. JAppl Toxicol 2003;23:275-278.
125.	http://phoenix-cfs.org/Cardio%20IVa%20Superoxide.htm
	126. Dulhunty A, Haarman C, Green D, Hart J. How many cysteine residues regulate ryanodine receptor channel activity? Antioxid Redox Signal 2000;2:27-34.
127.	Suhadolnik RJ, Reichenbach NL, Hitzges P, et al.

	Upregulation of the 2-5A synthetase/RNase L pathway associated with chronic fatigue syndrome. Clin Infect Dis 1994;18(Suppl 1):S96-S104.
128.	Suhadolnik RJ, Peterson DL, O'Brien K, et al. Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome. J Interferon Cytokine Res 1997;17:377-385.
129.	Shetzline SE, Suhadolnik RJ. Characterization of a 2',5'-oligoadenylate (25A)-dependent 35 kDa RNase: azido photoaffinity labeling and 2-5A-dependent activation. J Biol Chem 2001;276:23707-23711.
130.	Shetzline SE, Martinand-Mari C, Reichenbach NL, et al. Structural and functional features of the 37-kDa 2-5A-dependent RNase L in chronic fatigue syndrome. J Interferon Cytokine Res 2002;22:443-456.
131.	De Meirleir K, Bisbal C, Campine I, et al. A 37 kDa 2-5A binding protein as a potential biochemical marker for chronic fatigue syndrome. Am J Med 2000; 108:99-105.
132.	Suhadolnik RJ, Peterson DL, Reichenbach BS, et al. Clinical and biochemical characteristics differentiation chronic fatigue syndrome from major depression and healthy control populations: relation to dysfunction of the RNase L pathway. J Chronic Fatigue Syndr 2004;12(1):5-35.
133.	Fremont M, El Bakkouri K, Vaeyens F, et al. 2',5'-Oligoadenylate size is critical to protect RNase L against proteolytic cleavage in chronic fatigue syndrome. Exp Mol Pathol 2005;78:239-246.
134.	Choppa PC, Uojdani A, Tagle C, Andrin R, Magtoto L. Multiplex PCR for detection of <i>Mycoplasma fermentans</i> , M.

	hominia and <i>M. penetrans</i> in cell cultures and blood samples of patients with chronic fatigue syndrome. <i>Mol Cell Probes</i> 1998;12:301-308.
135.	Nicolson GL, Gan R, Haier J. Evidence for <i>Brucella</i> spp. and <i>Mycoplasma</i> spp. co-infections in blood of chronic fatigue syndrome patients. <i>J Chronic Fatigue Syndr</i> 2004;12(2):5-17.
136.	Nasralla M, Haier J, Nicolson GL. Multiple mycoplasmal infections detected in blood of chronic fatigue syndrome and fibromyalgia patients. <i>Eur J Clin Microbiol Infect Dis</i> 1999;18:859-865.
137.	Nicolson GL, Gan R, Haier J. Multiple co-infections(<i>Mycoplasma</i> , <i>Chlamydia</i> , human herpes virus-6) in blood of chronic fatigue syndrome patient: association of signs and symptoms. <i>APMIS</i> 2003;111:557-566.
138.	Nijs J, Nicolson GL, de Becker P, Coomans D, De Meirleir K. High prevalence of mycoplasmal infections among European chronic fatigue syndrome patients. Examination of four mycoplasmal species in chronic fatigue syndrome patients. <i>FEMS Immunol Med Microbiol</i> 2002;34:209-214.
139.	Lane RJ, Soteriou BA, Zhang H, Archard LC. Enterovirus related metabolic myopathy: a postviral fatigue syndrome. <i>J Neurol Neurosurg Psychiatry</i> 2003; 74:1382-1386.
140.	Douche-Aourik F, Berlier W, Feasson L, et al. Detection of enterovirus in human skeletal muscle from patients with chronic inflammatory muscle disease or fibromyalgia and healthy subjects. <i>J Med Virol</i> 2003;71:540-547.
141.	Lane RJM, Soteriou BA, Zhang H, Archard LC. Enterovirus related metabolic myopathy: a postviral fatigue syndrome. <i>J Neurol Neurosurg Psychiatry</i> 2003; 74:1382-1286.

142.	Dunstan RH, McGregor NR, Butt HL, Roberts TK. Biochemical and microbiological anomalies in chronic fatigue syndrome: the development of laboratory based tests and possible role of toxic chemicals. JNutrEnviron Med 1999;9:97-108.
143.	Jason LA, Taylor RR. Applying cluster analysis to define typology of chronic fatigue in medically-evaluated, random community sample. Psychol Health 2002; 17:323-337.
144.	Natelson BH, Weaver SA, Tseng CL, Ottenweller JE. Spinal fluid abnormalities in patients with chronic fatigue syndrome. Clin Diagn Lab Immunol 2005; 12:52-55.
145.	Ramsay MA. Myalgic Encephalomyelitis and Postviral Fatigue State: The Saga of Royal Free Disease. 2nd ed. London: Gower; 1988,
146.	Demitrack MA, Crofford U. Evidence for and pathophysiologic implications of the hypothalamic-pituitary-adrenal axis dysregulation in fibromyalgia and chronic fatigue syndrome. Ann NYAcad Sci 1998;840:684-697.
147.	Adler GK, Manfredsdottir VF, Rackow RM. Hypothalamic-pituitary-adrenal axis function in fibromyalgia and chronic fatigue syndrome. The Endocrinologist 2002; 12:513-524.
148.	Ottenweller JE, Sisto SA, McCarty RC, Natelson BH. Hormonal responses to exercise in chronic fatigue syndrome. Neuropsychobiology 2001;43:34-41.
149.	Scott LV, The J, Reznick R, Martin A, Sohaib A, Dinan TG. Small adrenal glands in chronic fatigue syndrome: a preliminary computer tomography study. Endocrinology 1999;24:759-768.

150.	Neeck G, Crofford U. Neuroendocrine perturbations in fibromyalgia and chronic fatigue syndrome. <i>Rheum Dis Clin North Am</i> 2000;26:989-1002.
151.	Torpy DJ. Neuroendocrinology, genetics and chronic fatigue syndrome. <i>CFS Res Rev</i> 2001;2(4):1-3.
152.	Baschetti R. Chronic fatigue syndrome, exercise, cortisol and lymphadenopathy. <i>J Intern Med</i> 2005;258:291-292.
153.	Segal TY, Hindmarsh PC, Viner RM. Disturbed adrenal function in adolescents with chronic fatigue syndrome. <i>JPediatrEndocrinol Metab</i> 2005; 18:295-301.
154.	LaManca JJ, Sisto SA, DeLuca J, et al. Influence of exhaustive treadmill exercise on cognitive functioning in chronic fatigue syndrome. <i>Am J Med</i> 1998; 105(3A):59S-65S.
155.	Peckerman A, LaManca JJ, Dahl KA, et al. Abnormal impedance cardiography predicts symptom severity in chronic fatigue syndrome. <i>Am J Med</i> 2003; 326:55-60.
156.	Peckerman A, LaManca JJ, Qureshi B, et al. Baroreceptive reflex and integrative stress responses in chronic fatigue syndrome. <i>Psychosom Med</i> 2003;65: 889-895.
157.	Aoyama T, Matsui T, Novikov M, et al. Serum and glucocorticoid-responsive kinase-1 regulates cardiomyocyte survival and hypertrophic response. <i>Circulation</i> 2005;111:1653-1659.
158.	Narayanan N, Yang C, Xur A. Dexamethasone treatment improves sarcoplasmic reticulum function and contractile performance in aged myocardium. <i>Mol Cell Biochem</i> 2004;266:31-36.
159.	Chiu CZ, Nakatani S, Zhang G, et al. Prevention of left

	ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol 2005;95:143-146.
160.	Iga K, Hori K, Gen H. Deep negative T waves associated with reversible left ventricular dysfunction in acute adrenal crisis. Heart Vessels 1992;7:107-111.
161.	Allolio B, Ehse W, Steffen HM, Muller R. Reduced lymphocyte beta 2adrenoceptor density and impaired diastolic left ventricular function in patients with glucocorticoid deficiency. Clin Endocrinol 1994;40:769-775.
162.	Boachour G, Tirot P, Varache N, et al. Hemodynamic changes in acute adrenal insufficiency. Intensive Care Med 1994;20:138-141.
163.	Emir M, Ozisik K, Cagli K, et al. Beneficial effect of methylprednisone on cardiac myocytes in a rat model of severe brain injury. Tohoku J Exp Med 2005; 207:119-124.
164.	Shojaiefard M, Christie DL, Lang F. Stimulation of the creatine transporter SLC6A8 by the protein kinases SGK1 and SGK3. Biochem Biophys Res Commun 2005;334:742-746.
165.	Boehmer C, Wilhelm V, Palmada M, et al. Serum and glucocorticoid inducible kinases in the regulation of the cardiac sodium channel SCN5A. Cardiovasc Res 2003;57:1079-1084.
166.	Conwell LS, Gray LM, Delbridge RG, Thomsett MJ, Batch JA. Reversible cardiomyopathy in paediatric Addison's disease-a cautionary tale. J Pediatr Endocrinol Metab 2003;16:1191-1195.

167.	Hyde BM, ed. The Clinical and Scientific Basis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Ottawa, Canada: The Nightingale Research Foundation; 1992.
------	--

[369] - [372]

HOOFDSTUK – 06

Hydroxocobalamine B12 en Siroxat

06-001	Ellis FR, Nasser S. A pilot study of vitamin B12 in the treatment of tiredness. Br J Nutr 1973;30:277-283. https://pubmed.ncbi.nlm.nih.gov/4583554/ - abstract
06-002	Bjorkegren K. Vitamin B12, chronic fatigue and injection therapy. Lakartidningen 1999;96:5610. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5301046/
▲ 06-003	Wiebe E. N of 1 trials. Managing patients with chronic fatigue syndrome: two case reports. Can Fam Physician 1996;42:2214-2217. Als pdf 4blz Vertaald Artikel
4.	http://www.drmyhil.co.uk/article.cfm?id=341 (404)
06-005	Lapp CW. Using vitamin B-12 for the management of CFS. The CFIDS Chronicle 1999;12(6):14-16. B12 Als Noors artikel Volledig in MAP **** ^o
6.	Hoh D. Treatment at the Cheney clinic. The CFIDS Chronicle 1998;1(4):13-14. niet gevonden
7.	Pall ML. Cobalamin used in chronic fatigue syndrome therapy is a nitric oxide scavenger. J Chronic Fatigue Syndr 2001;8(2):39-44.
8.	Gaby AR. Intravenous nutrient therapy: the "Myers' cocktail". Altern Med Rev 2002;7:389-403.
9.	Gaby AR. Literature review & commentary. Townsend Letter for Doctors & Patients 1997;Feb/Mar.
10.	http://utopia.knoware.nl/

11.	http://www.wholehealthmd.com/news/viewarticle/1,1513,1045,00.html
12.	Leroy J, Haney Davis I, Jason LA. Data derived from "Treatment Efficacy: A survey of 305 MCS patients" The CFIDS Chronicle 1996;Winter:52-53.
13.	Lawhorne L, Rindgahl D. Cyanocobalamin injections for patients without documented deficiency. JAMA 1989;261:1920-1923.
14.	Mellman h Willard HF, Youngdahl-Turner P, Rosenberg LE. Cobalamin coenzyme synthesis in normal and mutant human fibroblasts. Evidence for a processing enzyme activity deficient in cb1C cells. J Biol Chem. 1979;254:11847-11853.
15.	Rochelle LG, Morana SJ, Kruszyna H, et al. Interactions between hydroxocobalamin and nitric oxide (NO): Evidence for a redox reaction between NO and reduced cobalamin and reversible NO binding to oxidized cobalamin. J Pharmacol Expt Therapeut 1995;275:48-52. B12
16.	Ellis A, Lu H, Li CG, Rand MJ. Effects of agents that inactivate free radical NO(NO') released from the nitroxyl anion donor Angeli's salt. Br J Pharmacol 2001;134:521-528.
17.	Zheng D, Yan L, Birke RL. Electrochemical and spectral studies of the reaction of aquocobalamin with nitric oxide and nitric ion. Inorg Chem 2002;41: 2548-2555.
18.	Rajanayagam MAS, Li CG, Rand MJ. Differential effects of hydroxocobalamin in NO-mediated relaxations of rat aorta and anococcygeus muscle. Br J Pharmacol 1993;108:3-5. B12

19.	Greenberg SS, Xie J, Zatarain JM, Kapusta DR, Miller MJ. Hydroxocobalamin (vitamin B12a) prevents and reverses endotoxin-induced hypotension in rodents: role of nitric oxide. <i>J Pharmacol Exp Therapeut</i> 1995;273:257-265.
20.	Wanstall JC, Jeffery TK, Gambino A, et al. Vascular smooth muscle relaxation mediated by nitric oxide donors: a comparison with acetylcholine, nitric oxide and nitroxyl ion. <i>Br J Pharmacol</i> 2001; 134:463-472.
21.	Tracey A, Bunton D, Irvine J, MacDonald A, Shaw AM. Relaxation of bradykinin in bovine pulmonary supernumerary arteries can be mediated by both a nitric oxide-dependent and -independent mechanism. <i>Br J Pharmacol</i> 2002; 137:538-544.
22.	Nabeyrat E, Jones GE, Fenwick PS, et al. Mitogen-activated protein kinases mediate peroxynitrite-induced cell death in human bronchial epithelial cells. <i>Am J Physiol Lung Cell Mol Biol</i> 2003;284:L1112-L1120.
23.	Schubert R, Kein U, Wulfsen I, et al. Nitric oxide donor sodium nitroprusside dilates rat small arteries by activation of inward rectifies potassium channels. <i>Hypertension</i> 2004;43:891-896.
24.	Weinberg JB, Sauls DL, Misukonis MA, Shugars DC. Inhibition of productive human immunodeficiency virus-1 infection by cobalamins. <i>Blood</i> 1995;86: 1281-1287.
25.	Weinberg JB, Misukonis MA, Shami PJ et al. Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages. <i>Blood</i> 1995;86:1184-1195.
26.	van der Kuy PH, Merkus FW, Lohman JJ, ter Berg JW,

	Hooymans PM. Hydroxocobalamin, a nitric oxide scavenger, in the prophylaxis of migraine: an open pilot study. <i>Cephalagia</i> 2002;22:513-519. B12
27.	Simpson LO, Murdoch JC. Herbison GP. Red cell shape changes following trigger finger fatigue in subjects with chronic tiredness [CFS] and healthy controls. <i>New Zealand Medical Journal</i> 1993;106:104-107.
28.	http://listserv.nodak.edu/scripts/wa.exe.?A2=ind9905D&L=co-cure&P=R356
29.	Deliconstatinos G, Villiotou V, Stavrides JC, Salemes N, Gogas J. Nitric oxide and peroxynitrite production by human erythrocytes: a causative factor of toxic anemia in breast cancer patients. <i>Anticancer Res</i> 1995; 15:1435-1446.
30.	Kaslow JE, Rucker L, Onishi R. Liver extract-folic acid-cyanocobalamin vs placebo for chronic fatigue syndrome. <i>Arch Intern Med</i> 1989;149:2501-2503.
31.	Regland B, Andersson M, Abrahamsson L, Bagby J, Dyrehag LE, Gottfries CG. Increased concentrations of homocysteine in the cerebrospinal fluid in patients with fibromyalgia and chronic fatigue syndrome. <i>Scand J Rheumatol</i> 1997; 26:301-307.
32.	Newbold HL. Vitamin B-12: a placebo or neglected therapeutic tool. <i>Med Clin North Am</i> 1989;73:155-164.
33.	Akyol O, Zoroglu SS, Armutcu F, Sahin S, Gurel A. Nitric oxide as a pathophysiological factor in neuropsychiatric disorders. <i>In Vivo</i> 2004;18:377-390.
34.	Finkel MS, Laghrissi-Thode F, Pollock BG, Rong J. Paroxetine is a novel nitric oxide synthase inhibitor. <i>Psychopharmacol Bull</i> 1996;32:653-658.

	Seroxat https://pubmed.ncbi.nlm.nih.gov/8993087/
35.	Angulo J, Peiro C, Sanchez-Ferrer CF, et al. Differential effects of serotonin reuptake inhibitors on erectile responses, NO-production, and neuronal NO synthase expression in rat corpus cavernosum tissue. Brit J Pharmacol 2001;134: 1190-1194.
36.	Wegener G, Volke V, Harvey BH, Rosenberg R. Local, but not systemic, administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity. Brain Res 2003;959:128-134.
37.	Altschuler EL, Kast RE. Paroxetine for hepatopulmonary syndrome? Med Hypoth 2004;62:446-44733. Seroxat <u>Patienten met leverziekte!</u>
38.	Davidson JR. Treatment of posttraumatic stress disorder: the impact of paroxetine. Psychopharmacol Bull 2003;37(suppl 1):76-88. <u>PTSS</u> Seroxat
39.	Asnis GM, Kohn SR, Henderson M, Brown NL. SSRIs versus non-SSRIs in post-traumatic stress disorder: an update with recommendations. Drugs 2004; 64:3 83-404.
40.	Bourin M, Chue P, Guillon Y. Paroxetine: a review. CNS Drug Rev 2001; 7:25-47. Seroxat https://pubmed.ncbi.nlm.nih.gov/11420571/
06-041	Black DW. Paroxetine for multiple chemical sensitivity. Am J Psychiatry 2002;159:1436-1437. Seroxat https://pubmed.ncbi.nlm.nih.gov/11420571/
06-042	Stern P, Binkley K. Successful outcome in a patient with chemical sensitivity: treatment with psychological

	desensitization and selective serotonin reuptake inhibitor. Psychosomatics 1998;39:547-550. Cipramil https://pubmed.ncbi.nlm.nih.gov/9259230/
43.	Andine P, Ronnback L, Jarvholm B. Successful use of a selective serotonin reuptake inhibitor in a patient with multiple chemical sensitivities. Acta Psychiatr Scand 1997;96:82-83. https://pubmed.ncbi.nlm.nih.gov/9259230/ Cipramil

[372] - [377]

HOOFDSTUK – 07

1.	Pall ML, Satterlee JD Elevated nitric oxide/peroxynitrite mechanism for the common etiology of multiple chemical sensitivity, chronic fatigue syndrome and posttraumatic stress disorder. Ann NYAcad Sci 2001;933:323-329. https://pubmed.ncbi.nlm.nih.gov/12000033/
2.	Pall ML. NMDA sensitization and stimulation by peroxynitrite, nitric oxide and organic solvents as the mechanism of chemical sensitivity in multiple chemical sensitivity. FASEB J 2002;16:1407-1417. https://pubmed.ncbi.nlm.nih.gov/12205032/
3.	Pall ML. Elevated nitric oxidelperoxynitrite theory of multiple chemical sensitivity: central role on N-methyl-D-aspartate receptors in the sensitivity mechanism. Environ Health Perspect 2003;111: 1461-1464. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1241647/ <u>Ook volledig als pdf</u>
4.	Pall ML. The simple truth about multiple chemical sensitivity. Environ Health Perspect 2004;112:A266-A267. <u>Als pdf ophalen</u>
5.	Pall ML, Anderson JH. The vanilloid receptor as a putative target of diverse chemicals in multiple chemical sensitivity. Arch Environ Health 2004;59:363-375. https://pubmed.ncbi.nlm.nih.gov/16241041/
6.	Pall ML. Elevated nitric oxide/peroxynitrite neurochemical mechanism of multiple chemical sensitivity. In: Kohji Fukunaga ed. Neurochemistry, in press.

	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1241647/ Ook volledig als pdf https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1241647/pdf/ehp0111-001461.pdf
7.	Rosenthal N. Multiple chemical sensitivity: lessons from seasonal affective disorder. Toxicol Ind Health 1994;10:623-632. (gaat over lichttherapie bij winterdepressie !) <u>geen samenvatting</u> Wel later verhaal uit 2020
06-008	Ashford NA, Miller CS. Chemical Exposures: Low Levels and High Stakes. 2nd ed. New York: John Wiley & Sons, Inc;1998. Boek zie 01-041
9.	Sorg BA. Multiple chemical sensitivity: potential role for neural sensitization. Crit Rev Neurobiol 1999; 13:283-316.
10.	Straus DC, Cooley JD, Wong WC, Jumper CA. Studies on the role of fungi in sick building syndrome. Arch Environ Health 2003;58:475-478.
11.	Meggs WJ. RADS and RUDS-The toxic induction of asthma and rhinitis. Clin Toxicol 1994;32:487-501.
12.	Meggs WJ. Multiple chemical sensitivities-Chemical sensitivity as a symptom of airway inflammation. Clin Toxicol 1995;33:107-110.
13.	Meggs WJ, Elsheik T, Metzger WJ, Albernaz M, Bloch RM. Nasal pathology and ultrastructure in patients with chronic airways inflammation(RADS and RUDS) following irritant exposure. Clin Toxicol 1996;34:383-396.
14.	Meggs WJ. Mechanisms of allergy and chemical sensitivity. Toxicol Ind Health 1999;15:331-338.
15.	Lieberman AD, Craven MR. Reactive intestinal dysfunction syndrome (RIDS) caused by chemical exposure. Arch

	Environ Health 1998;53:354-358.
16.	Miller CS. Are we on the threshold of a new theory of disease? Toxicantinduced loss of tolerance and its relationship in addiction and abdiction. Toxicol Ind Health 1999;15:284-294.
17.	Ionescu G, Merck M, Bradford R. Simple chemiluminescence assays for free radicals in venous blood and serum samples: results in atopic dermatitis, psoriasis, MCS and cancer patients. Forsch Komplementarmed 1999;6:294-300.
18.	Levine SA, Parker J. Selenium and human chemical hypersensitivities: preliminary findings. Int J Biosocial Res 1982;3:44-47.
19.	Levine SA. Oxidants/anti-oxidants and chemical hypersensitivities (Part one). Int J Biosocial Res 1983;4:51-54.
20.	Levine SA. Oxidants/anti-oxidants and chemical hypersensitivities (Part two). Int J Biosocial Res 1983;4:102-105.
21.	Kuklinski B, Scheifer R, and Bleyer H. Hirnschrakenprotein S-100 und Xenobiotica-Susceptibilitat. Umwelt Medizin Gesellschaft 2003; 16:112-120.
22.	Corrigan FM, MacDonald S, Brown A, Armstrong K, Armstrong EM. Neurasthenic fatigue, chemical sensitivity and GABA a receptor toxins. Med Hypoth 1994;43:195-200.
23.	Narahashi T. Neuronal ion channels as the target of insecticides. Pharmacol Toxicol 1996;79:1-14.

24.	Sunol C, Vale C, Rodriguez-Farre E. Polychlorocycloalkane insecticide action on GABA- and glycine-dependent chloride flux. <i>Neurotoxicology</i> 1998;19: 573-580.
25.	Adamec R. Modelling anxiety disorders following chemical exposures. <i>Toxicol Indust Health</i> 1994;10391-420.
26.	Gupta RC, Milatovic D, Dettbarn WD. Nitric oxide modulates high-energy phosphates in brain regions of rat intoxicated with diisopropylphosphofluoridate or carbofuran: prevention by N-tert-butyl-alpha-phenylnitron or vitamin E. <i>Arch Toxicol</i> 2001;75:346-356.
27.	Wu A, Liu Y Effects of deltamethrin on nitric oxide synthase and poly(ADPribose) polymerase in rat brain. <i>Brain Res</i> 1999;850:249-252.
28.	El-Gohary M, Awara WM, Nassar S, Hawas S. Deltamethin-induced testicular apoptosis in rats: the protective effect of nitric oxide synthase inhibitor. <i>Toxicology</i> 1999;132:1-8.
29.	Dhouib M, Lugnier A. Induction of nitric oxide synthase by chlorinated pesticides (p,p'-DDT, chlordane, endosulfan) in rat liver. <i>Cent Eur J Public Health</i> 1496;4(supp148). https://pubmed.ncbi.nlm.nih.gov/9167060/ ^{oooo}
30.	Bell IR, Baldwin CM, Schwartz GE. Illness from low levels of environmental chemicals: relevance to chronic fatigue syndrome and fibromyalgia. <i>Am J Med</i> 1998;105:74S-82S. https://pubmed.ncbi.nlm.nih.gov/9790486/ Veel overlap
31.	Bell IR, Miller CS, Schwartz GE. An olfactory-limbic model of multiple chemical sensitivity: possible relationships to kindling and effective spectrum disorders. <i>Biol Psychiatry</i> 1992;32:218-242. https://pubmed.ncbi.nlm.nih.gov/1420641/

32.	Bell IR, Schwartz GE, Baldwin CM, Hardin EE. Neural sensitization and physiological markers in multiple chemical sensitivity. Regul Toxicol Pharmacol 1996;24:S39-S47. https://pubmed.ncbi.nlm.nih.gov/8921554/
33.	Bell IR, Szarek MJ, Dicensor DR, Baldwin CM, Schwartz GE, Bootzin RR. Patterns of waking EEG spectral power in chemical intolerant individuals during repeated chemical exposures. Int J Neurosci 1999;97:41-59. https://pubmed.ncbi.nlm.nih.gov/10681117/ EEG meting
34.	Sorg BA, Bell IR, eds. The role of neural plasticity in chemical intolerance. Ann NYAcad Sci Vol 933. New York: The New York Academy of Sciences;2001.
35.	Gadea A, Lopez-Colome AM. Glial transporters for glutamate, glycine and GABA L Glutamate transporters. J Neurosci Res 2001;63:456-460.
36.	Bliss TM, Ip M, Cheng E, et al. Dual-gene, dual-cell therapy against excitotoxic insult by bolstering neuroenergetics. J Neurosci 2004;24:6202-6208.
37.	Izquierdo I, Medina JH. Correlation between the pharmacology of longterm potentiation and the pharmacology of memory. Neurobiol Learn Mem 1995; 63:19-32.
38.	Jerusalinsky D, Kornisiuk E, Izquierdo I. Cholinergic neurotransmission and synaptic plasticity concerning memory processing. Neurochem Res 1997;22: 507-515.
39.	Ustinova EE, Schultz HD. Activation of cardiac vagal afferents by oxygen-derived free radicals in rats. Circ Res 1994;74:895-903.
40.	Schultz HD, Ustinova EE. Capsaicin receptors mediate free

	radical-induced activation of cardiac afferent endings. Cardiovascular Res 1998;38:348-355.
41.	Cerutti PA. Mechanisms of action of oxidant carcinogens. Cancer Detect Prev 1989;14:281-284.
42.	Chakraborti T, Ghosh SK, Michael JR, Batabyal SK, Chakraborti S. Targets of oxidative stress in cardiovascular system. Mol Cell Biochem 1998;187:1-10.
43.	Gopalakrishna R, Jaken S. Protein kinase C signaling and oxidative stress. Free Radic Biol Med 2000;28:1349-1361.
44.	Vellani V, Mapplebeck S, Morionda A, Davis JB, McNaughton PA. Protein kinase C activation potentiates gating of the vanilloid receptor VRI by capsaicin, protons, head and anandamide. J Physiol 2001;534:813-825.
45.	Zhou Y, Li GD, Zhao ZQ. State-dependent phosphorylation of epsilon isozyme of protein kinase C in adult rat dorsal root ganglia after inflammation and nerve injury. J Neurochem 2003;85:571-580.
46.	Abou-Donia MB, Goldstein LB, Dechovskaia A, Bullman S, Jones KH, Herrick EA, Abdel-Rahman AA, Khan WA. Effects of daily dermal application of DEET and permethrin alone and in combination, on sensorimotor performance, blood-brain barrier, and blood-testis barrier in rats. J Toxicol Environ Health A 2001;62:523-541.
47.	Miller C, Mitzel H. Chemical sensitivity attributed to pesticide exposure versus remodeling. Arch Environ Health 1995;50:119-129.
48.	Rea WJ. Chemical Sensitivity, Vol. 1, Boca Raton: Lewis Publishers;1992.
49.	Binkley K, King N, Poonai N, Seeman P, Ulpian C,

	Kennedy J. Idiopathic environmental intolerance: increased prevalence of panic disorder associated cholecystokinin B receptor allele 7. J Allergy Clin Immunol 2001;107:887-890.
50.	Haley RW, Billecke S, La Du BN. Association of the low PON] type Q (type A) arylesterase activity with neurological symptom complexes in Gulf War veterans. Toxicol Appl Phnnnacol 1999;157:227-233.
51.	McKeown-Eyssen G, Baines C, Cole DE, et al. Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR. Int J Epidemiol 2004;33:971-978.
52.	Coderre TJ, Melzack R. The role of NMDA receptor-operated calcium channels in persistent nociception after formalin-induced tissue injury. J Neurosci 1992; 12:3671-3675.
53.	Elliott KJ, Brodsky M, Hynansky AD, Foley KM, Inturrisi CE. Dextromethorphan suppresses both form alin -induced nociceptive behavior and the formalininduced increase in spinal cord c-fos mRNA. Pain 1995;61:401-409.
54.	Davis AM, Inturrisi CE. Attenuation of hyperalgesia by LY235959, a competitive N-methyl-D-aspartate receptor antagonist. Brain Res 2001;894:150-153.
55.	Haxhiu MA, Erokwu B, Dreshaz IA. The role of excitatory amino acids in airway reflex responses in anesthetized dogs. JAuton Nervous Syst 1997;67:192-199.
56.	Silverman RA, Osborn H, Runge J, et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest 2002; 122:396-398.

57.	Bessmertny O, DiGregorio RV, Cohen H, et al. A randomized clinical trial of nebulized magnesium sulfate in addition to albuterol in the treatment of acute mild-to-moderate asthma exacerbations in adults. <i>Ann Emerg Med</i> 2002;39:585-591.
58.	Becherel PA, Chosidow O, Le Goff L, et al. Inducible nitric oxide synthase and proinflammatory cytokine expression by human keratinocytes during acute urticaria. <i>Mol Med</i> 1997;3:686-694.
59.	Bayon Y, Alonso A, Sanchez Crespo M. Immunoglobulin-E/dinitrophenyl complexes induce nitric oxide synthesis in rat peritoneal macrophages by a mechanism involving CD23 and NF-kappa B activation. <i>Biochem Biophys Res Commun</i> 242:570-574.
60.	van Straaten EA, Koster-Kamphuis L, Bovee-Oudenhoven IM, van der Meer R, Forget PP Increase urinary nitric oxidation products in children with active coeliac disease. <i>Acta Paediatr</i> 1999;88:528-531.
61.	Fargeas MJ, Theodorou V, Weirich B, Fioramonte J, Bueno L. Decrease in sensitization rate and intestinal anaphylactic response after nitric oxide synthase inhibition in a food hypersensitivity model. <i>Gut</i> 1996;38:598-602.
62.	Barau E, Dupont C. Modifications of intestinal permeability during food provocation procedures in pediatric irritable bowel syndrome. <i>J Pediatr Gastroenterol Nutr</i> 1990; 11:72-77.
63.	McKemy DD, Neuhausser WM, Julius D. Identification of a cold receptor reveals a general role for TRP channels in thermosensation. <i>Nature</i> 2002;416:52-58.
64.	Story GM, Peier AM, Reeve AJ, et al. ANKTM1, a TRP-

	like channel expressed in nociceptive neurons is activated by cold temperatures. <i>Cell</i> 2003; 112: 819-129.
65.	Levallois P, Neutra R, Lee G, Hristova L. Study of self-reported hypersensitivity to electromagnetic fields in California. <i>Environ Health Perspect</i> 2002; 110 (Sup14):619-623.
66.	McKay BE, Koren SA, Persinger MA. Behavioral effects of combined perinatal L-NAME and 0.5 Hz magnetic field treatments. <i>Int J Neurosci</i> 2003; 113:119-139.
67.	Irmak MK, Fadillioglu E, Gulec M, et al. Effects of electromagnetic radiation from cellular telephone on the oxidant and antioxidant levels in rabbits. <i>Cell Biochem Funct</i> 2002;20:279-283.
68.	Kim SS, Shin HJ, Eom DW, et al. Enhanced expression of neuronal nitric oxide synthase and phospholipase C- γ in regenerating murine neuronal cells by pulsed electromagnetic fields. <i>Exp Mol Med</i> 2002;34:53-59.
69.	Yoshikawa T, Tanagawa M, Tanigawa T, et al. Enhancement of nitric oxide generation by low frequency electromagnetic field. <i>Pathophysiology</i> 2000;7:131-135.
70.	Miura M, Takayama K, Okada J. Increase in nitric oxide and cyclic GMP in rat cerebellum by radio frequency burst-type electromagnetic field radiation. <i>J Physiol</i> 1993;461:513-524.
71.	Graham-Bermann SA, Seng J. Violence exposure and traumatic stress symptoms as additional predictors of health problems in high-risk children. <i>J Pediatr</i> 2005; 146:349-354.
72.	Dobie DJ, Kivlahan DR, Maynard C, et al. Posttraumatic stress disorder in female veterans: association with self-reported health problems and functional impairment. <i>Arch</i>

	Intern Med 2004;164:394-400.
73.	Fagan J, Galea S, Ahern J, Bonner S, Vlahov D. Relationship of self-reported asthma severity and urgent health care utilization to psychological sequelae of the September 11, 2001 terrorist attack on the World Trade Center among New York City area residents. Psychosom Med 2003;65:993-996.
74.	Weisberg RB, Bruce SE, Machan JT, et al. Nonpsychiatric illness among primary care patients with trauma histories and posttraumatic stress disorder. Psychiatr Serv 53:848-854.
75.	Wamboldt MZ, Weintraub P, Krafchick D, Wamboldt FS. Psychiatric family history in adolescents with severe asthma. J Am Acad Adolesc Psychiatry 1996; 35:1042-1049.
76.	Massaro AF, Gaston D, Kita C, et al. Expired nitric oxide levels during treatment of acute asthma. Am J Respir Crit Care Med 1995;152:\$00-803.
77.	Kharitonov SA, Chung KF, Evans D, O'Connor BJ, Barnes PJ. Increased exhaled nitric oxide in asthma is mainly derived from the lower respiratory tract. Am J Respir Crit Care Med 1996;153:1773-1780.
78.	Deykin A, Halpern O, Massaro AF, Drazen JM, Israel E. Expired nitric oxide after bronchoprovocation and repeated spirometry in patients with asthma. Am J Respir Crit Care Med 1998;157:769-775.
79.	Persson MG, Zetterstrom O, Agrenius V, Ihre E, Gustafsson LE. Singlebreath nitric oxide measurements in asthmatic patients and smokers. Lancet 1994; 343:146-147.
80.	Nelson BV, Sears S, Woods J, et al. Expired nitric oxide as a

	marker for childhood asthma. J Pediatr 130:423-427.
81.	Arruda LK, Sole D, Baena-Cagnani CE, Naspitz CK. Risk factors for asthma and atopy. Curr Opin Allergy Clin-Immunol 2005;5:153-159.
82.	Mapp CE. Genetics and the occupational environment. Curr Opin Allergy Clin-Immunol 2005;5:113-118.
83.	Hynes HP, Brugge D, Osgood ND, et al. Investigations into the indoor environment and respiratory health in Boston public housing. Rev Environ Health 2004; 19:271-289.
84.	Arshad SH, Kurukulaaratchy RJ, Fenn M, Matthews S. Early life risk factors for current wheeze, asthma and bronchial hyperresponsiveness at 10 years of age. Chest 2005; 127:502-508.
85.	Sutherland ER, Brandorff JM, Martin RJ. Atypical bacterial pneumonia and asthma risk. J Asthma 2004;41:863-868.
86.	Millqvist E, Bengtsson U, Lowhagen O. Provocations with perfume in the eyes induce airway symptoms in patients with sensory hyperreactivity. Allergy 1999; 54:495-499.
87.	Pall ML. Levels of nitric oxide synthase product citrulline are elevated in sera of chronic fatigue syndrome patients. J Chronic Fatigue Svrulr 2002;10(3/4): 37-41.
88.	Kimata H. Effect of exposure to volatile organic compounds on plasma levels of neuropeptides, nerve growth factor and histamine in patients with self-reported multiple chemical sensitivity. In J H, vg Environ Health 2004;207:159-163.
89.	Millqvist E, Ternesten-Hasseus E, Stahl A, Bende M. Changes in levels of nerve growth factor in nasal secretions after capsaicin inhalation in patients with airway symptoms from scents and chemicals. Environ Health Perspect

	2005;113: 849-852.
90.	Shinohara N, Mizukoshi A, Yanagisawa Y. Identification of responsible volatile chemicals that induce hypersensitive reactions to multiple chemical sensitivity patients. J Expo Anal Environ Epidemiol 2004;14:84-91.
91.	Joffres MR, Sampalli T, Fox RA. Physiologic and symptomatic responses to low-level substances in individuals with and without chemical sensitivities: a randomized controlled blinded pilot booth study. Environ Health Perspect 2005;113: 1178-1183.

[377] – [382]

HOOFDSTUK – 08

1.	Wolfe D. Fibromyalgia. Rheum Dis Clin North Am 1990;16:681-698.
2.	Leventhal U, Naides SJ, Freundlich B. Fibromyalgia and parvovirus infection. Arthritis Rheum 1991;34:1319-1324.
3.	Bujak DI, Weinstein A, Dornbush RL. Clinical and neurocognitive features of the post Lyme syndrome. J Rheumatol 1996;23:1392-1397.
4.	Buskila D, Shnaider A, Neumann L, et al. Fibromyalgia in hepatitis C infection. Another infectious disease relationship. Arch Intern Med 1997; 157:2497-2500.
5.	Laine M, Luukkainen R, Jalava J, et al. Prolonged arthritis associated with sindbis-related (Pogosta) virus infection. Rheumatology 2000;39:1272-1274. 6. Massarotti EM. Lyme arthritis. Med Clin North Am 2002;86:297-309.
7.	Daoud KF, Barkhuizen A. Curr Pain Headache Rep 2002;6:284-288.
8.	Waylonis GW, Perkins RH. Post-traumatic fibromyalgia. A long-term follow-up. Am J Phys Med Rehabil 1994;73:403-412.
9.	Buskila D, Neumann L, Vaisberg G, Alakalay D, Wolfe F. Increased rates of fibromyalgia following cervical spine injury. A controlled study of 161 cases of traumatic injury. Arthritis Rheum 1997;40:446-452.
10.	Greenfield S, Fitzcharles MA, Esdaile JM. Reactive

	fibromyalgia syndrome. Arthritis Rheum 1992;35:678-681.
11.	Aaron LA, Bradley LA, Alacon GS, Triana Alexander M, Alexander RW, Martin MY,
12.	Alberts KR. Perceived physical and emotional trauma as precipitating events in fibromyalgia. Associations with health care seeking and disability status but not pain severity. Arthritis Rheum 1997;40:453-460.
13.	Al-Allaf AW, Dunbar KL, Hallum NS, et al. A case-control study examining the role of physical trauma in the onset of fibromyalgia syndrome. Rheumatology 2002;41:450-453.
14.	Gebhard F, Nussler AK, Rosch M, Pfetsch H, Künzl L, Bruckner UB. Early posttraumatic increase in the production of nitric oxide in humans. Shock 1998; 10:237-242.
15.	Schwentker A, Billiar TR. Nitric oxide and wound repair. Surg Clin North Am 2003;83:521-530.
16.	Prasad D. Dhillon MS, Khullar M, Nagi ON. Evaluation of oxidative stress after fractures. A preliminary study. Acta Oethop Belg 2003;69:546-55 1.
17.	Sun GB, Huang ZH, Sun YG, Yang WY. Intervention with nitric oxide synthase inhibitors for traumatic shock in rats. Di Yi Jun Yi Da Xue Xue Bao 2003; 23:306-309.
18.	Feng HM, Huang ZH, Huang XL, et al. Dynamic changes in serum level of nitric oxide and its mechanism in rats with traumatic shock. Di Yi Jun Yi Da Xue Xue Bao 2002;22:891-894.
19.	Wallis RA, Panizzon KL, Girard JM. Traumatic neuroprotection with inhibitors of nitric oxide and ADP-ribosylation. Brain Res 1996;710:169-177.

20.	Stoll G, Jander S, Schroeter M. Detrimental and beneficial effects of injuryinduced inflammation and cytokine expression in the nervous system. Adv Exp Med Biol 2002;513:87-113.
21.	Wada K, Chatzipanteli K, Busto R, Dietrich WD. Role of nitric oxide in traumatic brain injury in the rat. J Neurosurg 1998;89:807-818.
22.	Lewen A, Matz P, Chan PH. Free radical pathways in CNS injury. J Neurotrauma 2000;17:871-890.
23.	Khalidi A, Chiueh CC, Bullock MR, Woodward JJ. The significance of nitric oxide production in the brain after injury. Ann NYAcad Sci 2002;962:53-59.
24.	Obrenovitch TP, Urenjak J. Is extracellular glutamate the key to excitotoxicity after brain injury? J Neurotrauma 1997; 14:677-698.
25.	Alexander RW, Bradley LA, Alarcon GS, et al. Sexual and physical abuse in women with fibromyalgia: association with outpatient health care utilization and pain medication usage. Arth Care Res 1998;11:102-115.
26.	Anderberg UM, Marteinsdottir I, Theorell T, et al. The impact of life events in female patient with fibromyalgia and female health controls. Eur Psychiatry 2000;15:295-301.
27.	Goldberg RT, Pachas WN, Keith D, et al. Relationship between traumatic events in childhood and chronic pain. Disability Rehab 1999;21:23-30.
28.	Walker EA, Keegan D, Gardner G, et al. Psychosocial factors in fibromyalgia compared with rheumatoid arthritis: IL Sexual, physical and emotional abuse and neglect.

	Psychosom Med 1997;59:572-577.
29.	Winfield JB. Psychological determinants of fibromyalgia and related syndromes. Curr Rev Pain 2000;4:276-286.
30.	Hench PK, Mitler MM. Fibromyalgia 1. Review of a common rheumatologic syndrome. Postgrad Med 1986;80:47-56.
31.	Grafe A, Wollina U, Tebbe B, et al. Fibromyalgia in lupus erythematosus. Acta Derm Venereol 1999;79:62-64.
32.	Eisinger J, Gandolfo C, Zakarian H, Ayavou T. Reactive oxygen species, antioxidant status and fibromyalgia. J Musculoskeletal Pain 1997;5(4):5-15.
33.	Eisinger J, Zakarian H, Pouly F, Plantamura A, Ayavou T. Protein peroxidation, magnesium deficiency and fibromyalgia. Magnes Res 1996;9:313-316.
34.	Ayavou T. Statut anti-oxydant et fibromyalgia. Lyon Med 36:12-13.
35.	Hein G, Franke S. Are advanced glycation end-product-modified proteins of pathogenic importance in fibromyalgia? Rheumatology 2002;41:1163-1167.
36.	Eisinger J, Ayavou T, Plantamura A, Lawson K, Danneskold-Samsoe B. Lipid and protein peroxidations in fibromyalgia, Myalgies Int 2002;3:37-42.
37.	Bagis S, Tamer L, Sahin G, et al. Free radicals and antioxidants in primary fibromyalgia: an oxidative stress disorder? Rheumatol Int 2005;25:188-190.
38.	Ali M. Respiratory-to-fermentative (RTF) shift in ATP production in chronic energy deficit states. Townsend Lett Doctors Patients 2004;Aug/Sept:64-65.

39.	Ali M. Fibromyalgia: an oxidative-dysoxygenative disorder (ODD). J Integrative Med 1999;3:17-37.
40.	Klein R, Berg PA. High incidence of antibodies to 5-hydroxytryptamine, gangliosides and phospholipids in patients with chronic fatigue syndrome and fibromyalgia syndrome and their relatives: evidence for a clinical entity of both disorders. Eur J Med Res 1995; 1:21-26.
41.	Bramwell B, Ferguson S, Scarlett N, Macintosh A. The use of ascorbigen in the treatment of fibromyalgia patients: a preliminary trial. Alt Medical Revs 2000; 5:455-462.
42.	Merchant RE, Carmack CA, Wise CM. Nutritional supplementation with Chlorella pyrenoidosa for patients with fibromyalgia syndrome A: a pilot study. Phytotherapy Res 2000; 14:167-173.
43.	Edwards AM, Blackburn L, Christie S, et al. Food supplements in the treatment of primary fibromyalgia: a double-blind crossover trial of anthocyanidins and placebo. J Nutr Environ Med 2000;10:189-199.
44.	Lister RE. An open, pilot study to evaluate the potential benefits of coenzyme Q10 combined with Ginkgo biloba extract in fibromyalgia syndrome. J Int Med Res 2002;30:195-199.
45.	Wallace D, Linker-Israeli, Hallegua D, et al. Cytokines plan an aetiopathogenetic role in fibromyalgia-a hypothesis and a pilot study. Rheumatology 2001; 40:743-749.
46.	Patarca-Montero R. The Concise Encyclopedia of Fibromyalgia and Myofascial Pain. Binghamton, NY: Haworth Medical Press;2002.
47.	Thompson ME, Barkhuizen A. Fibromyalgia, hepatitis C

	infection and the cytokine connection. Curr Pain Headache Rep 2003;7:342-347.
48.	Gur A, Karakoc M, Nas, K, et al. Cytokines and depression in cases with fibromyalgia. J Rheumatol 2002;29:358-361.
49.	Gur A, Karakoc M, Erdogan S, Nas K, Cevik R, Sarac AJ. Regional cerebral blood flow and cytokines in young females with fibromyalgia. Clin Exp Rheumatol 2002;20:753-760.
50.	Salemi S, Rethage J, Wollina U, et al. Detection of interleukin 1 β (IL-1 β), IL-6, and tumor necrosis factor- α in skin of patients with fibromyalgia. J Rheumatol 2003;30:146-150.
51.	Larson AA, Giovengo SL, Russell IJ, Michalek JE. Pain 2000;87:201-211.
52.	Bradley LA, Weigent DA, Sotolongo A, et al. Blood serum levels on nitric oxide (NO) are elevated in women with fibromyalgia (FM): possible contributions to central and peripheral sensitization. Arthritis Rheum 2000;43(Suppl19):5173.
53.	Helme RD, Littlejohn GO, Weinstein C. Neurogenic flare responses in chronic rheumatic pain syndromes. Clin Exp Neurol 1987;23:91-94.
54.	Morris V, Cruwys S, Kidd B. Increased capsaicin-induced secondary hyperalgesia as a marker of abnormal sensory activity in patients with fibromyalgia. Neurosci Lett 1998;250:205-207.
55.	Staud R, Smitherman ML. Peripheral and central sensitization in fibromyalgia: pathogenetic role. Curr Pain Headache Rep 2002;6:259-266.

56.	Sorensen J, Bengtsson A, Backman E, et al. Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine and ketamine. Scand J Rheumatol 1995;24:360-365.
57.	Bennett R. Fibromyalgia, chronic fatigue syndrome and myofascial pain. Curr Opin Rheumatol 1998;2:95-103.
58.	Nicolodi M, Volpe AR, Sicuderi F. Fibromyalgia and headache: failure of serotonergic analgesia and N-methyl-D-aspartate-mediated neuronal plasticity: their common clues. Cephalalgia 1998; 18(Suppl 21):41-44.
59.	Graven-Nielsen T, Aspergren Kendall S, Hensiksson KG, et al. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain 2000;85:483-491.
60.	Stoll AL. Fibromyalgia symptoms relieved by flupirtine: an open label case series. Psychosomatics 2000;41:371-372.
61.	Buskila D. Fibromyalgia, chronic fatigue syndrome and myofascial pain syndrome. Curr Opin Rheumatol 2001;13:117-127.
62.	Henriksson KG, Sorensen J. The promise of N-methyl-D-aspartate receptor antagonists in fibromyalgia. Rheum Dis Clin North Am 2002;28:343-351.
63.	Hocking G, Cousins MJ. Ketamine in chronic pain management: an evidence-based review. Anesth Analg 2003;97:1730-1739.
64.	Staud SR, Vierck CJ, Robinson ME, Price DD. Effects of the N-methyl-D-aspartate receptors antagonist dextromethorphan on temporal summation of pain are similar in fibromyalgia patients and normal control subjects.

	J Pain 2005;6:323-332.
65.	Peres MF, Zukerman E, Senne Soares CA, et al. Cerebrospinal fluid glutamate levels in chronic migraine. Cephalalgia 2004;24:735-739.
66.	Smith JD, Terpening CM, Schmidt SOF, Gums JG. Relief of fibromyalgia symptoms following discontinuation of dietary excitotoxins. Ann Pharmacother 2001;35:702-706.
67.	Lidbeck J. Central hyperexcitability in chronic musculoskeletal pain: a conceptual breakthrough. Pain Res Manag 2002;7:81-92.
68.	Clauw DJ, Crofford LJ. Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol 2003;17:685-701.
69.	Desmeules JA, Cedraschi C, Rapiti E, et al. Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum 2003;48: 1420-1429.
70.	Staud R, Evidence of involvement of central neural mechanisms in generating fibromyalgia pain. Curr Rheumatol Rep 2002;4:299-305.
71.	Bradley LA, McKendree-Smith NL, Alarcon GS, Cianfrini LR. Is fibromyalgia a neurologic disease? Curr Pain Headache Rep 2002;6:106-114.
72.	Staud R, Price DD, Robinson ME, Mauderli AP, Vierck CJ. Maintenance of windup of second pain requires less frequent stimulation in fibromyalgia patients compared with normal controls. Pain 2004;110:689-696.
73.	Yunus MB. Central sensitivity syndromes: a unified concept for fibromyalgia and other similar maladies. Pibromyalgia

	Frontiers 2001;9(3):3-\$.
74.	Larson AA, Kovacs KJ. Nociceptive aspects of fibromyalgia. Curr Pain Headache Rep 2001;5:338-346.
75.	Henriksson KG. Hypersensitivity in muscle pain syndromes. Curr Pain Headache Rep 2003;7:426-432.
76.	Staud R. Evidence of involvement of central neural mechanisms in generating fibromyalgia pain. Current Science 2004;4:299-305.
77.	Markenson JA. Mechanisms of chronic pain. Am J Med 1996;101:6S-18S.
78.	Simone DA, Zhang X, Li J, et al. Comparison of responses of primate spinothalamic tract neurons to pruritic and algogenic stimuli. JNeurophys 2004;9 1: 213-222.
79.	Mantyh PW, Hunt SP. Setting the tone: superficial dorsal horn projection neurons regulate pain sensitivity. Trends Neurosci 2004;27:582-584.
80.	Saab CY, Park YC, Al-Chaer ED. Thalamic modulation of visceral nociceptive processing in adult rats with neonatal colon irritation. Brain Res 2004;1008: 186-192.
81.	Gauriau C, Bernard JF. A comparative reappraisal of projections from the superficial luminae of the dorsal horn of the rat: the forebrain. J Comp Neurol 2004; 468:24-56.
82.	Julien N, Goffaux P, Arsenault P, Marchand S. Widespread pain in fibromyalgia is related to a deficit in endogenous pain inhibition. Pain 2005; 114:295-302.
83.	Mountz JM, Bradley LA, Modell JG, et al. Fibromyagia in women. Abnormalities in regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low

	pain threshold levels. Arthritis Rheum 38:926-938.
84.	Wik G, Fischer H, Bragee B, Finer B, Fredrikson M. Functional anatomy of hypnotic analgesia: a PET study of patients with fibromyalgia. Ear J Pain 1999;3:7-12.
85.	Lekander M, Fredrikson M, Wik G. Neuroimmune relations in patients with fibromyalgia: a positron emission tomography study. Neurosci Lett 2000;282: 193-196.
86.	Kwiatek R, Barnden L, Tedman R, et al. Regional cerebral blood flow in fibromyalgia: a single-photon-emission computed tomography evidence of reduction in the pontine tegmentum and thalami. Arthritis Rheum 2000;43:2823-2833.
87.	Anon. A possible cause of fibromyalgia. Special Update Edition, The American Fibromyalgia Syndrome Association, Inc;2003:14-18.
88.	Zhou M. Canadian Association of Neuroscience review: Cellular and synaptic insights into physiological and pathological pain. Can J Neurol Sci 2005;32:27-36.
89.	Goettl VM, Huang Y, Hackshaw KV, Stephens RL Jr. Reduced basal release of serotonin from the basolateral thalamus of the rat in a model of neuropathic pain. Pain 2002;99:359-366.
90.	Bondy B, Spaeth M, Offenbaecher M, et al. The T102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia. Neurobiol Dis 1999;6:433-439.
91.	Cohen H, Buskila D, Neumann L, Ebstein RP. Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5-HTTLPR) polymorphism, and relationship to anxiety-related personality traits.

	Arthritis Rheum 2002;46:845-847.
92.	Neeck G. Neuroendocrine and hormonal perturbations and relations to the serotonergic system in fibromyalgia. Scand J Rheumatol Suppl 2000; 113:8-12.
93.	Miller LJ, Kubes KL. Serotonergic agents in the treatment of fibromyalgia syndrome. Ann Pharmacother 2002;36:707-712.
94.	Palkar AA, Bilal L, Masand PS. Management of Fibromyalgia. Curr Psychiatry Rep 2003;5:218-224.
95.	Spath M, Stratz T, Farber L, Haus U, Pongratz D. Treatment with fibromyalgia with tropisetron-dose and efficacy correlations. Scand J Rheumatol Suppl 2004;119:63-66.
96.	Cook DB, Lange G, Ciccone DS, et al. Functional imaging of pain in patients with primary fibromyalgia. J Rheumatol 2004;31:364-378.
97.	Chang L, Berman S, Mayer EA, et al. Brain responses to visceral and somatic stimuli in patients with irritable bowel syndrome with and without fibromyalgia. Am J Gastroenterol 2003;98:1354-1361.
98.	Gracely RH, Geisser ME, Giesecke T, et al. Pain catastrophizing and neural responses to pain among persons with fibromyalgia. Brain 2004; 127:835-843.

[382] - [387]

HOOFDSTUK – 09

1.	American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders. 4th ed. DSM-IV, Washington, DC: American Psychiatric Press; 1994. Reprinted with permission from APA.
2.	Miller CS. Are we on the threshold of a new theory of disease? Toxicantinduced loss of tolerance and its relationship in addiction and abdiction. Toxicollnd Health 1999; 15:284-294.
3.	Lipschitz EL Chronic fatigue syndrome and posttraumatic stress disorder. JAMA 2001;286:916-917.
4.	Cohen H, Neumann L, Haiman Y, Matar MA, Press J, Buskila D. Prevalence of post-traumatic stress disorder in fibromyalgia patients: overlapping syndromes of post-traumatic fibromyalgia syndrome? Semin Arthritis Rheum 2002;32:38-50.
5.	Friedman MJ. Neurobiological sensitization models of post-traumatic stress disorder: their possible relevance to multiple chemical sensitivity syndrome. Toxicol Ind Health 1994; 10:449-462.
6.	Gould E, Cameron HA. Early NMDA blockade impairs defensive behavior and increases cell proliferation in the dentate gyrus of developing rats. Behav Neurosci 1997;111:49-56.
7.	Adamec RE, Burton P, Shallow T, Budgell J. Unilateral block of NMDA receptors in the amygdala prevents

	predator-induced lasting increases in anxiety-like behavior and unconditioned startle-effective hemisphere depends on behavior. <i>Physiol Behav</i> 1999;65:739-751.
8.	Shors TJ, Elkabes S, Selcher JC, Black IB. Stress persistently increases NMDA receptor-mediated binding of (3H)PDBu (a marker for protein kinase C) in the amygdala and re-exposure to the stressful context reactivates the increase. <i>Brain Res</i> 1997;750:293-300.
9.	Miserendino MJ, Sananes CB, Melia KR, Davis M. Blocking of acquisition but not expression of conditioned fear-potentiated startle by NMDA antagonists in the amygdala. <i>Nature</i> 1990;345:716-718.
10.	Goldstein LE, Rasmusson AM, Bunney BS, Roth RH. The NMDA glycine site antagonist (+)-HA-966 selectively regulates conditioned stress-induced metabolic activation of the mesoprefrontal cortical dopamine but not serotonin systems: a behavioral, neuroendocrine, and neurochemical study in the rat. <i>J Neurosci</i> 1994; 14:4937-4950.
11.	Charney DS, Deutch AY, Krystal JH, Southwick SM, Davis M. Psychobiology mechanisms in posttraumatic stress disorder. <i>Arch Gen Psychiatry</i> 1993;50: 294-302.
12.	Chambers RA, Bremner JD, Moghaddam B, Southwick SM, Charney DS, Krystal JH. Glutamate and post-traumatic stress disorder: toward a psychobiology of dissociation. <i>Semin Clin Neuropsychiatry</i> 1999;4:274-281.
13.	Antelman SM, Yehuda R. Time-dependent change following acute stress: Relevance to the chronic and delayed aspects of PTSD. In: Murburg MM, ed. <i>Catecholamine Function in Post-Traumatic Stress Disorder: Emerging Concepts</i> . Washington, DC: American Psychiatric Press;

	1994:87-98.
14.	Post RM, Weiss SR, Smith M. Li H. McCann U. Kindling vs quenching: Implications for the evolution and treatment of posttraumatic stress disorder. Ann NYAcad Sci 1997;821:285-295.
15.	Hageman I, Andersen HS, Jorgensen MB. Post-traumatic stress disorder: a review of psychobiology and pharmacotherapy. Acta Psychiatr Scand 2001;104: 411-422.
16.	Heresco Levy U, Javitt DC. The role of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes. EurNeuropsychopharmacol 1998;8:141-152.
17.	McEwen BS. Possible mechanisms for atrophy in the human hippocampus. Mol Psychiatr 1997;2:255-262.
18.	Bremner JD. Does stress damage the brain? Biol Psychiatr 1999;45:797-805.
19.	Birmes P, Senard JM, Escande M, Schmitt L. Facteurs biologiques du stress post-traumatique: neurotransmission et neuromodulation. Encephale 2002; 28:241-247.
20.	McEwen B. Re-examination of the glucocorticoid hypothesis of stress and aging. Prog Brain Res 1992;93:365-378.
21.	Sapolsky R. Stress, glucocorticoids and damage to the nervous system. The current state of confusion. Stress 1996;1:1-16.
22.	Bremner J. Does stress damage the brain? Biol Psychiatry 1999;45:797-804.
23.	Strijbos PJ, Relton JK, Rothwell NJ. Corticotrophin-

	releasing factor antagonist inhibits neuronal damage induced by focal ischaemia or activation of NMDA receptors. Brain Res 1994;656:405-408.
24.	McEwen BS. Possible mechanisms for atrophy of the human hippocampus. Mol Psychiatry 1997;2:255-262.
25.	Coussens CM, Kerr DS, Abraham WC. Glucocorticoid receptor activation lowers the threshold for NMDA-receptor-dependent homosynaptic long-term depression in the hippocampus through activation of voltage-dependent calcium channels. J Neurophysiol 1997;78:2685-2696.
26.	Brook SM, Howard SA, Sapolsky RM. Energy dependency of glucocorticoid exacerbation of gp120 neurotoxicity. JNeurochem 1998;7L1187-1193.
27.	Hergovich N, Singer E, Agneter E, et al. Comparison of the effects of ketamine and memantine on prolactin and cortisol release in men, a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 2001;24:590593.
28.	Takahashi T, Kimoto T, Tanabe N, Hattori TA, Yasumatsu N, Kawato S. Corticosterone acutely prolonged N-methyl-D-aspartate receptor-mediated Ca ²⁺ elevation in cultured rat hippocampal neurons. J Neurochem 2002;83:1441-1451.
29.	McEwen BS, Magarinos AM. Stress effects on morphology and function of the hippocampus. Ann NYAcad Sci 1997;821:271-284.
30.	Howard SA, Nakayam AY, Brooke SM, Sapolsky RM. Glucocorticoid modulation of gp120-induced effects on calcium-dependent degenerative events in primary hippocampal and cortical cultures. Exp Neurol 1999;158164-170.

31.	Harvey AG, Brewin CR, Jones C, Kopelman MD. Coexistence of posttraumatic stress disorder and traumatic brain injury: towards a resolution of the paradox. J Int Neuropsychological Soc 2003;9:663-676.
32.	Heresco-Levy U, Kremer I, Javitt DC, et al. Pilot-controlled trial of Dcycloserine for the treatment of post-traumatic stress disorder. Int J Neatropsychopharnuacol 2002;5:301-307.
33.	Malek-Ahmadi P. Gabapentin and posttraumatic stress disorder. Ann Pharmacother 2003;37:664-666.
34.	Zullino DF, Krenz S, Besson J. AMPA blockade may be the mechanism underlying the efficacy of topiramate in PTSD. J Clin Psychiatry 2002;64:219-220.
35.	Laudanno OM, Cesolari JA, San Miguel P, Bedini OA. Role of inducible nitric oxide synthase in acute gastric mucosal damage in stress, in rats. Acta Gastroenterol Latinoam 1996;26:221-224.
36.	Martinez-Agustin 0, de Medina F. Effect of psychogenic stress on gastrointestinal function. J Physiol Biochem 2000;56:259-273.
37.	Alptekin N, Seckin S, Dogru Abbasoglu S, et al. Lipid peroxides, glutathione, y-glutamylcysteine synthetase and y-glutamyltranspeptidase activities in several tissues of rats following water-immersion stress. Pharmacol Res 1996;34: 167-169.
38.	Seckin S, Alptekin N, Dogru Abbasoglu S, et al. The effect of chronic stress on hepatic and gastric peroxidation in long-term depletion of glutathione in rats. Pharmacol Res 1997;36:55-57.

39.	Harvey BH, Oosthuizen F, Brand L, Wegener G, Stein DJ. Stress-restress evokes sustained iNOS activity and altered GABA levels and NMDA receptors in rat hippocampus. <i>Psychopharmacology</i> 2004; 175:494-502.
40.	Oosthuizen F, Wegener G, Harvey BH. Role of nitric oxide as inflammatory mediator in post-traumatic stress disorder (PTSD): evidence from an animal model. <i>Neuropsychiatric Dis Treat</i> 2005;L109-124.
41.	Harvey BH, Bothma T, Nel A, Wegener G, Stein DJ. Involvement of the NMDA receptor, NO-cyclic GMP and nuclear factor K- β in an animal model of repeated trauma. <i>Hum- Psychopharmacol Clin Exp</i> 2005;20:367-373.
42.	Packer MA, Stasiv Y, Benraiss A, et al. Nitric oxide negatively regulates mammalian adult neurogenesis. <i>Proc Natl Acad Sci USA</i> 2003;100:9566-9571.
43.	Cheng A, Wang S, Cai J, Rao MS, Mattson MP Nitric oxide acts in a positive feedback loop with BDNF to regulate neural progenitor cell proliferation and differentiation in the mammalian brain. <i>Dev Biol</i> 2003;258:319-333.
44.	Gibbs SM. Regulation of neuronal proliferation and differentiation by nitric oxide. <i>Mol Neurobiol</i> 2003;27:107-120.
45.	Cameron HA, McEwen BS, Gould E. Regulation of adult neurogenesis by excitatory input and NMDA receptor activation in the dentate gyrus. <i>J Neurosci</i> 1995;15:4687-4692.
46.	Gould E, McEwen BS, Tanapat P, Galea LA, Fuchs E. Neurogenesis in the dentate gyrus of the adult tree shrew is regulated by psychosocial stress and NMDA receptor activation. <i>J Neurosci</i> 1997; 17:2492-2498.

47.	McEwen B. Re-examination of the glucocorticoid hypothesis of stress and aging. Prog Brain Res 1992;93:365-378.
48.	Sapolsky R. Stress, glucocorticoids and damage to the nervous system. The current state of confusion. Stress 1996;1:1-16.
49.	Bremner J. Does stress damage the brain? Biol Psychiatry 1999;45:797-804.
50.	Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry, 2000;57:925-935.
51.	Gilbertson MW, Shenton MF, Ciszewski A, et al. Smaller hippocampal volume predicts pathologic vulnerability to psychological trauma. Nat Neurosci 2002; 5:1242-1247.
52.	Miserendino MJ, Sananes CB, Melia KR, Davis M. Blocking of acquisition but not expression of conditioned fear-potentiated startle by NMDA antagonists in the amygdala. Nature 1990;345:716-718.
53.	Falls WA, Miserendino MJ, Davis M. Extinction of fear-potentiated startle: blockade by infusion of an NMDA antagonist into the amygdala. J Neurosci 1992; 12:854-863.
54.	Bell IR, Miller CS, Schwartz GE, Peterson JM, Amend D. Neuropsychiatric and somatic characteristics of young adults with and without self-reported chemical odor intolerance and chemical sensitivity. Arch Environ Health 1996;S1:9-21. Staat al bij 03-039
55.	Sherman JJ, Turk DC, Okifuji A. Prevalence and impact of posttraumatic stress disorder-like symptoms on patients with fibromyalgia. Clin J Pain 2000;16: 127-134.

56.	Bremer JD. Hypotheses and controversies related to effects of stress on the hippocampus: an argument for stress-induced damage to the hippocampus in patients with posttraumatic stress disorder. <i>Hippocampus</i> 2001;11:75-81.
57.	Shin LM, Shin PS, Heckers S, et al. Hippocampal function in posttraumatic stress disorder. <i>Hippocampus</i> 2004; 14:292-300.
58.	Friedman A. Pyridostigmine brain penetration under stress enhances neuronal excitability and induces early immediate transcriptional response. <i>Nat Med</i> 1996;2:1382-1385.
59.	Hanin I. The Gulf War, stress, and a leaky blood-brain barrier. <i>Nat Med</i> 1996; 2:1307-1308.
60.	Pavolvsky L, Browne RO, Friedman A. Pyridostigmine enhances glutamatergic transmission in hippocampal CA1 neurons. <i>ExptNeaanol</i> 2003;179:181-187.
61.	Abdel-Rahman A, Shetty AK, Abou-Donia MB. Disruption of the blood-brain barrier and neuronal death in cingulated cortex, dentate gyrus, thalamus and hypothalamus in a rat model of Gulf-War syndrome. <i>Neurobiol Dis</i> 2002;10: 306-326.
62.	Abdel-Rahman A, Abou-Donia SM, El-Masry EM, et al. Stress and combined exposure to low doses of pyridostigmine bromide, DEET and permethrin produce neurochemical and neuropathological alterations in cerebral cortex, hippocampus and cerebellum. <i>J Toxicol Env Health</i> 2004;676:163-192.
63.	Song X, Tian HL, Bressler J, et al. Acute and repeated restraint have little effect on pyridostigmine toxicity or brain regional cholinesterase inhibition in rats. <i>Toxicol Sci</i> 2002;69:157-164.

64.	Pall ML. NMDA sensitization and stimulation by peroxynitrite, nitric oxide and organic. FASEB J 2002; 16:1407-1417.
65.	Sapolsky RM. Stress and plasticity in the limbic system. Neuroch.em Res 2003;28:1735-1742.
66.	McEwen BS. Plasticity of the hippocampus: adaptation to chronic stress and allostatic load. Ann NYAcnd Sci 2001;933:265-277.

[387] - [390]

HOOFDSTUK – 10

1.	The Iowa Persian Gulf Study Group. Self-reported illness and health status among Gulf War veterans-a population-based study. JAMA 1997;227:238-245.
2.	Kipen HM, Hallman W, Kang H, Fiedler N, Natelson BH. Prevalence of chronic fatigue and chemical sensitivities in Gulf Registry Veterans. Arch Environm Health 1999;54:313-318.
3.	Pollet C, Natelson BH, Lange G, et al. Medical evaluation of Persian Gulf veterans with fatigue and/or chemical sensitivity. J Med 1998;29:101-113.
4.	Nicolson GL, Nicolson NL. Gulf War illnesses: complex medical, scientific paradox. Med Confl Surviv 1998;14:156-165.
5.	Hodgson MJ, Kipen HM. Gulf War illnesses: causation and treatment. J Occup Environ Med 1499;41:443-452.
6.	Baker DG, Mendenhall CL, Simbartl LA, Magan LK, Steinberg JL. Relationship between posttraumatic stress disorder and self-reported physical symptoms in Persian Gulf War veterans. Arch Intern Med 1997;157:2076-2078.
7.	[no authors listed] Multiple chemical sensitivity: a consensus. Arch Environ Health 1999;54:147-149.
8.	Kang HK, Mahan CM, Lee KY, Magee CA, Murphy FM. Illnesses among United States veterans of the Gulf War: a population-based survey of 30,000 veterans. J Occup Environ Med 2000;42:491-501.

9.	Kang HK, Mahan CM, Lee KY, et al. Evidence for deployment-related Gulf War syndrome by factor analysis. Arch Environ Health 2002;57:61-68.
10.	Steele L. Prevalence and patterns of Gulf War illness in Kansas veterans: associations of symptoms with characteristics of person, place and time of military service. Am J Epidemiol 2000; 152:992-1002.
11.	Proctor SP, Heaton KJ, White RF, Wolfe J. Chemical sensitivity and chronic fatigue in Gulf War veterans: a brief report. J Occup Environ Med 2001;43:259-264.
12.	Reid S, Hotopf M, Hull L, et al. Multiple chemical sensitivity and chronic fatigue syndrome in British Gulf War veterans. Am J Epidemiol 2001; 153:604-609.
13.	Peckerman A, Dahl K, Chemitiganti R, et al. Effects of posttraumatic stress disorder on cardiovascular stress responses in Gulf War veterans with fatiguing illness. Auton Neurosci 2003; 108:63-72.
14.	Cook DB, Nagelkirk PR, Peckerman A, et al. Perceived exertion in fatiguing illness: Gulf War veterans with chronic fatigue syndrome. Med Sci Sports Exerc 2003;35:569-574.
15.	McCauley LA, Joos SK, Barkhuizen A, et al. Chronic fatigue in a population-based study of Gulf War veterans. Arch Environ Health 2002;57:340-348.
16.	Kang HK, Natelson BH, Mahan CM, Lee KY, Murphy FM. Post-traumatic stress disorder and chronic fatigue syndrome-like illness among Gulf War veterans: a population-based survey of 30,000 veterans. Am J Epidemiol 2003; 157: 141-148.
17.	Gray GC, Reed RJ, Kaiser KS, Smith TC, Gastanaga VM.

	Self-reported symptoms and medical conditions among 11,868 Gulf War-era veterans: the Seabee Health Study. Am J Epidemiol 2000;152:992-1002.
18.	Eisen SA, Kang HK, Murphy FM, et al. Gulf War veterans' health: medical evaluation of a U.S. cohort. Ann Intern Med 2005;142:881-890.
19.	Pall ML. Common etiology of posttraumatic stress disorder, fibromyalgia, chronic fatigue syndrome and multiple chemical sensitivity via elevated nitric oxide/peroxynitrite. Med Hypotheses 2001;57:139-145.
20.	Cowan DN, Lange JL, Heller J, Kirkpatrick J, DeBaakey S. A case-controlled study of asthma among U.S. Army Gulf War veterans and modeled exposure to oil well fire smoke. Mil Med 2002; 167:777-782.
21.	Lange JL, Schwartz DA, Doebbeling BN, Heller JM, Thorne PS. Exposures to the Kuwait oil fires and their association with asthma and bronchitis among gulf war veterans. Environ Health Perspect 2002;110:1141-1146.
22.	Unwin C, Blatchley N, Coker W, et al. Health of UK servicemen who served in Persian Gulf War. Lancet 1999;353:169-178.
23.	Dunphy RC, Bridgewater L, Price DD, et al. Visceral and cutaneous hypersensitivity in Persian Gulf war veterans with chronic gastrointestinal symptoms. Pain 2003;102:79-85.
24.	Homer RD, Kamins KG, Feussner JR, et al. Occurrence of amyotrophic lateral sclerosis among Gulf War veterans. Neurology 2003;61:742-749.
25.	Haley RW. Excess incidence of ALS in young Gulf War veterans. Neurology 2003;61:750-756.

26.	Binns JH, Cherry N, Golomb BA, et al. [Research Advisory Committee on Gulf War Veterans' Illnesses]. 2004 Report and Recommendations.
27.	Robbins PJ, Cherniak MG. Review of the biodistribution and toxicity of the insect repellent N,N-diethyl-m-toluamide (DEET). J Toxicol Environ Health 1986; 18:503-525.
28.	Amichai B, Lazarov A, Halevy S. Contact dermatitis from diethyltoluamide. Contact Dermatitis 1994;30:188.
29.	McKinlay JR, Ross V, Barrett TL. Vesiculobullous reaction to diethyltoluamide revisited. Cutis 1998;62:44.
30.	Moteiro-Riviere NA, Baynes RE, Riviere JE. Pyridostigmine bromide modulates topical irritant-induced cytokine release from human epidermal keratinocytes and isolated perfused porcine skin. Toxicology 2003;183:15-28.
31.	Jung M, Dritschilo A. NK-KB signalling pathway as a target for human tumor radiosensitization. Semin Radiat Oncol 2001;11:346-351.
32.	McBride WH, Pajonk F, Chiang CS, Sun JR. NF-KB, cytokines, proteasomes and low dose radiation exposure. Mil Med 2002;167(2 Suppl):66-67.
33.	Ibuki Y, Mizuno S, Goto R. γ -Irradiation-induced DNA damage enhances NO production via NF-KB activation in RAW264.7 cells. Biochim Biophys Acta 2003; 1593:159-167.
34.	Taysi S, Koc M, Buyukokuroglu MF, Altinkaynak K, Sahin YN. Melatonin reduces lipid peroxidation and nitric oxide during irradiation-induced oxidative injury in the rat liver. J Pineal Res 2003;34:173-177.
35.	Takeda I, Kizu Y, Yoshitaka O, Saito I, Yamane GY Possible

	role of nitric oxide in radiation-induced salivary gland dysfunction. RadiatRes 2003;159:465-470.
36.	Abou-Donia MB, Dechkovskaia AM, Goldstein LB, et al. Uranyl acetate-induced sensorimotor deficit and increased nitric oxide generation in the central nervous system in rats. Pharmacol Biochem Behav 2002;72:881-890.
37.	Briner W, Murray J. Effects of short-term and long-term depleted uranium exposure on open-field behavior and brain lipid oxidation in rats. Neurotoxicol Teratol 2005;27:135-144.
38.	Kengatharan KM, De Kimpe S, Robson C, Foster SJ, Thiemermann C. Mechanism of gram-positive shock: identification of peptidoglycan and lipoteichoic acid moieties essential in the induction of nitric oxide. J Exp Med 1998;188:305-315.
39.	Tournier JN, Jouan A, Mathieu J, Drouet E. Gulf war syndrome: could it be triggered by biological warfare-vaccines using pertussis as an adjuvant? Med Hypotheses 2002;58:291-292.
40.	Forstermann U, Goppelt-Strube M, Frolich JC, Busse R. Inhibition of acylcoenzyme A: lysolecithin acyltransferase activated the production of endothelial-derived relaxing factor. J Pharmacol Exp Therapeutics 1986;238:252-259.
41.	Forstermann U, Goppelt-Strube M, Frolich JC, Busse R. Thimerosal, an inhibitor of endothelial acyl-coenzyme A: lysolecithin acyltransferase, stimulates the production of a nonprostanoid endothelium-derived relaxing factor. Adv Prostaglandin Thromboxane Leukot Res 1987;17B:1108-1111.
42.	Mulsch A, Bohme E, Busse R. Stimulation of soluble

	guanylate cyclase by endothelium-derived relaxing factor from cultured endothelial cells. Eur J Phczrfnaco11987;135:247-250.
43.	Beny JL. Thimerosal hyperpolarizes arterial smooth muscles in an endothelium-dependent manner. Eur J Pharniacol 1990; 185:235-238.
44.	Crack P, Cocks T. Thimerosal blocks stimulated but not release of endothelium-derived relaxing factor (EDRF) in dog isolated coronary artery. Br J Pharmacol 1992;107:566-572.
45.	Chen YJ, Jiang H, Quilley J. The nitric oxide- and prostaglandin independent component of the renal vasodilator effect of thimerosal is mediated by epoxyeicosatienoic acids. J Pharmacol Exp Ther 2003;304:1292-1298.
46.	Haley RW, Billecke S, La Du BN. Association of the low PON 1 type Q (type A) arylesterase activity with neurological symptom complexes in Gulf War veterans. Toxicol Appl Pharmacol 1999; 157:227-233.
47.	Mackness B, Durrington PN, Mackness MI. Low paraoxonase in Persian Gulf War veterans self-reporting Gulf War syndrome. Biochem Biophys Res Commun 2000;276:729-733.
48.	Lockridge O. Project summary: Butyrylcholinesterase genetic variants in persons with Gulf War illness. Available at: http://www.gulflink.osd.mil.medsearch/GeneticStudies/DoD60.shtml . 1999.
49.	Loewenstein-Lichtenstein Y, Schwarz M, Glick D, et al. Genetic predisposition to adverse consequences of anti-cholinesterases in 'atypical' BCHE carriers. Nat Med

	1995;1:1082-1085.
50.	Miller CS, Prihoda TJ. A controlled comparison of symptoms and chemical intolerances reported by Gulf War veterans, implant recipients and persons with multiple chemical sensitivity. <i>Toxicol Ind Health</i> 1999; 15:386-397.
51.	Abu-Qare AW, Abou-Donia MB. Combined exposure to sarin and pyridostigmine bromide increased levels of rat urinary 3-nitrotyrosine and 8-hydroxy2'-deoxyguanosine, biomarkers of oxidative stress. <i>Toxicol Lett</i> 123:51-58.
52.	Abu-Qare AW, Suliman HB, Abou-Donia MB. Induction of 3-nitrotyrosine, a marker of oxidative stress, following administration of pyridostigmine bromide, DEET (N,N-diethyl-m-toluamide) and permethrin, along and in combination in rats. <i>Toxicol Lett</i> 2001;121:127-134.
53.	Abdel-Rahman AA, Shetty AK, Abou-Donia MB. Disruption of the bloodbrain barrier and neuronal cell death in cingulate cortex, dentate gyrus, thalamus and hypothalamus in a rat model of Gulf War syndrome. <i>Neurobiol Dis</i> 2002;10: 306-326.
54.	Abu-Qare AW, Abou-Donia MB. Combined exposure to DEET (N,N-dithylm-toluamide) and permethrin-induced release of rat brain mitochondrial cytochrome C. <i>J Toxicol Environ Health A</i> 2001;63:243-252.
55.	Abdel-Rahman AA, Dechkovskaia AM, Goldstein LB, et al. Neurological deficits induced by malathion, DEET. and permethrin, alone and in combination in adult rats. <i>J Toxicol Environ Health A</i> 2004;67:331-356.
56.	Abou-Donia MB, Suliman HB, Khan WA, Abdel-Rahman AA. Testicular germ cell apoptosis in stressed rats following combined exposure to pyridostigmine bromide, N,N-diethyl-

	m-toluamide (DEET), and permethrin. J Toxicol Environ Health A 2003;66:57-73.
57.	Olgun S, Gogal RM Jr., Adeshina F, et al. Pesticide mixtures potentiate the toxicity in murine thymocytes. Toxicol 2004;196:181-195.
58.	Reaney P. Gulf War illness may never be explained-scientist. Reuters News Service, October 19. http://www.planetark.org/avantgo/dailynewsstory.cfm?newsid=27740 . Accessed October 2004.

[390] - [394]

HOOFDSTUK – 11

1.	Cathebras P, Lauwers A, Rousset H. Fibromyalgia. a critical review. Ann MedInterne 1998;149:406-414.
2.	Neumann L, Buskila D. Epidemiology of fibromyalgia. Curr Pain Headache Rep 2003;7:362-368.
3.	Shaver JL. Fibromyalgia syndrome in women. Nurs Clin North Am 2004; 39:195-204.
4.	Bennett RM Fibromyalgia: the commonest cause of widespread pain. Compr Ther1995;21:269-275.
5.	Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995; 38:19-28.
6.	White KP, Speechley M, Harth M, Ostbye T. The London fibromyalgia epidemiology study: the prevalence of fibromyalgia in London, Ontario. J Rheumatol 1999;26:1570-1576.
7.	Buskila D. Fibromyalgia, chronic fatigue syndrome and myofascial pain syndrome. Curr Opin Rheumatol 2001;13:117-127.
8.	Carmona L, Ballina K, Gabriel R, Laffon A: EPISER Study Group. The burden of musculoskeletal diseases in the general population of Spain: results from a national survey. Anti Rheum Dis 2001;60:1040-1045.
9.	Prescott I, Kjoller M, Jacobsen S, et al. Fibromyalgia in the adult Danish population: L A prevalence study. Scand J

	Rheumatol 1993;22:233-237.
10.	Makela M, Heliovaara M. Prevalence of primary fibromyalgia in the Finnish population. BMJ 1991;303:216-219.
11.	Alvarez Nemegyei J, Nuno Gutierrez BL, Alcocer Sanchez JA. Rheumatic diseases and labor disability in adult rural population. Rev Med Inst Mex Seguro Soc 2005;43:287-292.
12.	Cardiel MH, Rojas-Serrano J. Community based study to estimate prevalence, burden of illness and help seeking behavior in rheumatic diseases in Mexico City. A COPCORD study. Clin Exp Rheumatol 2002;20:617-624.
13.	Clark P, Burgos-Vargas R, Medina-Palma C, Lavielle P, Marina FF. Prevalence of fibromyalgia in children: a clinical study of Mexican children. JRheumatol 1998;25:2009-2014.
14.	Haq SA, Darmawan J, Islam MN, et al. Prevalence of rheumatic diseases and associated outcomes in rural and urban communities in Bangladesh: a COPCORD study. J Rheumatol 2005;32:348-353.
15.	Senna ER, De Barros AL, Silva EO, et al. Prevalence of rheumatic diseases in Brazil: a study using the COPCORD approach. J Rheumatol 2004;31:594-597.
16.	Topbas M, Cakirbay H, Gulec H, et al. The prevalence of fibromyalgia in women aged 20-64 in Turkey. Scand J Rheumatol 2005;34:140-144.
17.	White KP, Thompson J. Fibromyalgia syndrome in an Amish community: a controlled study to determine disease and symptom prevalence. J Rheumatol 2003; 30:1835-1840.
18.	Sorg BA. Multiple chemical sensitivity: potential role for

	neural sensitization. Crit Rev Neurobiol 1999;13:283-316.
19.	Caress SM, Steinemann AC. National prevalence of asthma and multiple chemical sensitivity: an examination of potential overlap. J Occup Environ Med 2005;47:518-522.
20.	Caress SM, Steinemann AC. A national population study of the prevalence of multiple chemical sensitivity. Arch Environ Health 2004;59:300-305.
21.	Caress SM, Steinemann AC. Prevalence of multiple chemical sensitivities: a population-based study in the southeastern United States. Am J Public Health 2004; 94:746-747.
22.	Caress SM, Steinemann AC. A review of a two-phase population study of multiple chemical sensitivities. Environ Health Perspect 2003;111: 1490-1497.
23.	Kreutzer R, Neutra RR, Lashuay N. Prevalence of people reporting sensitivities to chemicals in a population-based study. Am JEpidemiol 1999;150:1-12.
24.	Joffres M, Williams T, Sabo B, Rox R. Environmental sensitivities: prevalence of major symptoms in a referral centre: The Nova Scotia Environmental Sensitivities Research Center. Environ Health Perspect 2001;109:161-165.
25.	Hausteiner C, Bornschein S, Hansen J, Zilker T, Forstl H. Self-reported chemical sensitivity in Germany: a population-based survey. 2005;208:271-278.
26.	Yule W. Posttraumatic stress disorder in the general population and in children. J Clin Psychiatry 2001;62(Suppl 17):23-28.
27.	Breslau N. The epidemiology of posttraumatic stress

	disorder: what is the extent of the problem? J Clin Psychiatry 2001;62(Suppl 17):16-22.
28.	Kessler RC. Posttraumatic stress disorder: the burden to the individual and to society. J Clin Psychiatry 2001;62(Suppl 17):13-14.
29.	Martenyi F. Posttraumatic stress disorder (PTSD). Orv Hetil 2004;145: 2315-2322.
30.	Lecrubier Y Posttraumatic stress disorder in primary care: a hidden diagnosis. J Clin Psychiatry 2004;65(Suppl 1):49-54.
31.	Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Arch Gen Psychiatr_y, 1995;52:1048-1060.
32.	Stein MB, Walker JR, Hazen AL, Forde DR. Full and partial posttraumatic stress disorder: findings from a community survey. Ain J Ps ychintr_y 1997; 154:1114-1119.
33.	Frans O, Rimmo PA, Aberg L, Fredrikson M. Trauma exposure and posttraumatic stress disorder in the general population. Acta Psychiatr Scand 2005; 111:291-299.
34.	De Albuquerque A, Soares C, De Jesus PM, Alves C. Posttraumatic stress disorder (PTSD). Assessment of its rate of occurrence in the adult population of Portugal. Acta Med Prot 2003;16:309-320.
35.	Arillo Crespo A, Aguinaga Ontoso I, Guillen Grima F. Prevalence of mental diseases in women of an urban area. Aten Primaria 1998;21:265-269.
36.	Bleich A, Gelkopf M, Solomon Z. Exposure to terrorism, stress-related mental health symptoms, and coping behavior among a nationally representative sample in Israel. JAMA 2003;290:612-620.

37.	Atari N, Buchwald D. Chronic fatigue syndrome: a review. Am J Psychiatry 2003; 160:221-236.
38.	Jason LA, Richman JA, Rademaker AW, et al. A community based study of chronic fatigue syndrome. Arch. Intern Med 1999;159:2129-2137.
39.	Huibers MJH, Kant IJ, Swaen GMH, Kasl SV Prevalence of chronic fatigue syndrome-like caseness in the working population: results from the Maastricht cohort study. Occup Environ Med 2004;61:464-466.
40.	Evengard B, Jacks A, Pedersen NL, Sullivan PF. The epidemiology of chronic fatigue in the Swedish Twin Registry. Psychol Med 2005;35:1317-1326.
41.	Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med 2000;160:221-227.
42.	Buchwald D, Garrity D. Comparison of patients with chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities. Arch Intern Med 1994; 154: 2049-2053.
43.	Ciccone DS, Natelson BH. Comorbid illness in women with chronic fatigue syndrome: a test of a single syndrome hypothesis. Psychosom Med 2003;65:268-275.
44.	Aaron LA, Herrell R, Ashton S, et al. Comorbid clinical conditions in chronic fatigue syndrome: a co-twin study. J Gen Intern Med 2001;16:24-31.
45.	White KP, Speechley M, Harth M, Ostbye T. Co-existence of chronic fatigue syndrome with fibromyalgia syndrome in the general population: a controlled study. Scand J

	Rheumntol 2000;29:44-5 1.
46.	Reynolds KJ, Vernon SD, Bouchery E, Reeves WC. The economic impact of chronic fatigue syndrome. Cost Eff Resou Alloc 2004;2:4.
47.	Assefi NP, Coy TV, Uslan D, Smith WR, Buchwald D. Financial, occupational, and personal consequences of disability in patients with chronic fatigue syndrome and t3bromyalgia compared with other fatiguing conditions. J Rheumatol 2003;30:804-808.
48.	Wolfe F, Anderson J, Harkness D, et al. Work and disability status of persons with fibromyalgia. J Rheumatol 1997;24:1171-1178.
49.	Henriksson C, Burckhardt C. Impact of iïbromyalgia on everyday life: a study of women in the USA and Sweden. Disabil Rehabil 1996; 18:241-248.
50.	Henriksson C, Liedberg G. Factors of importance for work disability of women with fibromyalgia. J Rheumatol 2000;27:1271-1276.
51.	Robinson RL, Birnbaum HG, Morley MA, et al. Economic cost and epidemiological characteristics of patients with Obromyalgia pains. J Rheumatol 2003; 30:1318-1325. studies reported in a highly selected group of patients, over 2/3 claimed work disability.
52.	Terr AI. Environmental Illness: a clinical review of 50 cases. Arch Intern Med 1986;146:145-149.
53.	Black DW, Rathe A, Goldstein RB. Environmental illness: a controlled study of 26 patients with '20th century disease.' JAMA 1990;264:3166-3170.
54.	Smith MW, Schnurr PP, Rosenbeck RA. Employment

	outcomes and PTSD symptom severity. Ment Health Serv Res 2005;7:89-101.
55.	Matthews LR. Work potential of road accident survivors with posttraumatic stress disorder. Behav Res Ther 2005;43:475-483.
56.	Mueser KT, Essock SM, Haines M, Wolfe R, Xie H. Posttraumatic stress disorder, supported employment, and outcomes in people with severe mental illness. CNS Spectr 2004;9:913-925.
57.	MacDonald HA, Colotia V, Flamer S, Karlinsky H. Posttraumatic stress disorder (PTSD) in the workplace: a descriptive study of workers experiencing PTSD resulting from work injury. J Occup Rehabil 2003;13:63-77.
58.	Prigerson HG, Maciejewski PK, Rosenheck RA. Combat trauma: trauma with highest risk of delayed onset and unresolved posttraumatic stress disorder symptoms, unemployment, and abuse among men. J Nerv Ment Dis 2001;189: 99-108.
59.	Breslau N, Lucia VC, Davis GC. Partial PTSD versus full PTSD: an empirical examination of associated impairment. Psychol Med 2004;34:1205-1214.

[394 - [394]

HOOFDSTUK – 12

1.	Vasquez-Vivar J, Hogg N, Martasek P et al. Tetrahydrobiopterin-dependent inhibition of superoxide generation from neuronal nitric oxide synthase. J Biol Chem 1999;274:26736-26742.
2.	Andrew PJ, Mayer B. Enzymatic function of nitric oxide synthases. Cardiovasc Res 1999;43:521-531.
3.	Gorren AC, Schrammel A, Riethmuller C, et al. Nitric oxide-induced autoinhibition of neuronal nitric oxide synthase in the presence of the autoxidation-resistant pteridine 5-methyltetrahydrobiopterin. Biochem J 2000;347(Pt2);475-484.
4.	Huisman A, Vos I, van Faasen EE, et al. Anti-inflammatory effects of tetrahydrobiopterin on early rejection in renal allografts: modulation of inducible nitric oxide synthase. FASEB J 2002;16:1135-137.
5.	Cardounel AJ, Xia Y, Zweier JL. Endogenous methylarginines modulate superoxide as well as nitric oxide generation from neuronal nitric oxide synthase: differences in the effects of monomethyl- and dimethylarginines in the presence and absence of tetrahydrobiopterin. J Biol Chem 2005;280:7540-7549.
6.	Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric oxide synthase. J Biol Chem 2003;278:22546-22554.

7.	Alp NJ, Channon KM. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. <i>Arterioscler Thromb Vasc Biol</i> 2004;24:413-420.
8.	Kawashima S. Malfunction of vascular control in lifestyle-related diseases: endothelial nitric (NO) synthase/NO system in atherosclerosis. <i>J Pharmacol Sci</i> 2004;96(4):411-419.
9.	Delgado-Estaban M, Almeida A, Medina JM. Tetrahydrobiopterin deficiency increases neuronal vulnerability to hypoxia. <i>J Neurochem</i> 2002;82:1148-1159.
10.	Milstien S, Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. <i>Biochem Biophys Res Commun</i> 1999; 263:681-684.
11.	Kohnen SL, Mouithys-Mickalad AA, Deby-Dupont GP, et al. Oxidation of tetrahydrobiopterin by peroxynitrite or oxoferryl species occurs by a radical pathway. <i>Free Radic Res</i> 2001;35:709-721.
12.	Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric oxide synthase. <i>J Biol Chem</i> 2003;278:22546-22554.
13.	Kuhn DM, Geddes TJ. Tetrahydrobiopterin prevents nitration of tyrosine hydroxylase by peroxynitrite and nitrogen dioxide. <i>Mol Pharmacol</i> 2003;64:946-953.

[394 - [399]

HOOFDSTUK – 13

1.	Davidoff AL, Fogarty L. Methodological flaws of psychogenic MCS studies. Arch Environ Health 1994;49:316-324.
2.	Davidoff AL, Fogarty LM, Keyl PM. Outpatient inferences from data on psychologic/psychiatric symptoms in multiple chemical sensitivity syndrome. Arch Environ Health 2000;55:165-175.
3.	Goudsmit E. Response to Renckens. Psychosom Obster Gynecol 2001; 22:61-63.
4.	Komaroff AL. The biology of chronic fatigue syndrome. Am J Med 2000; 108:169-171.
5.	www.anapsid.org/cnd/files/mscseige.pdf
▲ 13-006	Radcliffe MJ, Ashurst P, Brostoff J. Unexplained illness: the mind versus the environment. J R Soc Med 1995;88:678-679. https://pubmed.ncbi.nlm.nih.gov/8786587/ / pdf
7.	Http://listserv.nodak.edu/cgi-bin/wa.exe?A2=ind0310b&L=co-cure&F=&S=&P=3853
8.	Dalen P. Forward. In Skewed. London: Slingshot Publications; 2003:ix-xiii. Boek https://slingshotpublications.com/skewed.html
9.	Martin J Walker. Skewed, London: Slingshot Publications, 2003. Boek https://slingshotpublications.com/martin-j-walker
10.	Jason LA, Richman JA, Friedberg F, Wagner L, Taylor R, Jordan KM. Politics, science and the emergence of `new

	disease': the case of chronic fatigue syndrome. <i>Anaer Psychol</i> 1998;52:973-983. https://pubmed.ncbi.nlm.nih.gov/9301342/
11.	Hedrick TE. Response to functional somatic syndromes. <i>Ann Intern Med</i> 2000; 132:327.
12.	Clemenger A. Response to functional somatic syndromes. <i>Ann Intern Med</i> 2000; 132:327-328.
13.	Albrecht F. Response to functional somatic syndromes. <i>Ann Intern Med</i> 2000;132:328-329.
14.	English TL. Response to functional somatic syndromes. <i>Ann Intern Med</i> 2000;132:329.
15.	Gots RE. Multiple chemical sensitivities: distinguishing between psychogenic and toxicodynamic. <i>Reg Toxicol Pharmacol</i> 1996;24:S8-S15.
16.	Barsky AJ, Borus JE Functional somatic syndromes. <i>Ann Intern Med</i> 1999; 130:910-921.
17.	Weissmuller GA, Ebel H, Hornberg C, Kwan O, Friel J. Are syndromes in environmental medicine variants of somatoform disorders? <i>Met/ Hypoth</i> 2003;61:419-430.
18.	Kellner R. Psychosomatic syndromes, somatization and somatoform disorders. <i>Psychother Psychosom</i> 1994;61:4-24.
19.	Groopman J. Hurting all over. <i>New Yorker</i> 2000;Nov 13:78-92.
20.	Staudenmayer H. Environmental Illness: Myth and Reality. Boca Raton, FL: Lewis Publishers; 1999.
21.	Wessely S, Nimnuan C, Sharpe M. Functional somatic syndromes: one or many? <i>Lancet</i> 1999;354:936-939.
22.	Binder LM, Campbell KA. Medically unexplained

	symptoms and neuropsychological assessment. J Clin Exp Neuropsychol 2004;26:369-392.
23.	Staudenmayer H, Binkley KE, Leznoff A, Phillips S. Idiopathic environmental intolerance Part 1: A causation analysis applying Bradford Hill's criteria to the toxicogenic theory. Toxicol Rev 2003;22:235-246.
24.	Staudenmayer H, Binkley KE, Leznoff A, Phillips S. Idiopathic environmental intolerance Part 2: A causation analysis applying Bradford Hill's criteria to the psychogenic theory. Toxicol Rev 2003;22:247-261.
25.	Sirois F. Perspectives on epidemic hysteria. In: Ilza Veith, ed. Hysteria: The History of a Disease, Chicago: University of Chicago Press;1965:217-236.
26.	Smith GR. Somatization disorder in the medical setting. U.S. Dept. of Health and Human Services, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration. Bethesda, MD: National Institute of Mental Health; 1990.
27.	Janca A. Rethinking somatoform disorders. Curr Opin Psychiatry 2005; 18:65-71.
28.	Epstein RM, Quill TE, McWhinney IR. Somatization reconsidered: incorporating the patient's experience of illness. Arch Intern Med 1999;159:215-222.
29.	American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders 4th ed. DSM-IV, Washington, DC: American Psychiatric Press; 1994. Reprinted with permission of APA.
30.	Gervais RO, Russell AS, Green P, et al. Effort testing in patients with fibromyalgia and disability incentives. J Rheumatol 2001;28:1892-1899.

31.	Mittenberg W, Patton C, Canyock EM, Condit DC. Base rates of malingering and symptom exaggeration. J Clin Exp Neuropsychol 2002;24:1094-1102.
32.	Khostanteen I, Tunks ER, Goldsmith CH, Ennis J. Fibromyalgia: can one distinguish it from simulation? An observer-blind controlled study. J Rheumatol 2000;27:2671-2676.
33.	Prins JB, Jongen PJ, van der Meer JW, Bleijenberg. Abnormal neuropsychological findings are not necessarily a sign of cerebral impairment: a matched comparison between chronic fatigue syndrome and multiple sclerosis. Neuropsychiatry Neuropsychol Behav Neurol 2000; 13:199-203.
34.	Porter, Roy. ed. The Cambridge Illustrated History of Medicine, UK: Cambridge;1996.
35.	Lurie, Hugh James. Clinical Psychiatry for the Primary Physician. Nutley, NJ: Roche Laboratories; 1976.
36.	Stoudemire, Alan. Human Behavior: An Introduction for Medical Students. Philadelphia: J.B. Lippincott Co; 1994.
37.	Deary V. Explaining the unexplained? Overcoming the distortions of a dualist understanding of medically unexplained illness. J Ment Health 2005; 14: 213-221.
38.	Mayou R, Kirmayer LJ, Simon G, Kroenke K, Sharpe M. Somatoform disorders: a time for a new approach in DSM-V. Am J Psychiatry 2005;162:847-855.
39.	Black DW Paroxetine for multiple chemical sensitivity. Am J Psychiatry 2002; 159:1436-1437. seroxat https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.159.8.1436-a
40.	Aring CD. Observations of multiple sclerosis and conversion

	hysteria. Brain 1965;88:663-674.
41.	Shaskan D, Yarnell H, Alper K. Physical, psychiatric and psychometric studies of post-encephalitic Parkinsonism. J Nerv Ment Dis 1942;96:652-662.
42.	Booth G. Psychodynamics of Parkinsonism. Psychosom Med 1948;10:1-14. 43. Trakas DA. Cutaneous clues to a psychiatric syndrome. Psychosomatics 1966;7:221-223.
44.	Campbell's Urology, 4th ed. Philadelphia, PA: W. B. Saunder's Company; 1979.
45.	Martin MJ. Psychogenic factors in headache. Med Clin North Am 1978; 62:559-570.
46.	Dorfman W. Closing the Gap between Medicine and Psychiatry. Springfield, IL: Charles C Thomas, Publisher;1966. Reprinted with permission from the publisher.
47.	Haley RW, Billecke S, La Du BN. Association of the low PON 1 type Q (type A) arylesterase activity with neurological symptom complexes in Gulf War veterans. Toxicol Appl Pharmacol 1999; 157:227-233.
48.	Furlong CE, Cole TB, Jarvik GP, et al. Role of paraoxonase (PON 1) status in pesticide sensitivity: genetic and temporal determinants. Neurotoxicology 2005; 26:651-659. https://pubmed.ncbi.nlm.nih.gov/16112327/
49.	McKeown-Eyssen G, Baines C, Cole DE, et al. Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR. Int J Epidemiol 2004;33:971-978. https://pubmed.ncbi.nlm.nih.gov/15256524/

50.	Binkley K, King N, Poonai N, Seeman P, Ulpian C, Kennedy K. Idiopathic environmental intolerance: increased prevalence of panic disorder-associated cholecystokinin B receptor allele 7. <i>J Allergy Clin Immunol</i> 2001;107:887-890.
51.	Pall ML. NMDA sensitization and stimulation by peroxynitrite, nitric oxide and organic solvents as the mechanism of chemical sensitivity in multiple chemical sensitivity. <i>FASEB J</i> 2002;16:1407-1417.
52.	Stanley I, Salmon P, Peters S. Doctors and social epidemics: the problem of persistent unexplained physical symptoms, including chronic fatigue. <i>Br J Gen Pract</i> 2002;52:355-356.
53.	Pall ML. Chronic fatigue syndrome/myalgic encephalomyelitis. <i>Br J Gen Pract</i> 2002;52:762.
54.	Stanley I, Salmon P, Peters S. Authors' response. <i>Br J Gen Pract</i> 2002; 52:763-764.
55.	Bohr TW. Fibromyalgia and myofascial pain syndrome. Do they exist? <i>Neurol Clin</i> 1995;13:365-384. Reprinted with permission from Elsevier.
56.	Staudenmayer H. Clinical consequences of the EI/MCS "diagnosis": two paths. <i>Regul Toxicol Pharmacol</i> 1996;24:S96-S 110. Reprinted with permission from Elsevier.
57.	Hazemaier I, Rasker JJ. Fibromyalgia and the therapeutic domain. A philosophical study on the origins of fibromyalgia in a specific social setting. <i>Rheumatol</i> 2003;42:507-515.
58.	Haq SA, Darmawan J, Islam MN, et al. Prevalence of rheumatic diseases and associated outcomes in rural and urban communities in Bangladesh: a COPCORD study. <i>J Rheumatol</i> 2005;32:348-353.

59.	Cardiel MH, Rojas-Serrano J. Community based study to estimate prevalence, burden of illness and help seeking behavior in rheumatic diseases in Mexico City. A COPCORD study. Clin Exp Rheumatol 2002;20:617-624.
60.	Topbas M, Cakirbay H, Gulec H, Akgol E, Ak I, Can G. The prevalence of fibromyalgia in women aged 20-64 in Turkey. Scand JRheumatol 2005;34:140-144.
61.	White KP, Thompson J. Fibromyalgia syndrome in the Amish community: a controlled study to determine disease and symptom prevalence. J Rheumatol 2003; 30:1835-1940.
62.	Hill AB. The environment and disease: association or causation. Proc R Soc Med 1965;58:295-300.
13-063	Ashford NA, Miller CS. Chemical Exposures: Low Levels and High Stakes. 2nd ed. New York: John Wiley & Sons, Inc;1998. Boek zie 01-041
64.	http://www.mcsrr.org/resources/bibliography/allchrono.html
65.	Miller CS. Toxicant-induced loss of tolerance-an emerging theory of disease? Environ Health Perspect 1997;105(Suppl 2):445-453.
66.	Cullen MR, ed. Workers with multiple chemical sensitivities. Occup Med: State Art Rev 1987;2:655-806.
67.	Cone JE, Sult TA. Acquired intolerance to solvents following pesticide/ solvent exposure in a building: a new group of workers at risk for multiple chemical sensitivities? Toxicol Ind Health 8:29-39.
68.	Miller CS, Mitzel HC. Chemical sensitivity attributed to pesticide exposure versus remodeling. Arch Environ Health 1995;50:119-129.

69.	Welch LS, Sokas R. Development of multiple chemical sensitivity after an outbreak of sick-building syndrome. Toxicol Ind Health 1992;8:47-50.
70.	Davidoff AL, Keyl PM. Symptoms and health status in individuals with multiple chemical sensitivities syndrome from four reported sensitizing exposures and a general population comparison group. Arch Environ Health 1996;51:201-213.
71.	Miller CS, Gammage RB, Jankovic JT. Exacerbation of chemical sensitivity: a case study. Toxicol Ind Health 1999;15:398-402. https://pubmed.ncbi.nlm.nih.gov/10416291/
72.	Lee TG. Health symptoms caused by molds in a courthouse. Arch Environ Health 2003;58:442-446.
73.	Corrigan FM, MacDonald S, Brown A, Armstrong K, Armstrong EM. Neurasthenic fatigue, chemical sensitivity and GABAa receptor toxins. Med Hypoth 1994;43:195-200. geen samenvatting
74.	Cone JE, Harrison R, Reiter R. Patients with multiple chemical sensitivities: clinical diagnostic subsets among an occupational health clinic population. Occup Med 1987;2:721-738.
75.	Adamec R. Modelling anxiety disorders following chemical exposures. Toxicol Ind Health 1994;10:391-420.
76.	Ziem G, and McTamney J. Profile of patients with chemical injury and sensitivity Environ Health Perspect 199T,105(Suppl 2):417-436.
▲ 13-077	Lohmann K, Prohl A, Schwarz E. Multiple chemical sensitivity disorder in patients with neurotoxic illnesses.

	Gesundheitswesen 1996;58:322-331. https://pubmed.ncbi.nlm.nih.gov/8766847/ Samenvatting
78.	Altenkirch H, Hopmann D, Brockmeier B, and Walter G. Neurological investigations in 23 cases of pyrethroid intoxication reported by the German Federal Health Office. Neurotoxicology 1996;17:645-651.
79.	Terr A. Environmental illness: a review of 50 cases. Arch Intern Med 1986; 146:145-149.▲
80.	Terr A. Clinical ecology in the workplace. J Occup Med 1989;31:257-261.
81.	Lee YL, Pai MC, Chen JH, Guo YL. Central neurological abnormalities and multiple chemical sensitivity caused by chronic toluene exposure. Occup Med (Lond) 2003;53:479-482.
82.	Caress SM, Steinemann AC. A review of a two-phase population study of multiple chemical sensitivities. Environ Health Perspect 2003;111:1490-1497.
83.	Simon GE. Epidemic multiple chemical sensitivity in an industrial setting. Toxicol Ind Health 1992;8(4):41-46.
84.	Henry CJ, Fishbein L, Meggs WJ, et al. Approaches for assessing health risks from complex mixtures in indoor air: a panel overview. Environ Health Perspect 1991;95:135-143.
85.	Fernandez-Sola, J, Lluís Padierna M, Nogue Xarau S, Munne Mas P. Chronic fatigue syndrome and multiple chemical hypersensitivity after insecticide exposition. Med Clin (Barc) 2005;124(12):451-453.
86.	Johnson, Alison, ed. Casualties of Progress: Personal Histories from the Chemically Sensitive. MCS Information Exchange, Brunswick, ME, 2000.

87.	Shinohara N, Y Yanagisawa. Responsible chemicals and behaviors for hypersensitive symptoms in patients with multiple chemical sensitivity. Jap J Clin Ecol 2004;13:93-101.
88.	Kawamoto MM, Esswein EJ, Wallingford KM, Wothington KA. Health Hazard Evaluation Report 96-0012-2652 Brigham and Women's Hospital Boston, MA September 1997. United States Government (NIOSH).
89.	Shinohara N, Mizukoshi A, Yanagisawa Y. Identification of responsible volatile chemicals that induce hypersensitive reactions to multiple chemical sensitivity patients. J Exposure Anal Environ Epidemiol 2004;14:84-91.
90.	Miller CS. Mechanisms of action of addictive stimuli. Addiction 2000; 96:115-139.
91.	Meggs WJ. Neurogenic inflammation and sensitivity to environmental chemicals. Environ Health Perspect 1993;101:234-238.
92.	van der Kuy PH, Lohman JJ. The role of nitric oxide in vascular headache. Pharm World Sci 2003;25:146-151.
93.	Jensen R. Peripheral and central mechanisms in tension-type headache: an update. Cephalalgia 2003;23(Suppl 1):49-52.
94.	Taylor RR, Friedberg F, Jason LA. A Clinician's Guide to Controversial Illnesses: Chronic Fatigue Syndrome, Fibromyalgia and Multiple Chemical Sensitivities. Sarasota, FL: Professional Resource Press;2001.

[399] - [417]

HOOFDSTUK – 14

1.	Miller, C. S. Are we on the threshold of a new theory of disease? Toxicantinduced loss of tolerance and its relationship to addiction and abdiction. Toxicol Irul Health 1999;15: 284-294.
2.	Kuhn T. The Structure of Scientific Revolutions. 3rd ed. Chicago: University of Chicago Press;] 966.
3.	Dorland's Illustrated Medical Dictionary. 24th ed. Philadelphia: W. B. Saunders Company; 1965.
4.	Stedman's Medical Dictionary, 26th ed.; Baltimore: Williams & Wilkins; 1995.
5.	Takumida M, Anniko M, Popa R, Zhang DM. Pharmacological models for inner ear therapy with emphasis on nitric oxide. Acta Otolaryngol 2001; 1 21:16-20.
6.	Shulman A. Neuroprotective drug therapy: a medical and pharmacological treatment for tinnitus control. Int 7innitus J 1997;3:77-93.
7.	Denk D-M, Heinzl H, Franz P, Ehrenberger K. Caroverine in tinnitus treatment. Acta Otolaryngol 1997;117:825-830.
8.	Oestreicher E, Arnold W, Ehrenberger K, Felix D. New approaches for inner ear therapy with glutamate antagonists. Acta Otolnryngol 1999; 119:174-178.
9.	Shulman A, Strashun AM, Goldstein BA. GABA,- Benzodiazepine-chloride receptor-targeted therapy for

	tinnitus control: preliminary report. <i>Int Tinnitus J</i> 2002;8:30-36.
10.	Raponi G, Alpini D, Volonte S, Capobianco S, Cesarini A. The role of free radicals and plasmatic antioxidant in Meniere's syndrome. <i>Int Tinnitus J</i> 2003; 9:104-108.
11.	Takumida M, Anniko M, Ohtani M. Radical scavengers for Meniere's disease after failure of conventional therapy: a pilot study. <i>Acta Otolaryngol</i> 2003; 123: 697-703.
12.	Shulman A. Noise, calpain, calpain inhibitors and neuroprotection: a preliminary report of tinnitus control. <i>Int Tinnitus J</i> 1998;4:134-140.
13.	Sziklai L The significance of the calcium signal in the outer hair cells and its possible role in tinnitus of cochlear origin. <i>Eur Arch Otorhinolaryngol</i> 2004; 261:517-525.
14.	Eybalin M. Neurotransmitters and neuromodulators in the mammalian cochlea. <i>Physiol Rev</i> 1993;73:309-373.
15.	Johnson KL, Carrasco V, Prazma J, et al. Role of nitric oxide in kainic acid-induced elevation of cochlear compound action potential thresholds. <i>Acta Otolaryngol (Stockh)</i> 1998; 118:660-665.
16.	Kumerova AO, Lece AG, Skesters AP, Orlikov GA, Seleznev JV, Rainsford KD. 2000 Antioxidant defense and trace element imbalance in patients with postradiation syndrome. <i>Biol Trace Element Res</i> 77:1-12.
17.	Loganovsky KN. Vegetative-vascular dystonia and osteoarthritic syndrome or chronic fatigue syndrome as a characteristic after-effect of radioecological disaster: the Chernobyl accident experience. <i>J Chronic Fatigue Syndr</i> 1999;7(3):3-16.

18.	Pastel RH. Radiophobia: long-term psychological consequences of Chernobyl. <i>Mil Med</i> 2002; 167(2 Suppl): 134-136.
19.	Barnes JG. 'Sensitivity syndromes' related to radiation exposure. <i>Med Hypoth</i> 2001;57:453-458.
20.	Linard C, Marquette C, Mathieu J, Pennequin A, Clarencon D, Mathe D. Acute induction of inflammatory cytokine expression after γ -irradiation in the rat: effect of an NF-KB inhibitor. <i>Int J Radiat Oncol Biol Phys</i> 2004; 58:427-434.
21.	Li N, Karin M. Ionizing radiation and short wavelength UV activate NF-KB through two distinct mechanisms. <i>Proc Natl Acad Sci USA</i> 1998; 95:13012-13017.
22.	Prasad AV, Mohan N, Chandrasekar B, Meltz ML. Activation of nuclear factor kappa B in human lymphoblastoid cells by low-dose ionizing radiation. <i>Radiat Res</i> 1994; 138:367-372.
23.	Wang T, Zhang X, Li JJ. The role of NF-KB in the regulation of cell stress responses. <i>Int Immunopharmacol</i> 2002;2:1509-1520.
24.	Taysi S, Koc M, Muyukokuroglu MF, Altinkaynak K, Sahin YN. Melatonin reduces lipid peroxidation and nitric oxide during irradiation-induced oxidative injury in the rat liver. <i>J Pineal Res</i> 2003;34:173-177.
25.	Abou-Donia MB, Dechkovskaia AM, Goldstein LB, Shah DU, Bullman SL, Khan WA. Uranyl acetate-induced sensorimotor deficit and increased nitric oxide generation in the central nervous system in rats. <i>Pharmacol Biochem Behav</i> 2002; 72:881-890.
26.	Takeda I, Kizu Y, Yoshitaka O, Saito I, Yamane GY Possible

	role of nitric oxide in radiation-induced salivary gland dysfunction. Radiat Res 2003; 159:465-470.
27.	Ibuki Y, Mizuno S, Goto R. γ -Irradiation-induced DNA damage enhances NO production via NF- κ B. Biochim Biophys Acta 2003;1593:159-167.
28.	Burlakova EB, Antova YS. Mechanism of biological action of low-dose irradiation. In: Bulokova, EB ed. Consequences of the Chernobyl Catastrophe on Human Health. Nova Science;1999.
29.	Briner W, Murray J. Effects of short-term and long-term depleted uranium exposure on open-field behavior and brain lipid oxidation in rats. Neurotoxicol Teratol 2005;27:135-144.
30.	Romanenko A, Morimura IK, Wanibuchi H, et al. Increased oxidative stress with gene alteration in urinary bladder urothelium after the Chernobyl accident. Int J Cancer 2000;86:790-798.
31.	Lykholat EA, Chemaya VI. Parameters of peroxidation and proteolysis in the organism of the liquidators of Chernobyl accident consequences. Ukr Biokhim Zh 1999;71:82-85.
32.	Chen Y, Rubin P, Williams J, Hernady E, Smudzin T, Okunieff P. Circulating IL-6 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 2001; 49:641-648.
33.	Chiang CS, Hong JH, Stalder A, Sun JR, Withers HR, McBride WH. Delayed molecular responses to brain irradiation. In J Radiat Biol 1997;72:45-53.
34.	Akiyama M. Late effects of radiation on the human immune system: an overview of immune response among the

	atomic-bomb survivors. Int J Radiat Biol 1995;68:497-508.
35.	Vozianov AF, Drannik GN, Petrovskaya IA, Musii MI. Immunity disorders and the increased fatigability syndrome in the residents of the city of Kiev. Vrach Delo 1991;(II):14-17.
36.	Vyatleva OA, Katargina TA, Puchinskaya LM, Yurkin MM. Electrophysiological characterization of the functional state of the brain in mental disturbances in workers involved in the clean-up following the Chernobyl atomic energy station accident. Neurosci Behav Physiol 1997;27:166-172.
37.	Rimar VV. Changes in the auditory system related to cerebral circulation in the Ukraine population after the Chernobyl disaster. Rev Larvngol Otl Rhinol (Bord) 1999;120:89-92.
38,	Loganovsky KN, Yuryev KL. EEG patterns in persons exposed to ionizing radiation as a result of the Chernobyl accident: part 1: conventional EEG analysis. JNeuropsychintry Clin Neurosci 2001; 13:441-458.
39.	Bruck W, Stadelmann C. Inflammation and degeneration in multiple sclerosis. Neurol Sci 2003;24(Suppl 5):S265-S267.
40.	Poser CM. Trauma to the central nervous system may result in formation of enlargement of multiple sclerosis plaques. Arch Neurol 2000;57:1074-1077.
41.	Sobel RA. The pathology of multiple sclerosis. Neurol Clin 1995;13:1-21. 42. Gilden DH. Viruses in multiple sclerosis. JAMA 2001;286:3127-3129.
43.	Steiner I, Wirguin I. Multiple sclerosis-in need of a critical reappraisal. Med Hypoth 2000;54:99-106.
44.	Barnett MH, Prineas JW Relapsing and remitting multiple

	sclerosis: pathology of the newly forming lesion. <i>Ann Neurol</i> 2004;55:458-468.
45.	Hernan MA, Zhang SM, Lipworth L, Olek MJ, Ascherio A. Multiple sclerosis and age at infection with common viruses. <i>Epidemiology</i> 2001;12:301-306.
46.	Nielsen NM, Wohlfahrt J, Melbye M, et al. Multiple sclerosis and poliomyelitis. A Danish historical cohort study. <i>Acta Neurol Scand</i> 2000;101:384-387.
47.	Granieri E. Exogenous factors in aetiology of multiple sclerosis. <i>J Neurovirol</i> 2000;6(Supp12): S 141-S 146.
48.	Munger KL, Peeling RW, Hernan MA, et al. Infection with <i>Chlamydia pneumoniae</i> and risk of multiple sclerosis. <i>Epidemiology</i> 2003; 14:141-147.
49.	Ruse T, Moen BE, Kyvik KR. Organic solvents and the risk of multiple sclerosis. <i>Epidemiology</i> 2002;13:718-720.
50.	Reis J, Dietermann JL, Warter JM, Poser CM. A case of multiple sclerosis triggered by organic solvents. <i>Neurol Sci</i> 2001;22:155-158.
51.	Mohr DC, Hart SL, Julian L, Cox D, Pelletier D. Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. <i>BMJ</i> 2004; 328:731.
52.	Buljevac D, Hop WC, Reedeker W, et al. Self reported stressful life events and exacerbations in multiple sclerosis: prospective study. <i>BMJ</i> 2003;327:646.
53.	Ordonez G, Pineda B, Garcia-Navarrete R, Sotelo J. Brief presence of varicella-zoster viral DNA in mononuclear cells during relapses of multiple sclerosis. <i>Arch Neurol</i> 2004;61:529-532.

54.	Wallin MT, Page WF, Kurtzke JF. Multiple sclerosis in US veterans of the Vietnam era and later military service: race, sex and geography. <i>Ann Neurol</i> 2004; 55:65-71.
55.	van der Mei IA, Posonby AL, Dwyer T, et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: a case-control study. <i>BMJ</i> 2003;327:316.
56.	Hayes CE. Vitamin D: a natural inhibitor of multiple sclerosis. <i>Proc NutrSoc</i> 2000;59:531-535.
57.	Chang JM, Kuo MC, Kuo HT, et al. 1-alpha,25-Dihydroxyvitamin D3 regulates inducible nitric oxide synthase messenger RNA expression and nitric oxide release in macrophage-like RAW 264.7 cells. <i>J Lab Clin Med</i> 2004;143:14-22.
58.	Lefebvre d'Hellencourt C, Montero-Menei CN, Bernard R, Couez D. Vitamin D3 inhibits proinflammatory cytokines and nitric oxide production in the EOC13 microglial cell line. <i>J Neurosci Res</i> 2003;71:575-582.
59.	Smith KJ, Lassmann H. The role of nitric oxide in multiple sclerosis. <i>Lancet Neurol</i> 2002;1:232-241.
60.	Cross AH, San M, Stern MK, et al. A catalyst of peroxynitrite decomposition inhibits murine experimental autoimmune encephalitis. <i>J Neuroimmunol</i> 2000; 107:21-28.
61.	Liu JS, Zhao ML, Brosnan CF, Lee SC. Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. <i>Am J Pathol</i> 2001;158: 2057-2066.
62.	Spitsin S, Hooper DC, Leist T, et al. Inactivation of peroxynitrite in multiple sclerosis patients with oral administration of inosine may suggest possible approaches to

	therapy of the disease. Mutt Scler 2001;7:313-319.
63.	Hunter MI, Nlamedim BC, Davidson DL. Lipid peroxidation products and antioxidant proteins in plasma and cerebrospinal fluid from multiple sclerosis patients. Neurochem Res 1985;10:1645-1652.
64.	Clabrese V, Raffaele R, Cosentino E, Rizza V. Int J Clin Pharmacol Res 1994;14:119-123.
65.	Vladimirova O, O'Connor J, Cahill A, et al. Oxidative damage to DNA in plaques of MS brains. Mult Scler 1998;4:413-418.
66.	Greco A, Minghetti L, Sette G, Fieschi C, Levi G. Cerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis. Neurology 1999;53:1876-1879.
67.	Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol 2004;251:261-268.
68.	Imitola J, Chitnis T, Khouri SJ. Cytokines in multiple sclerosis: from bench to bedside. Pharmacol Ther 2005;106:163-177.
69.	Biernacki K, Antel JP, Blain M, Narayanan S, Arnold DL, Prat A. Interferon beta promotes nerve growth factor secretion in the course of multiple sclerosis. Arch Neurol 2005;62:563-568.
70.	Schulte-Herbruggen O, Nassenstein C, Lommatzsch M, et al. Tumor necrosis factor-alpha and interleukin-6 regulate secretion of brain-derived neurotrophic factor in human monocytes. J Neuroimmunol 2005;160:204-209.

71.	Flachenecker P, Bihler I, Weber F, et al. Cytokine mRNA expression in patients with multiple sclerosis and fatigue. <i>Mult Scler</i> 2004;10: 165-169.
72.	Miterski B, Bohringer S, Klein W, et al. Inhibitors in the NF-kappa B cascade comprise prime candidate genes predisposing to multiple sclerosis, especially in selected combinations. <i>Genes Immun</i> 3:211-219.
73.	Kaltschmidt B, Spama T, Kaltschmidt C. Activation of NF-kappa B by reactive oxygen intermediates in the nervous system. <i>Antioxid Redox Signal</i> 1999;1:129-144.
74.	Bonetti B, Stegagno C, Cannella B, et al. Activation of NF-kappa B and c-jun transcription factors in multiple sclerosis lesions. Implications for oligodendrocyte pathology. <i>Am J Pathol</i> 1999;155:1433-1438.
75.	Gveric D, Kaltschmidt C, Cuzner ML, Newcombe J. Transcription factor NFkappa B and inhibitor I kappaB-alpha are localized in macrophages in active multiple sclerosis lesions. <i>J Neuropathol Exp Neurol</i> 1998;57:168-178.
76.	Paul C, Bolton C, Modulation of blood-brain barrier dysfunction and neurological deficits during acute experimental allergic encephalomyelitis by the N-methyl-D-aspartate receptor antagonist memantine. <i>J Pharmacol Exp Ther</i> 2002; 302:50-57.
77.	Sarchielli P, Greco L, Floridi A, Floridi A, Gallai V. Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid. <i>Arch Neurol</i> 2003;60: 1082-1088.
78.	Pitt D, Nagelmeier IE, Wilson HC, Raine CS. Glutamate uptake by oligodendrocytes: Implications for excitotoxicity in multiple sclerosis. <i>Neurology</i> 2003;61: 1113-1120.

79.	Srinivasan R, Sailsuta N, Hurd R, Nelson S, Pelletier D. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. <i>Brain</i> 2005;128:1016-1025.
80.	Kent-Braun JA, Sharma KR, Miller RG, Weiner MW. Postexercise phosphocreatine resynthesis is slowed in multiple sclerosis. <i>Muscle Nerve</i> 1994; 17:835-841.
81.	Hooper DC, Scott GS, Zborek A, et al. Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, bolld CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis. <i>FASEB J</i> 2000;14:691-698.
82.	Smith KJ, Kapoor R, Felts PA. Demyelination: the role of reactive oxygen and nitrogen species. <i>Brain Pathol</i> 1999;9:69-92.
83.	Scott GS, Virag L, Szabo C, Hooper DC. Peroxynitrite-induced oligodendrocyte toxicity is not dependent on poly(ADP-ribose) polymerase activation. <i>Glia</i> 2003;41:102-116.
84.	Touil T, Deloire-Grassin MS, Vital C, Petry KG, Brochet B. In vivo damage of CNS myelin and axons induced by peroxynitrite. <i>Neuroreport</i> 2001; 12:3637-3644.
85.	Santiago E, Perez-Mediavilla LA. Lopez-Moratalla N. The role of nitric oxide in the pathogenesis of multiple sclerosis. <i>J Physiol Biochem</i> 1998;54:229-237.
86.	Yamashita Y, Fujimoto C, Nakajima E, Isagai T, Matsuishi T. Possible association between congenital cytomegalovirus infection and autistic disorder. <i>J Autism Dev Disord</i> 2003;33:455-459.

87.	Ivarsson SA, Bjerre I, Vegfors P, Ahlfors K. Autism is one of several disabilities in two children with congenital cytomegalovirus infection. <i>Neuropediatrics</i> 1990;21:102-103.
88.	Deykin EY, MacMahon B. Viral exposure and autism. Chess S. 1977 Followup report on autism in congenital rubella. <i>Am J Epidemiol</i> 1979;109:628-638.
89.	Sweeten TL, Posey DJ, McDougle CJ. Brief report: autistic disorder in three children with cytomegalovirus infection. <i>J Autism Dev Disord</i> 2004;34:583-586.
90.	Wilkerson DS, Volpe AG, Dean RS, Titus JB. Perinatal complications as predictors of infantile autism. <i>Int J Neurosci</i> 2002;112:1085-1098.
91.	Barak Y, Kimhi R, Stein D, Gutman J, Weizman A. Autistic subjects with comorbid epilepsy: a possible association with viral infections. <i>Child Psychiatry Hum Dev</i> 1999;29:245-251.
92.	Chess S. Follow-up report on autism in congenital rubella. <i>J Autism Child Schizophr</i> 1977;7:69-81.
93.	Libbey JE, Sweeten TL, McMahon WM, Fujinami RS. Autistic disorder and viral infections. <i>JNeurovirol</i> 2005;11:1-10.
94.	Shi L, Fatemi SH, Sidwell RW, Patterson PH. Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. <i>JNeurosci</i> 2003;23:297-302.
95.	Pletnikov MV, Moran TH, Carbone KM. Borna disease virus infection of the neonatal rat: developmental brain injury model of autism spectrum disorders. <i>Front Biosci</i>

	2002;7:d593-607.
96.	Hornig M, Briesse T, Lipkin WI. Bornavirus tropism and targeted pathogenesis: virus-host interactions in a neurodevelopmental model. <i>Adv Virus Res</i> 2001; 56:557-582.
97.	Geier DA, Geier MR. A two-phased population epidemiological study of the safety of thimerosal-containing vaccines: a follow-up analysis. <i>Med Sci Monit</i> 2005;11:CR 160-170.
98.	Bernard S, Enayati A, Roger H, Binstock T, Redwood L. The role of mercury in the pathogenesis of autism. <i>Mol Psychiatry</i> 2002;7(Suppl)2:S42-S43.
99.	Geier MR, Geier DA. Neurodevelopmental disorders after thimerosal-containing vaccines: a brief communication. <i>Exp Biol Med</i> 2003;228:660-664.
100.	Blaxill MF, Redwood L, Bernard S. Thimerosal and autism? A plausible hypothesis that should not be dismissed. <i>Med Hypotheses</i> 2004;62:788-794.
101.	Holmes AS, Blaxill MF, Haley BE. Reduced levels of mercury in first baby haircuts of autistic children. <i>Int J Toxicol</i> 2003;22:277-285.
102.	Forstermann U, Goppelt-Strube M, Frolich JC, Busse R. Inhibition of acylcoenzyme A: lysolecithin acyltransferase activated the production of endothelial-derived relaxing factor. <i>J Pharmacol Exp Therapeutics</i> 1986;238:252-259.
103.	Forstermann U, Goppelt-Strube M, Frolich JC, Busse R. Thimerosal, an inhibitor of endothelial acyl-coenzyme A: lysolecithin acyltransferase, stimulates the production of a nonprostanoid endothelium-derived relaxing factor. <i>Adv</i>

	Prostaglandin Thromboxane Leukot Res 1987;17B:1108-1111.
104.	Mulsch A, Bohme E, Busse R. Stimulation of soluble guanylate cyclase by endothelium-derived relaxing factor from cultured endothelial cells. Eur J Pharmacol 1987;135:247-250.
105.	Beny JL. Thimerosal hyperpolarizes arterial smooth muscles in an endothelium-dependent manner. Eur J Pharmacol 1990; 185:235-238.
106.	Crack P, Cocks T. Thimerosal blocks stimulated but not release of endothelium-derived relaxing factor (EDRF) in dog isolated coronary artery. Br J Pharmacol 1992;107:566-572.
107.	Chen YJ, Jiang H, Quilley J. The nitric oxide- and prostaglandin independent component of the renal vasodilator effect of thimerosal is mediated by epoxyeicosatrienoic acids. J Pharmacol Exp Ther 2003;304:1292-1298.
108.	Edelson SB, Cantor DS. Autism: xenobiotic influences. Toxicol Inct Health 1998;14:799-81t.
109.	McGinnis WR. Oxidative stress in autism. Altem. Ther Health Med 2004; 10:22-36.
110.	Blaylock RL. Interactions of cytokines, excitotoxins and reactive nitrogen and oxygen species in autism spectrum disorders. JAm Neutraceutical Assoc 2003; 6:21-35.
111.	Angeli A, Minetto M, Dovio A, Paccotti P. The overtraining syndrome in athletes: a stress-related disorder. J Endocrinol Invest 2004;27:603-612.
112.	Steinacker JM, Lormes W, Reissnecker S, Liu Y. New

	aspects of the hormone and cytokine response to training. Eur J Appl Physiol 2004;91:382-391.
113.	Pearce FZ. A practical approach to the overtraining syndrome. Curr Sports Med Rep 2002;1:179-183.
114.	MacKinnon LT. Special feature for the Olympics: effects of exercise on the immune system: overtraining effects on immunity and performance in athletes. Immunol Cell Biol 2000;78:502-509.
115.	Pederson BK, Rohde T, Zacho M. Immunity in athletes. J Sports Med Phys Fitness 1996;36:236-245.
116.	Lehmann M, Foster C, Dickhuth HH, Gastmann U. Autonomic imbalance hypothesis and overtraining syndrome. Med Sports Exerc 1998;30:1140-1145.
117.	Smith LL. Cytokine hypothesis of overtraining: a physiological adaptation to excessive stress? Med Sci Sports Exerc 2000;32:317-331.
118.	Robson P. Elucidating the unexplained underperformance syndrome in endurance athletes: the interleukin-6 hypothesis. Sports Med 2003;33:771-781.
119.	Stefano GB, Prevot V, Cadet P, Dardik L. Vascular pulsations stimulating nitric oxide release during cyclic exercise may benefit health: a molecular approach (review). Int J Mol Med 2001;7:119-129.
120.	MacDonald KL, Osterholm MT, LeDell KH, et al. A case-control study to assess possible triggers and cofactors in chronic fatigue syndrome. Am J Med 1996; 100:548-554.
121.	Jackson MJ, Khassaf M, Vasilaki S, McArdle F, McArdle A. Vitamin E and the oxidative stress of exercise. Ann NY Acad Sci 2004;1031:158-168.

122.	Ji LL, Gomez-Cabrera MC, Steihafel N, Vina J. Acute exercise activates nuclear factor (NF)-kappa B signaling pathway in rat skeletal muscle. <i>FASEB J</i> 2004; 18:1499-1506.
123.	Inhan N, Kamanli A, Ozmerdivenli R, Ilhan N. Variable effects of exercise intensity on reduced glutathione, thiobarbituric acid reactive substance levels, and glucose concentration. <i>Arch Med Res</i> 2004;35:294-300.
124.	Aoi W, Naito Y, Takanami Y, et al. Oxidative stress and delayed-onset muscle damage after exercise. <i>Free Radic Biol Med</i> 2004;37:480-487.
125.	Lauer N, Suvorava T, Ruther U, et al. Critical involvement of hydrogen peroxide in exercise-induced up-regulation of endothelial NO synthase. <i>Cardiovasc Res</i> 2005;65:254-262.
126.	Karamouzis I, Christoulas K, Grekas D, et al. The response of muscle interstitial F2-isoprostane (8-ISO-PGF2alpha) during dynamic muscle contractions in humans. <i>Prostaglandins Leukot Essent Fatty Acids</i> 2004;71:87-90.
127.	Bailey DM, Young IS, McEneny J, et al. Regulation of free radical outflow from an isolated muscle bed in exercising humans. <i>Am J Physiol Heart Circ Physiol</i> 2004;287: H 1689-H] 699.
128.	Cavas L, Tarhan L. Effects of vitamin-mineral supplementation on cardiac marker and radical scavenging enzymes, and MDA levels in young swimmers. <i>Int J Sport Nutr Exerc Metab</i> 2004;14:133-146.
129.	MacDonald KL, Osterholm MT, LeDell KH, et al. A case-control study to assess possible triggers and cofactors in chronic fatigue syndrome. <i>Am J Med</i> 1996; 100:548-554.

130.	Hennekins CH, Lee IM, Cook NR, et al. Self-reported breast implants and connective tissue diseases in female health professionals. A retrospective cohort study. JAMA 1996;275:616-621.
131 .	Vasey FB. Clinical experience with systemic illness in women with silicone breast implants: comment on the editorial by Rose. Arthritis Rheum 1997;40:1545.
132.	Brown SL, Pennello G, Berg WA, Soo MS, Middleton MS. Silicone gel breast implant rupture, extracapsular silicone, and health status in a population of women. J Rheumatol 2001;28:996-1003.
133.	Brown SL, Duggirala HJ, Pennello G. An association of silicone-gel breast implant rupture and fibromyalgia. Curr Rheumatol Rep 2002;4:293-298.
134.	Solomon G. A clinical and laboratory profile of symptomatic women with silicone breast implants. Semin Arthritis Rheum 1994;24(Suppl 1):29-37.
135.	Cuellar ML, Gluck O, Molina JF, et al. Silicone breast implant-associated musculoskeletal manifestations. Clira Rheumatol 1995; 14:667-672.
136.	Vermeulen RC, Scholte HR. Rupture of silicone breast implants and symptoms of pain and fatigue. J Rheumatol 2003;30:2263-2267.
137.	Blackburn WD Jr, Grotting JC, Everson MP. Lack of evidence of systematic inflammatory rheumatic disorders in symptomatic women with breast implants. Plast Reconstr Surg 1997;99:1054-1060.
138.	Freundlich B, Altman C, Snadorfi N, Greenberg M, Tomaszewski J. A profile of symptomatic patients with

	silicone breast implants: a Sjogren's-like syndrome. SeminArt/iritis Rheum 1994;24(Suppl 1):44-53.
139.	Fenske TK. Human adjuvant disease revisited: a review of eleven post-augmentation mammoplasty patients. Clin Exp Rheumatol 1994;12:477-481.
140.	Lipworth L, Tarone RE, McLaughlin JK. Breast implants and fibromyalgia: a review of the epidemiological evidence. Anti Plast Surg 2004;52:284-287.
141.	Miller CS, Prihoda TJ. A controlled comparison of symptoms and chemical intolerances reported by Gulf War veterans, implant recipients and persons with multiple chemical sensitivity. Toxicol Ind Health 1999; 15:386-397.
142.	Shanklin DR, Smalley DL. Pathogenetic and diagnostic aspects of siliconosis. Rev Environ Health 2002;17:85-105.
143.	Smalley DL, Shanklin DR, Hall MF, Stevens MV, Hanissian A. Immunologic stimulation of T lymphocytes by silica after use of silicone mammary implants. FASEB J 1995;9:424-427.
144.	Castranova V. Signalling pathways controlling the production of inflammatory mediators in response to crystalline silica exposure: role of reactive oxygen/ nitrogen species. Free Radic Biol Med 2004;37:916-925.
145.	Misson P, van den Brule S, Barbarin V, Lison D, Huaux F. Markers of lymphocyte differentiation in experimental silicosis. J Leukoc Biol 2004;76:926-932.
146.	Fubini B, Hubbard A. Reactive oxygen species (ROS) and reactive nitrogen species (RNS) generation by silica in inflammation and fibrosis. Free Radic Biol Med 2003;34:1507-1516.

147.	Zeidler PC, Castranova V. Role of nitric oxide in pathological responses of the lung to exposure to environmental/occupational agents. Redox Rep 2004; 9:7-18.
148.	Chen F, Shi X. NF-kappa B, a pivotal transcription factor in silica-induced diseases. Mol Cell Biochem 2002;235:169-176.
149.	Iribarren P, Correa SG, Sodero N, Riera CM. Activation of macrophages by silicones: phenotype and production of oxidant metabolites. BMC Immunol 2002;3:6.
150.	Ojo-Amaize EA, Lawless OJ, Peter JB. Elevated concentrations of interleukin-1 beta and interleukin-1 receptor antagonist in plasma of women with silicone breast implants. Clin Diagn Lab Immunol 1996;3:257-259.
151.	Mena EA, Kossovsky N, Chu C, Hu C. Inflammatory intermediates produced by tissues encasing silicone breast prostheses. J Invest Surg 1995;8:31-42.
152.	Pollock JS, Webb W, Callaway D, et al. Nitric oxide synthase isoform expression in porcine model of granulation tissue formation. Surgery 2001;129: 341-350.
153.	G1. Paice E. Fortnightly review: reflex sympathetic dystrophy. BMJ 1995; 310:1645-1648.
154.	Marsden CD, Obeso JA, Traub MM, et al. Muscle spasms with Sudeck's atrophy after injury. Br Med J 1984;288:173-176.
155.	Veldman PHJM, Reynen HM, Arntz IE, Goris RJA. Signs and symptoms of reflex sympathetic dystrophy: a prospective study of 829 patients. Lancet 1993; 342:1012-1016.

156.	Weber M, Neundorfer B, Birklein F. Sudeck's atrophy: pathophysiology and treatment of complex pain syndrome. Dtsch Med Wochenshr 2002;127:384-389.
157.	Imanuel HM, Levy FL, Geldwert JJ. Sudeck's atrophy: a review of the literature. J Foot Surg 1981;20:243-246.
158.	Cordioli E, Tondini C, Pizzi C, Premuda G. Sudeck's atrophy: a review of the literature. Minerva Med 1994;85:265-270.
159.	Williams WR. Reflex sympathetic dystrophy. Rheumatol Rehabil 1977; 16:119-124.
160.	Sarangi PP, Ward AJ, Smith EJ, Staddon GE, Atkins RM. Algodystrophy and osteoporosis after tibial fractures. J Bone Joint Surg 1993;75:450-452.
161,	van der Laan L, Goris RJ. Sudeck's syndrome. Was Sudeck right? Unfallchirurg 1997;100:90-99.
162.	Bruckbauer HR, Preac Mursic V, Herzer P, Hofmann H. Sudeck's atrophy in Lyme borreliosis. Infection 1997;25:372-376.
163.	Sahin M, Bernay I, Canturk F, Demarcali AE. Reflex sympathetic dystrophy secondary to organophosphate intoxication induced neuropathy. Ann Nucl Med 1994;8:299-300.
164.	Friedman LS, Brautbar N, Barach P, Wolfe AH, Richter ED. Creatine phosphate kinase elevations signaling muscle damage following exposures to anticholinesterases: 2 sentinel patients. Arch Environ Health 2003;58:167-170.
165.	Lin TC, Wong CS, Chen FC, Lin SY, Ho ST. Long-term epidural ketamine and bupivacaine attenuate reflex sympathetic dystrophy neuralgia. Can J Anaesth

	1998;45:175-177.
166.	Schwartzman TJ, Popescu A. Reflex sympathetic dystrophy. Curr Rheumatol Rep 2002;4:165-169.
167.	Von Eisenhart-Rothe R, Rittmeister M. Drug therapy in complex regional pain syndrome type I. Orthopade 2004;33:796-803.
168.	Harden R, Norman MD. Pharmacotherapy of complex regional pain syndrome. Pain Science Rational Polypharmacy 2005;84(Suppl):S 17-S28.
	169. Tews DS, Apoptosis and muscle fibre loss in neuromuscular disorders. Neuromuscul Disord 2002; 12:613-622.
170.	Li YP, Atkins CM, Sweatt JD, Reid MB. Mitochondria mediate tumor necrosis factor-alpha/NF-kappa B signaling in skeletal muscle. Antioxid Redox Signal 1999;1:97-104.
171.	Mentaverri R, Kamel S, Wattel A, Regulation of bone resorption and osteoclast survival by nitric oxide: possible involvement of NMDA receptor. J Cell Biochem 2003;88:1145-1156.
172.	Hukkanen V, Broberg E, Salmi A, Eralinna JP Cytokines in experimental herpes simplex virus infection. Int Rev Immunol 2002;21:355-371.
173.	Imanishi J. Expression of cytokines in bacterial and viral infections and their biochemical targets. J Biochem 2000; 127:525-530.
174.	Skoldenberg B. Herpes simplex encephalitis. Scand J Infect Dis Suppl 1996;100:8-13.
175.	Treede RD, Meyer RA, Raja SN, Campbell JN. Peripheral

	and central mechanisms of cutaneous hyperalgesia. Prog Neurobiol 1992;38:397-421.
176.	Meller ST, Pechman PS, Gebhart GF, Maves TJ. Nitric oxide mediates the thermal hyperalgesia produced in a model of neuropathic pain in the rat. Neuroscience 1992;50:7-10.
177.	Zimmermann M. Pathobiology of neuropathic pain. Eur J Pharmacol 2001; 429:23-37.
178.	Wagner R, Myers RR. Endoneurial injection of TNF- α produces neuropathic pain behaviors. Neuroreport 1996;7:2897-2901.
179.	Leung A, Wallace MS, Ridgeway B, Yaksh T. Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain 2001;91:177-187.
180.	Walker KM, Urban L, Medhurst SJ, et al. The VR 1 antagonist capsazepine reverses mechanical hyperalgesia in models of inflammatory and neuropathic pain. Pharmacol Exp Ther 2003;304:56-62.
181.	DeLeo JA, Colburn RW, Nichols M, Malhotra A. Interleukin-6-mediated hyperalgesia/allodynia and increased IL-6 expression is a rat mononeuropathy model. J Interferon Cytokine Res 1996; 16:695-700.
182.	Bonezzi C, Demartini L. Treatment options in postherpetic neuralgia. Acta Neurol Scand Suppl 1999;173:25-35.
183.	Backonja M, Galnzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther 2003;25:81-104.

184.	Brill S, Sedgwick PM, Hamann W, Di Vadi PP. Efficacy of intravenous magnesium in neuropathic pain. <i>Br J Anesth</i> 2002;89:711-714.
185.	Douglas MW, Johnson RW, Cunningham AL. Tolerability of treatments for postherpetic neuralgia. <i>Drug Saf</i> 2004;27:1217-1233.
186.	Klepstad P, Borchgrevink PC. Four years' treatment with ketamine and a trial of dextromethorphan in a patient with severe post-herpetic neuralgia. <i>Acta Anaesthesiol Scand</i> 1997;41:422-431.
187.	Kotani N, Kudo R, Sakurai Y, et al. Cerebrospinal fluid interleukin 8 concentrations and the subsequent development of postherpetic neuralgia. <i>Am J Med</i> 2004; 116:318-324.
188.	Zak-Prelich M, McKenzie RC, Sysa-Jedrzejowska A, Norval M. Local immune responses and systemic cytokine responses in zoster: relationship to the development of postherpetic neuralgia. <i>Clin Exp Immunol</i> 2003;131:318-323.
189.	Kotani N, Kushikata T, Hashimoto H, et al. Intrathecal methylprednisolone for intractable postherpetic neuralgia. <i>N Engl J Med</i> 2000;343:1514-1519.
190.	Sterling M, Jull G, Vincenzino B, Kenardy J. Sensory hypersensitivity occurs soon after whiplash injury and its associated poor recovery. <i>Pain</i> 2003;104: 509-517.
191.	Haldorsen T, Waterloo K, Dahl A, et al. Symptoms and cognitive dysfunction in patients with the late whiplash syndrome. <i>Appl Neuropsychol</i> 2003;10:170-175.
192.	Antepohl W, Kiviloog L, Andersson J, Gerdle B. Cognitive

	impairment in patients with chronic whiplash-associated disorder-a matched control study. <i>NeuroRehabilitation</i> 2003;18:307-315.
193.	Bosma FK, Kessels RP. Cognitive impairments, psychological dysfunction and coping styles in patients with chronic whiplash syndrome. <i>Neuropsychiatr, Neuropsychol Behav Neurol</i> 2002; 15:56-65.
194.	Sullivan MJ, Hall E, Barolacci R, Sullivan ME, Adams H. Perceived cognitive deficits, emotional distress and disability following whiplash injury. <i>Pain Res Manag</i> 2002;7:120-126.
195.	Treleaven J, Jull G, Sterling M. Dizziness and unsteadiness following whiplash injury: characteristic features and relationship with cervical joint position error. <i>J Rehabil Med</i> 2003;35:36-43.
196.	Wenzel HG, Haug TT, Mykletun A, Dahl AA. A population study of anxiety and depression among persons who report whiplash traumas. <i>J Psychosom Res</i> 2002;53:831-835.
197.	Alexander MP. The evidence for brain injury in whiplash injuries. <i>Pain Res Manag</i> 2003;8:19-23.
198.	Curatolo M, Petersen-Felix S, Arendt-Nielsen L, et al. Central hypersensitivity in chronic pain after whiplash injury. <i>Clin J Pain</i> 2001;17:306-315.
199.	Banic B, Petersen-Felix S, Andersen OK, et al. Evidence for spinal cord hypersensitivity in chronic pain after whiplash injury and in fibromyalgia. <i>Pain</i> 2004; 107:7-15.
200.	Klobas L, Tegelberg A, Axelsson S. Symptoms and signs of temporomandibular disorders in individuals with chronic whiplash-associated disorders. <i>Swed Dent J</i> 2004;28:29-36.

201.	Ushida T, Tani T, Kanbara T, et al. Analgesic effects of ketamine ointment in patients with complex regional pain syndrome type I. <i>Reg Anesth Pain Med</i> 2002; 27:524-528.
202.	Summers WK. Alzheimer's disease, oxidative injury and cytokines. <i>JAlzheimer's Dis</i> 2004;6:673-68 1.
203.	Schmidt ML, Lee VM-Y, Saido T, et al. Amyloid plaques in Guam amyotrophic lateral sclerosis/parkinsonism-dementia complex contain species of A β similar to those found in the amyloid plaques in Alzheimer's disease and pathological aging. <i>Acta Neuropnthol</i> 1998;95:117-122.
204.	Brownson DM, Mabry TJ, Leslie SW. The cycad neurotoxicity amino acid, beta-N-methylamino-L alanine (BMAA), elevates intracellular calcium levels in dissociated rat brain cells. <i>J Ethnopharm.acol</i> 2002;\$2:159-167.
205.	Allen CN, Omelchenko I, Ross SM, Spencer P. The neurotoxin, beta-N-methylamino-L-alanine (BMAA) interacts with the strychnine-insensitive glycine modulatory siteof the N-methyl-D-aspartate receptor. <i>Neuropharmacol</i> 1995;34: 651-658.
206.	Khabazian I, Bains JS, Williams DE, et al. Isolation of various forms of stero?-D-glucoside from the seed of <i>Cycas circinalis</i> : neurotoxicity and implications of ALS-parkinsonism dementia complex. <i>J Neurochem</i> 2002;82:516-523.
207.	Takahashi H, Snow BJ, Bhatt MH, et al. Evidence or a dopaminergic deficit in sporadic amyotrophic lateral sclerosis on positron emission scanning. <i>Lancet</i> 1993;342:1016-1018.
208.	Hartman RE, Laurer H, Longhi L, et al. Apolipoprotein E4 influences amyloid deposition but not cell loss after

	traumatic brain injury in a mouse model of Alzheimer's disease. J Neurosci 2002;22:10083-10087.
209.	Li YJ, Hauser MA, Scott WK, et al. Apolipoprotein E controls the risk and age of onset of Parkinson's disease. Neurology 2004;62:2005-2009.
210.	Drory VE, Birnbaum M, Korczyn AD, Chapman J. Association of APOE $\epsilon 4$ allele with survival in amyotrophic lateral sclerosis. JNeurol Sci 2001; 190:17-20.
211.	Masliah E, Rockenstein E, Veinbergs I, et al. β -amyloid peptides enhance α -synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci USA 2001; 98:12245-12250.
212.	Hageman G, van der Hoek J, van Hout M, et al. Parkinsonism, pyramidal signs, polyneuropathy and cognitive decline after long-term occupational exposure. J Neurol 1999;246:198-206.
213.	Uitti RJ, Snow BJ, Shinotoh H, et al. Parkinsonism induced by solvent abuse. Ann Neurol 1994;35:616-619.
214.	Ohlson CG, Hogstedt C. Parkinson's disease and occupational exposure to organic solvents, agricultural chemicals and mercury-a case-referent study. Scand J Work Environ Health 1981;7:252-256.
215.	Kuriwaki R, Mitsui T, Fujiwara S, Nishida Y, Matsumoto T. Loss of postural reflexes in long-term occupational solvent exposure. Eur Neurol 2002;47:85-87.
216.	Cintra A, Andbjør B, Finnman UB, et al. Subacute toluene exposure increases DA dysfunction in the 6-OH dopamine lesioned nigrostriatal dopaminergic system of the rat.

	Neurosci Lett 1996;217:61-65.
217.	Kamel F, Hoppin JA. Association of pesticide exposure with neurologic dysfunction and disease. Environ Health Perspect 2004;112:950-958.
218.	Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of mepiridine analog synthesis. Science 1983;219:979-980.
219.	Lockwood AH. Pesticides and parkinsonism: is there an etiological link? Curr Opin Neurol 2000; 13:687-690.
220.	Uversky VN. Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res 2004;318:225-241.
221.	Thiruchelavam M, Richfield EK, Goodman BM, Baggs RB, Cory-Slechta DA. Developmental exposure to the pesticides paraquat and maneb and the Parkinson's disease phenotype. Neurotoxicology 23:627-633.
222.	Racette BA, McGee-Minnich L, Moerlein SM, et al. Welding-related parkinsonism: clinical features, treatment and pathophysiology. Neurology 2001; 56:8-13.
223.	Hudness HK. Effects of environmental Mn exposures: a review of the evidence from non-occupational exposure studies. Neurotoxicology 1999;20:379-397.
224.	Olanow CW. Manganese-induced parkinsonism and Parkinson's disease. Ann NY Acad Sci 2004;1012:209-223.
225.	Lee JW. Manganese intoxication. Arch Neurol 2000;57:597-599.
226.	Jakowec MW, Petzinger GM. 1-methyl-4-phenyl-1,2,3,6-

	tetrahydropyridinelesioned model of Parkinson's disease, with emphasis in mice and nonhuman primates. <i>Comp Med</i> 2004;54:497-513.
227.	Przedborski S, Vila M. The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. <i>Ann NY Acad Sci</i> 2003;991:641-646.
228.	Przedborski S, Jackson-Lewis V, Djaldetti R, et al. The parkinsonian toxin MPTP: action and mechanism. <i>Restor Neurol Neurosci</i> 2000; 16:135-142.
229.	Denicola A, Radi R. Peroxynitrite and drug-dependent toxicity. <i>Toxicology</i> 2005;208:273-288.
230.	Tarabin V, Schwaninger M. The role of NF-KB in 6-hydroxydopamine- and TNF α -induced apoptosis of PC 12 cells. <i>Naunyn Schiedebergs Arch Pharmacol</i> 2004;369:563-569.
231.	Halasz AS, Palfi M, Tabi T. Magyar K, Szoko E. Altered nitric oxide production in mouse brain after administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine or methamphetamine. <i>Neurochem Int</i> 2004;44:641-646.
232.	Testa CM, Sherer TB, Greenamyre 7T. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. <i>Brain Res Mol Brain Res</i> 2005; 134:109-18.
233.	Bhashkatova V, Alam M, Vanin A, Schmidt WJ. Chronic administration of rotenone increases levels of nitric oxide and lipid peroxidation products in rat brain. <i>Exp Neurol</i> 2004;186:235-241.
234.	Vogt M, Bauer MK, Ferrari D, Schulze-Osthoff K.

	Oxidative stress and hypoxia/reoxygenation trigger CD95 (APO-1)/Fas ligand expression in microglial cells. FEBS Lett 1998;429:67-72.
235.	Zhou LZ, Johnson AP, Rando TA. NF-kappa B and AP-1 mediate transcriptional responses to oxidative stress in skeletal muscle cells. Free Radic Biol Med 2001;31:1405-1416.
236.	Barlow BK, Lee DW, Cory-Slechta DA, Opanashuk LA. Modulation of antioxidant defense systems by the environmental pesticide maneb in dopaminergic cells. Neurotoxicology 2005;26:63-75.
237.	Vaccari A, Saba P, Mocci I, Ruin S. Dithiocarbamate pesticides affect glutamate transport in brain synaptic vesicles. J Pharmacol Exp Ther 1999;288:1-5.
238.	Barhoumi R, Faske J, Liu X, Tjalkens RB. Manganese potentiates lipopolysaccharide-induced expression of NOS2 in C6 glioma cells through mitochondrialdependent activation of nuclear factor kappa B. Brain Res Mol Brain Res 2004; 122: 167-179.
	239. Jayakumar AR, Rama Rao KV, Kalaiselvi P, Norenberg MD. Combined effects of ammonia and manganese on astrocytes in culture. Neurochem Res 2004; 29:2051-2056.
240.	Filipov NM, Seegal RF, Lawrence DA. Manganese potentiates in vitro production of proinflammatory cytokines and nitric oxide by microglia through a nuclear factor kappa B-dependent mechanism. Toxicol Sci 2005;84:139-148.
241.	Erikson KM, Aschner M. Manganese neurotoxicity and glutamate-GABA interaction. Neurochem Int 2003;43:475-480.

242.	Hennekens CH, Buring JE. In: Mayrent SL ed. Epidemiology in Medicine. Boston: Little Brown and Co; 1989.
243,	Jellinger KA. Head injury and dementia. Curr Opin Neurol 2004;17: 719-723.
244.	Hinkebein JH, Martin TA, Callahan CD, Johnstone B. Traumatic brain injury and Alzheimer's: deficit profile similarities and the impact of normal aging. Brain 2003;126:1035-1042,
245.	Fleminger S, Oliver DL, Lovestone S, Rabe-Hesketh S, Giora A. Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on: a partial replication. J Neurol Neurosurg Psychiatry, 2003;74:857-862.
246.	Baldi I, Lebailly P, Mohammed-Brahim B et al. Neurodegenerative diseases and exposure to pesticides in the elderly. Am J Epidemiol 2003;157:409-414.
247.	Bidstrup P, Bonnel JA, Beckett AG. Paralysis following poisoning by a new organic phosphorus insecticide (Mipafox): report of two cases. Br Med J 1953; 1:1068-1072.
248.	Fonseca RG, Resende LAL, Silva MD, Camargo A. Chronic motor neuron disease possibly related to intoxication with organochlorine insecticides. Acta Neurol Scand 1993;88:56-58.
249.	Burns CJ, Beard KK, Cartmill JB. Mortality in chemical workers potentially exposed to 2,4-dichlorophenoxyacetic acid (2,4-D) 1945-94: an update. Occup Environ Med 2001;58:24-30.
250.	Bradberry SM, Proudfoot AT, Vale JA. Poisoning due to

	chlorophenoxy herbicides. Toxicol Rev 2004;23:65-73.
251.	Brooks BR. Risk factors in the early diagnosis of ALS: North American epidemiological studies. ALS CARE GROUP. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1 (Suppl 1): S 19-S26.
252.	Beckman JS, Estevez AG, Crow JP, Barbeito L. Superoxide dismutase and the death of motoneurons in ALS. Trends Neurosci 2001;24(11 Suppl):S15-S20.
253.	Aslan M, Ozbun T. Oxidative stress in neurodegenerative diseases. In: Ozbun T, Chevion M. eds. Frontiers in Neurodegenerative Disorders and Aging: Fundamental Aspects. IOS Press;2004.
254.	Dawson VL, Dawson TM. Nitric oxide neurotoxicity. J Chem Neuroanat 1996;10:179-190.
255.	Torreilles F, Salman-Tabcheh S, Guerin M, Torreilles J. Neurodegenerative disorders: the role of peroxynitrite. Brain Res Brain Res Rev 1999;30:153-163.
256.	Heales SJ, Bolanos JP, Stewart VC, Brookes PS, Land JM, Clark JB. Nitric oxide, mitochondria and neurologic disease. Biochim Biophys Acta 1999; 1410: 215-228.
257.	Simonian NA, Coyle JT. Oxidative stress in neurodegenerative diseases. Annu Rev Pharmacol Toxicol 1996;36:83-106.
258.	Di Matteo V, Esposito E. Biochemical and therapeutic effects of antioxidants in the treatment of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Curr Drug Targets CNS Neurol Disord 2003;2:95-107.
259.	Takeuchi M, Mizuno T, Zhang G, et al. Neuritic beading

	induced activated microglia is an early feature of neuronal dysfunction toward neuronal death by inhibition of mitochondrial respiration and axonal transport. J Biol Chem 2005;280: 10444-10454.
260.	Sonkusare SK, Kaul CL, Ramarao P. Dementia in Alzheimer's disease and other neurodegenerative disorders-memantine, a new hope. Pharmacol Res 2005; 51:1-17.
	261. Hallett PJ, Standaert DG. Rationale for use of NMDA receptor antagonists in Parkinson's disease. Pharmacol Ther 2004;102:155-174.
262.	Greenamyre JT, MacKenzie G, Peng TI, Stephans SE. Mitochondrial dysfunction in Parkinson's disease. Biochem Soc Symp 1999;66:85-97.
263.	Hsu M, Srinivas B, Kumar J, Subramanian R, Anderson J. Glutathione depletion resulting in selective mitochondrial complex I inhibition in dopaminergic cells is via an NO-mediated pathway not involving peroxynitrite: implications for Parkinson's disease. JNeurochem 2005;92:1091-1103.
264.	Berg D, Youdin MB, Riederer P. Redox imbalance. Cell Tissue Res 2004; 318:201-213.
265.	Tieu K, Ischiropoulos H, Przedborski S. Nitric oxide and reactive oxygen species in Parkinson's disease. IUBMB 2003;55:329-335.
266.	Ebadi M, Sharma SK. Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease. Antioxid Redox Signal 2003;5:319-335.
267.	Hirsch EC, Breidert T, Rousselet E, et al. The role of glial reaction and inflammation in Parkinson's disease. Ann NYAcad Sci 2003;991:214-228.

268.	Mandel S, Grunblatt E, Riederer P, Gerlach M, Levites Y, Youdim MB. Neuroprotective strategies in Parkinson's disease: an update. <i>CNS Drugs</i> 2003; 17:729-762.
269.	Griffin WS, Mrak RE. Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer's disease. <i>J Leukoc Biol</i> 2002;72:233-238.
270.	Bonfoco E, Krainc D, Ankarcrona M, Nicotera P, Lipton SA. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with' N-methyl-d-aspartate or nitric oxide/superoxide in cortical cell cultures. <i>Proc Natl Acad Sci USA</i> 1995;92:7162-7166.
271.	Kreiger C, Lanius RA, Pelech SL, Shaw CA. Amyotrophic lateral sclerosis: the involvement of intracellular Ca ²⁺ and protein kinase C. <i>Trends Pharmacol Sci</i> 1996;17:114-120.
272.	Williamson KS, Gabbita SP, Mou S, et al. The nitration product 5-nitrogamma-tocopherol is increased in the Alzheimerbrain. <i>Nitric Oxide</i> 2002;6:221-227.
273.	Migliori L, Fontana I, Colognato R, et al. Searching for the role of the most suitable biomarkers of oxidative stress in Alzheimer's disease and in other neurodegenerative diseases. <i>Neurobiol Aging</i> 2005;26:587-595.
274.	Boll MC, Alcaraz-Zubeldia M, Montes S, Murillo-Bonilla L, Rios C. Raised nitrate concentration and low SOD activity in the CSF of sporadic ALS patients. <i>Neurochem Res</i> 2003;28:699-703.
275.	Charbrier PE, Demerle-Pallardy C, Auguet M. Nitric oxide synthases: targets for therapeutic strategies in neurological diseases. <i>Cell Mol Life Sci</i> 1999;55: 1029-1035.

276.	Antunes F, Nunes C, Larjinha J, Cadenas E. Redox interactions of nitric oxide with dopamine and its derivatives. <i>Toxicology</i> 2005;208:207-212.
277.	Chung KK, Thomas B, Li X, et al. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. <i>Science</i> 2004;304: 1328-1331.
278.	Kao SC, Krichevsky AM, Kosick KS, Tsai LH. BACE1 suppression by RNA interference in primary cortical neurons. <i>J Biol Chem</i> 2004;279:1942-1949.
279.	Tamagno E, Bardini P, Obbili A, et al. Oxidative stress increases expression and activity of BACE in NT2 neurons. <i>Neurobiol Dis</i> 2002;10:279-288.
280.	Tamagno E, Guglielmotto M, Bardini P, et al. Dehydroepiandrosterone reduces expression and activity of BACE in NT2 neurons exposed to oxidative stress. <i>Neurobiol Dis</i> 2003;14:291-301.
281.	Apelt J, Bigl M, Wunderlich P, Schliebs R. Aging-related increase in oxidative stress correlates with developmental pattern of β -secretase activity and β -amyloid plaque formation in transgenic Tg2576 mice with Alzheimer-like pathology. <i>Int J Dev Neurosci</i> 2004;22:475-484.
282.	Tong Y, Zhou W, Fung V, et al. Oxidative stress potentiates BACE1 gene expression and A(β) J Neural Transrra 2005;112:455-469.
283.	Parihar MS, Hemnani T. Alzheimer's disease pathogenesis and therapeutic interventions. <i>J Clin Neurosci</i> 2004; 11:456-467.
284.	Jang JH, Surh YJ. AP-1 mediates β -amyloid-induced iNOS expression in PC 12 cells via the ERK2 and p38 MAPK

	signaling pathways. Biochem Biophys Res Commun 2005;331:1421-1428.
285.	Floden AM, Li S, Combs CK. β -amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors. J Neurosci 2005;25:2566-2575.
286.	Kadowski H, Nishitoh H, Urano F, et al. Amyloid beta induces neuronal cell death through ROS-mediated ASK1 activation. Cell Death Differ 2005;12:19-24.
287.	Keil U, Bonert A, Marques CA, et al. Elevated nitric oxide production mediates β -amyloid-induced mitochondrial failure. Pol J Pharmacol 2004;56: 631-634.
288.	von Bernhardt R, Eugenin J. Microglia reactivity to β -amyloid is modulated by astrocytes and proinflammatory factors. Brain Res 2004;1025:186-193.
289.	Ma G, Chen S. Diazoxide and N-omega-nitro-L-arginine counteracted A beta 1-42-induced cytotoxicity. Neuroreport 2004; 15:1813-1817.
290.	Wang Q, Rowan MJ, Anwyl R. β -amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. J Neurosci 2004;24:6049-6056.
291.	Tran MH, Yamada K, Nakajima A, et al. Tyrosine nitration of synaptic protein synaptophysin contributes to amyloid beta-peptide-induced cholinergic dysfunction. Mol Psychiatry 8:407-412.
292.	Saez TE, Pehar M, Vargas M, Barbeito L, Maccioni RB. Astrocytic nitric oxide triggers tau hyperphosphorylation in

	hippocampal neurons. In Vivo 2004; 18:275-280.
293.	Wang DL, Ling ZQ, Cao FY, Zhu LQ, Wang JZ. Melatonin attenuates isoproterenol-induced protein kinase A overactivation and tau hyperphosphorylation in rat brain. J Pineal Res 2004;37:11-16.
294.	Zhu LQ, Wang SH, Ling ZQ, Wang DL, Wang, JZ. Effect of inhibiting melatonin biosynthesis on spatial memory retention and tau phosphorylation in rat. J Pineal Res 2004;37:71-77.
295.	Gomez-Ramos A, Diaz-Mido J, Smith MA, Perry G, Avila J. Effect of lipid peroxidation product acrolein on tau phosphorylation in neural cells. J Neurosci Res 2003;71:863-870.
296.	Egana JT, Zambrano Cm Nunez MT, Gonzalez-Billaut C, Maccioni RB. Iron-induced oxidative stress modify tau phosphorylation patterns in hippocampal cell cultures. Biometals 2003;16:215-223.
297.	Ho PI, Ortiz D, Rogers E, Shea TB. Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res 2002;70:694-702.
298.	Mandelkow EM, Stamer K, Vogel R, Thies E, Mandelkow E. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging 2003;24:1079-1085.
299.	Sanelli TR, Sopper MM, Strong MJ. Sequestration of nNOS in neurofilamentous aggregate bearing neurons in vitro leads to enhanced NMDA-mediated calcium influx. Brain Res 2004;1004:8-17.

300.	Lin CL, Bristol LA, Dykes-Hoberg M, Crawford T, Clawson L, Rothstein JD. Aberrant RNA processing in neurodegenerative disease: the cause for the absent EAAT2, a glutamate transporter in amyotrophic lateral sclerosis. <i>Neuron</i> 1998;20: 589-602.
301.	Margakis NJ, Dykes-Hoberg M, Rothstein JD. Altered expression of the glutamate transported EAAT2b in neurologic disease. <i>2004 Ann Neurol</i> 2004;55:469-477.
302.	Hoogland G, van Oort RJ, Proper EA, et al. Alternative splicing of glutamate transporter EAAT2 RNA in neocortex and hippocampus of temporal lobe of epilepsy patients. <i>Epilepsy Res</i> 59:75-82.

[417] - [437]

HOOFDSTUK – 15

1.	Logan AC, Wong C. Chronic fatigue syndrome: oxidative stress and dietary modifications. <i>Altern Med Rev</i> 2001;6:450-459.
2.	Werbach M. Nutritional strategies for treating chronic fatigue syndrome. <i>Altern Med Rev</i> 2000;5:93-108.
3.	Rigden S, Barrager E, Bland JS. Evaluation of the effect of a modified entero-hepatic resuscitation program in chronic fatigue syndrome patients. <i>J Adv Med</i> 1998;11:247-252.
4.	Smith JD, Terpening CM, Schmidt SO, Gums JG. Relief of fibromyalgia following discontinuation of dietary excitotoxins. <i>Ann Pharmacother</i> 2001;35:702-706.
5.	Blaylock RL. <i>Excitotoxins: The Taste That Kills Santa Fe</i> , NM: Health Press.
6.	Miller CS, Mitzel HC. Chemical sensitivity attributed to pesticide exposure versus remodeling. <i>Arch Environ Health</i> 1995;50:119-129.
7.	Teitelbaum J. E, ffective treatment for CFS/FM - Part I& IL Syllabus AAEM, 38th Annual Meeting, The Walking Wounded: Identifying the Causes and Exploring the Newest Treatment Options for Chronic Fatigue Syndrome, Fibromyalgia and Environmental Sensitivities,2003:73-118.
8.	Nicolson GL. Nutritional supplement restores mitochondrial functionn and reduces moderately severe fatigue in aged subjects. Syllabus AAEM, 38th Annual Meeting, The Walking Wounded: Identifying the Causes and Exploring the

	Newest Treatment Options for Chronic Fatigue Syndrome, Fibromyalgia and Environmental Sensitivities; 2003:231-264.
9.	Krop J. Lyme disease: a missed diagnosis in chronic illness. Syllabus AAEM, 38th Annual Meeting, The Walking Wounded: Identifying the Causes and Exploring the Newest Treatment Options for Chronic Fatigue Syndrome, Fibromyalgia and Environmental Sensitivities;2003:265-280.
10.	Rea WJ. Chronic fntigue, fibrom yalgia and environmental sensitivities: oxygen extraction deficits and complex neurological immune dysfunction. An environmental medicine perspective. Syllabus AAEM, 38th Annual Meeting, The Walking Wounded: Identifying the Causes and Exploring the Newest Treatment Options for Chronic Fatigue Syndrome, Fibromyalgia and Environmental Sensitivities;2003: 317-349.
11.	Gerdes K. Zips from the trenches: some useful tricks learned in practice. Syllabus AAEM, 38th Annual Meeting, The Walking Wounded: Identifying the Causes and Exploring the Newest Treatment Options for Chronic Fatigue Syndrome, Fibromyalgia and Environmental Sensitivities,2003:365-374.
12.	Ionescu JG. Oxidative therapies for severe infection, MCS and cancer. Syllabus AAEM, 38th Annual Meeting, The Walking Wounded: Identifying the Causes and Exploring the Newest Treatment Options for Chronic Fatigue Syndrome, Fibromyalgia and Environmental Sensitivities,2003:461-488.
13.	LaCava NT. A retrospective review of a therapeutic trial of IV alpha lipoic acid in chronically ill patients. Syllabus

	AAEM, 38th Annual Meeting, The Walking Wounded: Identifying the Causes and Exploring the Newest Treatment Options for Chronic Fatigue Syndrome, Fibromyalgia and Environmental Sensitivities; 2003:489-508.
14.	Block MA. First do no harm, next try magnesium. Syllabus AAEM, 38th Annual Meeting, The Walking Wounded: Identifying the Causes and Exploring the Newest Treatment Options for Chronic Fatigue Syndrome, Fibromyalgia and Environmental Sensitivities ;2003:617-621.
15.	Huang HY, Appel U. Supplementation of diets with a-tocopherol reduces serum concentrations of y- and c-tocopherol in humans. JNutr 2003;133:3137-3140.
16.	Olmedilla B, Granado F, Southon S, et al. A European multicentre, placebocontrolled supplementation study with a-tocopherol, carotene-rich palm oil, lutein or lycopene: analysis of serum responses. Clin Sci 2002;102:447-456.
17.	Bates CJ, Chen SJ, Macdonald A, Holden R. Quantitation of vitamin E and carotenoid pigment in cataractous human lenses, and the effect of dietary supplement. Int J Vitam Nutr Res 1996;66:316-321.
18.	Handelman GJ, Epstein WL, Peerson J, et al. Human adipose a-tocopherol and y-tocopherol kinetics during and after 1 y of a-tocopherol supplementation. Am J Clin Nutr 1994;59:1025-1032.
19.	Parker RS, Sontag TJ, Swanson JE, McCormick CC. Discovery, characterization, and significance of the cytochrome P450 omega- hydroxy lase pathway of vitamin E catabolism. Ann NYAcad Sci 2004;1031:13-21.
20.	Brigelius-Flohe R. Induction of drug metabolizing enzymes by vitamin E. J Plant Phvsiol 2005;162:797-802.

21.	Christen S, Woodall AA, Shigenaga MK, et al. gamma-Tocopherol traps mutagenic electrophiles such as NO(x) and complements alpha-tocopherol: physiological implications. Proc Natl Acad Sci USA 1997;94:3217-3222.
22.	Hoglen NC, Liegler DC. Products from reaction of peroxynitrite with gammatocopherol. Methods Enzymol 1999;301:483-490.
23.	Wolf G. gamma-Tocopherol: an efficient protector of lipids against nitric oxide-initiated peroxidative damage. Nutr Rev 1997;55:376-378.
24.	Sen CK, Khanna S, Roy S. Tocotrienol: the natural vitamin E to defend the nervous system? Ann NYAcad Sci 2004;1031:127-142.
25.	Schaffer S, Muller WE, Eckert GP Tocotrienols: constitutional effects in aging and disease. J Nutr 2005;135:151-154.
26.	Kamat JP, Devasagayam TP. Tocotrienols from palm oil as potent inhibitors of lipid peroxidation and protein oxidation in rat brain mitochondria. Neurosci Lett 1995;195:179-182.
27.	Snodderly DM. Evidence for protection against age-related macular degeneration by carotenoids and antioxidant vitamins. Am J Clin Nutr 1995;62(6 Suppl): 1448S-1461S.
28.	Richer S. Multicenter ophthalmic and nutritional age-related macular degeneration study-part2: antioxidant intervention and conclusions. J Am Optometr Assoc 1996;47:30-49.
29.	Jampol LM, Ferris FL 3rd. Antioxidants and zinc to prevent progression of age-related macular degeneration. JAMA 2001;286:2466-1468.
30.	Richer S, Stiles W, Statkute L, et al. Double-masked,

	placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study. <i>Optometry</i> 2004;75:216-230.
31.	Hogg R, Chakravarthy U. AMD and micronutrient antioxidants. <i>Curr Eye Res</i> 2004;29:387-401.
32.	Head KA. Natural therapies for ocular disorders, part one: diseases of the retina. <i>Altern Med Rev</i> 1999;4:342-359.
33.	Taylor HR, Tikellis G, Robman LD, et al. Vitamin E supplementation and macular degeneration: randomized controlled trial. <i>BMJ</i> 2002;325:11-16.
34.	Packer L. a-Lipoic acid: a metabolic antioxidant which regulated NF-KB signal transduction and protects against oxidative injury. <i>Drug Metab Rev</i> 1998; 30: 245-275.
35.	Rahman I, Biswas SK, Jimenez LA, Torres M, Forman HJ. Glutathione, stress responses, and redox signaling in lung inflammation. <i>Antioxid Redox Signal</i> 2005;7:42-59.
36.	Cos P, De Bruyne T, Heremans N, et al. Proanthocyanidins in health care: current and new trends. <i>Curr Med Chem</i> 11:1345-1359.
37.	Rahman I, Marwick J, Kirkham P. Redox modulation of chromatin remodeling: impact on histone acetylation and deacetylation, NF-KB and pro-inflammatory gene expression. <i>Biochem Pharmacol</i> 2004;68:1255-1267.
38.	Pande V, Ramos MJ. Nuclear factor kappa B: a potential target for anti-HIV chemotherapy. <i>Curr Med Chem</i> 2003;10:1603-1615.
39.	Haddad JJ. Science review: redox and oxygen-sensitive transcription factors in the regulation of oxidant-mediated

	lung injury: role of nuclear factor-kappa B. Crit Care 2002;6:481-490.
40.	Kretz-Remy C, Arrigo AP. Selenium: a key element that controls NF-KB activation and IK B half life. Biofactors 2001;14:117-125.
41.	Yoshikawa T, Yoshida N. Vitamin E and leukocyte-endothelial cell interactions. Antioxid Redox Signal 2000;2:821-825.
42.	Sen CK. Cellular thiols and redox-regulated signal transduction. Curr Top Cell Regul 2000;36:1-30.
43.	Kodama M, Kodama T, Muramaki M. The value of the dehydroepiandrosterone-annexed vitamin C treatment in the clinical control of chronic fatigue syndrome L A pilot study of the new vitamin C infusion treatment with volunteer CFS patients. In Vivo 1996;10:575-584.
44.	Kodama M, Kodama T, Muramaki M. The value of the dehydroepiandrosterone-annexed vitamin C treatment in the clinical control of chronic fatigue syndrome IL Characterization of CFS patients with special reference to their reponse to a new vitamin C infusion treatment. In wo 1996;10:585-596.
45.	Heuser G, Vojdani A. Enhancement of natural killer cell activity and T- and B-cell function by buffered vitamin C in patients exposed to toxic chemicals: the role of protein kinase C. Immunopharmacol Imm-unotoxicol 1997; 19:291-312.
46.	Conklin KA. Coenzyme Q 10 for prevention of anthracycline-induced cardiotoxicity. Integr Cancer Ther 2005;4:110-130.

47.	Chow CK. Dietary coenzyme Q 10 and mitochondrial status. <i>Methods Enzymol</i> 2004;382:105-112.
48.	Cooper JM, Schapira AH. Friedreich's ataxia: disease mechanisms, antioxidant and coenzyme Q10 therapy. <i>Biofactors</i> 2003;18:163-171.
49.	Fosslien E. Review: mitochondrial medicine-cardiomyopathy caused by defective oxidative phosphorylation. <i>Ann Clin Lab Sci</i> 2003;33:371-395.
50.	Zeviani M, Carelli V. Mitochondrial disorders. <i>Curr Opin Neurol</i> 2003;16: 585-594.
51.	Lisdero CL, Carreras MC, Meulmans A, et al. The mitochondrial interplay of ubiquinol and nitric oxide in endotoxemia. <i>Meth Enzymol</i> 2004;382:67-81.
52.	Shopfer F, Riobo N, Carreras MC, et al. Oxidation of ubiquinol by peroxynitrite: implications for protection of mitochondria against nitrosative damage. <i>Biochem J</i> 2000;349:35-42.
53.	Lass A, Sohal RS. The effect of coenzyme Q(10) and α-tocopherol content of mitochondria on the production of superoxide anions. <i>FASEB J</i> 2000; 14:87-94.
54.	Beal ME Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases. <i>Biofactors</i> 1999;9:261-266.
55.	Dlugosz A, Sawicka E. The chemoprotective effect of coenzyme Q on lipids in the paint and laquer industry workers. <i>Int J Occup Med Environ Health</i> 11:153-163.
56.	Chew GT, Watts GE Coenzyme Q 10 and diabetic endotheliopathy: oxidative stress and the 'recoupling hypothesis'. Also states that "long term safety and

	tolerability of CoQ supplementation has been consistently confirmed in several published animal and human trials." Q J Med 2004;97:537-548.
57.	Bell DS. The Doctor's Guide to Chronic Fatigue Syndrome. Reading, MA: Addison Wesley Publishing Co.; 1995.
58.	Lister RE. An open, pilot study to evaluate the potential benefits of coenzyme Q 10 combined with Ginkgo biloba extract in fibromyalgia syndrome. J/nt Med Res 2002;30:195-199.
59.	Reinhard P, Schweinsberg F, Wernet D, Kotter I. Selenium status in fibromyalgia. Toxicol Lett 1998;96/97:177-180.
60.	Klotz LO, Sies H. Defenses against peroxynitrite: selenocompounds and flavonoids. Toxicol Lett 2003; 140-141:125-132.
61.	Arteel GE, Mostert V, Oubrahim H, et al. Protection by selenoprotein P in human plasma against peroxynitrite-mediated oxidation and nitration. Biol Chem 1998;379:1201-1205.
62.	Saito Y, Takahashi, K. Characterization of selenoprotein P as a selenium supply protein. Eur J Biochem 2002;269:5746-575 1.
63.	Benton D. Selenium intake, mood and other aspects of psychological functioning. NutrNeurosci 2002;5(6):363-374.
64.	Panasenko OM, Sharov VS, Brivaba K, Sies H. Interaction of peroxynitrite with carotenoids in human low density lipoproteins. Arch Biochem Biophys 2000; 373:302-305.
65.	Lavelli V, Hippeli S, Peri C, Elstner EE Evaluation of radical scavenging activity of fresh and air-dried tomatoes

	by three model reactions. J Agric Food Chern 1999;47:3826-3831.
66.	Kontush A, Weber W, Beisiegel U. Alpha- and beta-carotenes in low density lipoproteins are the preferred target for nitric oxide-induced oxidation. Atherosclerosis 2000; 148:87-93.
67.	Pannala AAS, Singh S, Rice-Evans C. Interaction of carotenoids and tocopherols with peroxynitrite. Methods Enzymol 1999;301:319-332.
68.	Bohm F, Edge R, McGarvey DJ, Truscott TG. Beta-carotene with vitamins E and C offers synergistic cell protection against NOx. FEBS Lett 1998;436:387-389.
69.	Scheidegger R, Pande AK, Bounds PL, Koppenol WH. The reaction of peroxynitrite with zeaxanthin. Nitric Oxide 1998;2:8-16.
70.	Kikugawa K, Hiramoto K, Tomiyama S, Asano Y. β -Carotene effectively scavenges toxic nitrogen oxides: nitrogen dioxide and peroxynitrous acid. FEBS Lett 1997;404:175-178.
71.	Edwards AM, Blackburn A, Christie S, Townsend A, David A. Food supplements in the treatment of fibromyalgia: a double-blind, crossover trial of anthocyanidins and placebo. J Nutr Env Med 2000;10:189-199.
72.	Singal A, Kaur S, Tirkey N, Chopra K. Green tea extract catechins ameliorate chronic fatigue-induced oxidative stress in mice. J Med Food 2005;8:47-52.
73.	Singh A, Naidu PS, Gupta S, Kulkarni SK. Effect of natural and synthetic anti oxidants in a mouse model of chronic fatigue syndrome. J Med Food 2002;5:211-220.

74.	Santos MR, Mira L. Protection by flavonoids against the peroxynitrite mediated oxidation of dihydrorhodamine. Free Rndic Res 2004;38:1011-1018.
75.	Yokozawa T, Rhyu DY, Cho EJ. (-)-Epicatechin 3-0-gallate ameliorates the damages related to peroxynitrite production by mechanisms distinct from those of other free radical inhibitors. J Pharin Pharmacol 2004;56:231-239.
76.	Kim JY, Jung KJ, Choi JS, Chung HY. Hesperetin: a potent antioxidant against peroxynitrite. Free Radic Res 2004;38:761-769.
77.	Olas B, Nowak P, Wachowicz B. Resveratrol protects against peroxynitriteinduced thiol oxidation in blood platelets. Cell Mol Biol Lett 2004;9:577-587.
78.	Saint-Cricq De Gaulejac N, Provost C, Vivas N. Comparative study of polyphenol scavenging activities assessed by different methods. JAgric Food Chem 1999;47:425-431.
79.	Behar-Cohen FF, Heydolph S, Faure V, et al. Peroxynitrite cytotoxicity on bovine retinal pigmented epithelial cells in culture. Biochem Biophys Res Commun 1996;226:842-849.
80.	Mantle D, Eddeb F, Pickering AT. Comparison of relative antioxidant activities of British medicinal plant species in vitro. J Ethnopharmacol 2000;72:47-51.
81.	Marcocci L, Maguire JJ, Droy-Lefaix MT, and Packer L. The nitric oxidescavenging properties of Ginkgo biloba extract EGb 761. Biochem Biophys Res Commun 1994;201:748-755.
82.	Pillai SP, Mitscher LA, Menon SR, Pillai CA, Shankel DM. Antimutagenic/ antioxidant activity of green tea components

	and related compounds. J Environ Pathol Toxicol Oncol 1999;18:147-158.
83.	Getha T, Garg A, Chopra K, Pal Kant I. Delineation of antimutagenic activity of catechin, epicatechin and green tea extract. Mutat Res 2004;556:65-74.
84.	Nakagawa T, Yokozawa T. Direct scavenging of nitric oxide and superoxide by green tea. Food Chem Toxicol 2002;40:1745-1750.
85.	Yokozawa T, Rhyu DY, Cho EJ. (-)-Epicatechin 3-O-gallate ameliorates the damages related to peroxynitrite production by mechanisms distinct from those of other free radical inhibitors. J Pharm Pharmacol 2004;56:231-239.
86.	Kruk I, Aboul-Enein HY, Michalska T, Lichszteld K, Kladna A. Scavenging of reactive oxygen species by the plant phenols genistein and oleuropein. Luminescence 2005;20:81-90.
87.	VafeiAdou K, Weinberg PD. Antioxidant and free radical scavenging activity of isoflavone metabolites. Xenobiotica 2003;33:913-925.
88.	Bahoran T, Gressier B, Trotin F, et al. Oxygen species scavenging activity of phenolic extracts from hawthorn fresh plant organs and pharmaceutical preparations. Arzneihmittelforschung 1996;46:1081-1089.
89.	Ichikawa H, Ichianagi T, Xu B, et al. Antioxidant activity of anthocyanin extract from purple black rice. J Med Food 2001;4:211-218.
90.	Seki M, Kobayashi H. Inhibition of xanthine oxidase by flavonoids. Biosci Biotech Biochem 1999;63:1787-1790.
91.	Feher J, Lang I, Nekam K, Gergely P, Muzes G. In vivo

	effect of free radical scavenger hepatoprotective agents on superoxide dismutase (SOD) activity in patients. Tokai J Exp Clin Med 1990;15:129-134.
92.	Ghyczy M, Boros M. Electrophilic methyl groups present in the diet ameliorate pathological states induced by reductive and oxidative stress: a hypothesis. Br J Nutr 2001;85:409-414.
93.	Sanchez-Perez AM, Montoliu C, Felipo V. Trialkylglycines: a new family of compounds with in vivo neuroprotection. CNS Drug Reviews 2003;9:263-274.
94.	Llansola M, Erceg S, Hernandez-Viadel M, Felipo V. Prevention of ammonia and glutamate neurotoxicity by carnitine: molecular mechanisms. Metab Brain Dis 2002; 17:389-397.
95.	Bigini P, Larini S, Pasquali C, Muzio V, Menini T. Acetyl-L-carnitine shows neuroprotective and neurotrophic activity in primary culture of rat embryo motoneurons. Neurosci Lett 2002;329:334-338.
96.	Llansola M, Felipo V. Carnitine prevents NMDA receptor mediated activation of MAP-kinase and phosphorylation of microtubule-associated protein 2 in cerebellar neurons in culture. Brain Res 2002;947:50-56.
97.	Felipo V, Hermenegildo C, Montoliu C, Llansola M, Minana MD. Neurotoxicity of ammonia and glutamate: molecular mechanisms and prevention. Neurotoxicol 1998;19:675-681.
98.	Ghyczy M, Torday C, Boros M. Simultaneous generation of methane carbon dioxide, and carbon monoxide from choline and ascorbic acid: a defensive mechanism against reductive stress? FASEB J 2003; 17:1124-1126.

99.	Fetrow CW, Avila JR. Efficacy of the dietary supplement S-adenosyl-Lmethionine. <i>Annals Pharmacother</i> 2001;35:1414-1425.
100.	Craig SA. Betaine in human nutrition. <i>Am J Clin Nutr</i> 2002;80:239-249.
101.	Plioplys AV, Plioplys S. Amantadine and L-carnitine treatment of chronic fatigue syndrome. <i>Neuropsychobiology</i> 1997;35:16-23.
102.	Vermeulen RC, Scholte HR. Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome. <i>Psychosom Med</i> 2004; 66:276-282.
103.	Kuratsune H, Yamaguti K, Lindh G, et al. Brain regions involved in fatigue sensation: reduced acetylcarnitine uptake into the brain. <i>Neuroimage</i> 2002;17: 1256-1265.
104.	Kuratsune H, Yamaguti K, Lindh G, et al. Low serum levels of serum acylcarnitine in chronic fatigue syndrome and chronic hepatitis type C, but not other diseases. <i>Int J Mol Med</i> 1998;2:51-56.
105.	Liu J, Head, E, Kuratsune H, Cotman CW, Ames BN. Comparison of the effects of L-carnitine and acetyl-L-carnitine on carnitine levels, ambulatory activity, and oxidative stress biomarkers in the brain of old rats. <i>Ann NY Acad Sci</i> 2004; 1033:117-131.
106.	Paradies G, Petrosillo G, Pistolese M, Ruggiero FM. Reactive oxygen species affect mitochondrial electron transport complex I activity through oxidative cardiolipin damage. <i>Gene</i> 2002;286:135-141.
107.	Zanelli SA, Solenski NJ, Rosenthal RE, Fiskum G.

	Mechanisms of neuroprotection by acetyl-L-carnitine. Ann NYAccul Sci 2005;1053:153-161.
108.	Binienda Z, Przybyla-Zawislak B, Virmani A, Schmued L. L-carnitine and neuroprotection in the animal model of mitochondrial dysfunction. Neurosci Lett 2004;367:264-267.
109.	Inano A, Sai Y, Nikaido H, et al. Acetyl-L-carnitine permeability across the blood-brain barrier and involvement of carnitine transported OCTN2. Biophar Drug Dispos 2003;24:357-365.
110.	Kuratsune H, Watanabe Y, Yanaguti K, et al. High uptake of [2-(11)] acetylL-carnitine into the brain: a PET study. Biochem BioplTys Res Commun 1997;23L 488-493.
111.	Ellithorpe RR, Settinery RA, Nicolson GL. Pilot study: reduction of fatigue by use of a supplement containing dietary glycophospholipids. JAm. Neutraceutical Assoc 2003;6:23-28.
112.	Agadjanyan M, Vasilevko V, Ghochikyan A, et al. Nutritional supplement (NT Factor) restores mitochondrial function and reduces moderately severe fatigue in aged subjects. J Chronic Fatigue Synclr 2003;11(4):1-12.
113.	van der Kuy PH, Merkus FW, Lohman JJ, ter Berg JW, Hooymans PM. Hydroxocobalamin, a nitric oxide scavenger, in the prophylaxis of migraine: an open pilot study. Cephalagia 2002;22:513-519.
114.	Delpre G, Stark P, Niv Y Sublingual therapy for cobalamin deficiency as an alternative to oral and parenteral cobalamin supplementation. Lancet 1999;354: 740-741.
115.	Sharabi A, Cohen E, Sulkes J, Garty M. Replacement

	therapy for vitamin B 12 deficiency: comparison between the sublingual and the oral route. Br J Clin Pharmacol 2003;56:635-638.
116.	Botez MI, Motez T, Leveille J, et al. Neuropsychological correlates of folic acid deficiency: facts and hypotheses. In: Botez MI, Reynolds EH, eds. Folic Acid in Neurology, Psychiatry, and Internal Medicine. New York: Raven Press; 1979.
117.	Kaslow JE, Rucker L, Onishi R. Liver extract-folic acid-cyanocobalamin vs placebo for chronic fatigue syndrome. Arch Intern Med 1989;149:2501-2503.
118.	Stanger O, Weger M. Interactions of homocysteine, nitric oxide, folate and radicals in the progressively damaged endothelium. Clin Chem Lab Med 2003;41: 1444-1454.
119.	Sawabe K, Wakasugi KO, Hasegawa H. Tetrahydrobiopterin uptake in supplemental administration: elevation of tissue tetrahydrobiopterin in mice following uptake of exogenously oxidized product 7,8-dihydrobiopterin and subsequent reduction of an anti-folate-sensitive process. JPharmacol Sci 2004;96:124-133.
120.	McCarty MF. Supplemental arginine and high-dose folate may promote bone health by supporting the activity of endothelial-type nitric oxide synthase in bone. Med Hypoth 2005;64:1030-1033.
121.	Shi W, Meininger CJ, Haynes TE, Hatakeyama K, Wu G. Regulation of tetrahydrobiopterin synthesis and bioavailability in endothelial cells. Cell Biochem Bioph' vs 2004;41:415-434.
122.	Griffith TM, Chaytor AT, Bakker LM, Edwards DH. 5-methyltetrahydrofolate and tetrahydrobiopterin can

	modulate electronically mediated endotheliumdependent vascular relaxation. Proc Natl Acad Sci USA 2005;102:7008-7013.
123.	Gorren AC, Schrammel A, Riethmuller C, et al. Nitric oxide-induced autoinhibition of neuronal nitric oxide synthase in the presence of the autoxidationresistant pteridine 5-methyltetrahydrobiopterin. Biochem J 2000;347:475-484.
124.	Stroes ES, van Faassen EE, Yo M, et al. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res 2000;86:1129-1134.
125.	Hyndman ME, Verma S, Rosenfeld RJ, Anderson TJ, Parsons HG. Interaction of 5-methyltetrahydrofolate and tetrahydrobiopterin on endothelial function. Am J Physiol Heart Circ Physiol 2002;282:H2167-H2172.
126.	Ihlemann N, Rask-Madsen C, Perner A, et al. Tetrahydrobiopterin restore endothelial dysfunction induced by an oral glucose challenge in healthy subjects. Am J Physiol Heart Circ Physiol 2003;285:H875-882.
127.	Shimizu S, Ishii M, Miyasaka Y, et al. Possible involvement of hydroxyl radical on the stimulation of tetrahydrobiopterin synthesis by hydrogen peroxide and peroxynitrite in vascular endothelial cells. Int J Biochem Cell Biol 2005;37: 864-875.
128.	Ebadi M, Gessert CF, Al-Sayegh A. Drug-pyridoxal phosphate interactions. Q Rev Drug Metab Drug Interact 1982;4:L289-331.
129.	Kaneda K, Kikuchi M, Kashii S, et al. The effects of B vitamins on glutamateinduced neurotoxicity in retinal cultures. Eur J Pharmacol 1997;322:259-264.

130.	Dawber, Diane. Lifting the Bull: Overcoming Chronic Back Pain, Fibromyalgia and Environmental Illness. Quarry Press; 1999.
131.	Wang HS, Kuo MF, Chou ML, et al. Pyridoxal phosphate is better than pyridoxine for controlling idiopathic intractable epilepsy. Arch Dis Child 2005; 90:512-515.
132.	Matsubara K, Mori M, Akagi R, Kato N. Anti-angiogenic effect of pyridoxal 5'-phosphate, pyridoxal and pyridoxamine on embryoid bodies derived from mouse embryonic stem cells. In J Mol Med 2004; 14:819-823.
133.	Hustad S, McKinley MC, McNulty H, et al. Riboflavin, flavin mononucleotide, and flavin adenine dinucleotide in human plasma and erythrocytes at baseline and after low-dose riboflavin supplementation. Clin Chem 2002;48:1571-1577.
134.	Prentice AM, Bates CJ. A biochemical evaluation of the erythrocyte glutathione reductase (EC 1.6.4.2) test for riboflavin status 2. Dose-response relationships in chronic marginal deficiency. Br J Nutr 1981;45:53-65.
135.	Clements JE, Anderson BB. Glutathione reductase activity and pyridoxine (pyridoxamine) oxidase activity in the red cell. Biochem Biophys Acta 1980;632: 159-163.
136.	Droge Wm Holm E. Role of cysteine and glutathione in HIV infection and other diseases associated with muscle wasting and immunological dysfunction. FASEB J 1997; 11:1077-1089.
137.	Bounous G, Molson J. Competition for glutathione precursors between the immune system and skeletal muscle: pathogenesis of chronic fatigue syndrome. Med Hypoth 1999;53:347-349.

138.	Witschi A, Reddy S, Stofer B, Lauterburg BH. The systemic availability of oral glutathione. <i>Eur J Clin Pharmacol</i> 1992;43:667-669.
139.	Kannan R, Mittur A, Bao Y, Tsuruo T, Kaplowitz N. GSH transport in immortalized mouse brain endothelial cells: evidence for apical localization of a sodium-dependent GSH transporter. <i>Neurochem</i> 1999;73:390-399.
140.	Kannan R, Bao Y, Mittur A, Andley UP, Kaplowitz N. Glutathione transport in immortalized HLE cells and expression of transport in HLE cell poly(A)+ RNA injected <i>Xenopus</i> oocytes. <i>Invest Ophthalmol Vis Sci</i> 1998;39:1379-1386.
141.	Kannan R, Mittur A, Bao Y, Tsuruo T, Kaplowitz N. GSH transport in immortalized mouse brain endothelial cells: evidence for apical localization of a sodium-dependent GSH transporter. <i>J Neurochem</i> 1999;73:390-399.
142.	Zlokovic BV, Mackic JB, McComb JG, et al. Evidence for transcapillary transport of reduced glutathione in vascular perfused guinea-pig brain. <i>Biochem Biophys Res Commun</i> 1994;201:402-408.
143.	Mathisen GA, Fonnum F, Paulsen RE. Contributing mechanisms for cysteine excitotoxicity in cultured granule cells. <i>Neurochem Res</i> 1996;21:293-298.
144.	Janaky R, Varga V, Hermann A, Saransaari P, Oja SS. Mechanisms of Lcysteine neurotoxicity. <i>Neurochem Res</i> 2000;25:1397-1405.
145.	Piani D, Fontana A. Involvement of the cystine transport system xc- in the macrophage-induced glutamate-dependent cytotoxicity in neurons. <i>J Immunol</i> 1994; 152:3578-3585.

146.	Warr O, Takahashi M, Attwell D. Modulation of extracellular glutamate concentration in rat brain slices by cystine-glutamate exchange. J Physiol 1999; 514:783-793.
147.	http://www.cfsresearch.org/cfs/cheney/5.htm
148.	http://www.cfsresearch.org/efslresearch/treatment/13.htm
149.	http://www.cfsresearch.org/cfs/cheney/14.htm
150.	http://www.cfsresearch.org/cfs/conferences/4.htm
151.	Sen CK, Packer L. Thiol homeostasis and supplements in physical exercise. Am J Clin Nutr 2000;72(2 Suppl):653S-669S.
152.	Smith AR, Shenvi SV, Widlanski M, Suh JH, Hagen TM. Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr Med Chem 2004;11:1135-1146.
153.	Wollin SD, Jones PJ. Alpha-lipoic acid and cardiovascular disease. J Nutr 2003;133:3327-3330.
154.	Moini H, Packer L, Saris NE. Antioxidant and prooxidant activities of alpha-lipoic acid and dihydrolipoic acid. Toxicol Appl Pharmacol 2002; 182:84-90.
155.	Packer L, Kraemer K, Rimbach G. Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition 2001;17:888-895.
156.	Packer L, Tritschler HJ, Wessel K. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med 1997;22:359-378.
157.	Trujillo M, Folkes L, Bartsaghi S, et al. Peroxynitrite-derived carbonate and nitrogen dioxide radicals readily react with lipoic acid and dihydrolipoic acid. Free Radic Biol

	Med 2005;39:279-288.
158.	Bast A, Haenen GR. Interplay between lipoic acid and glutathione in the protection of microsomal lipid peroxidation. Biochim Biophys Acta 1988;963:558-561.
159.	Porras P, Pedrejas JR, Martinez-Galisteo E, et al. 2002 Glutaredoxins catalyze the reduction of glutathione by dihydrlipoamide with high efficiency.
160.	Turner RE, Langkamp-Henken B, Littell RC, Lukowski MJ, Suarez MF. Comparing nutrient intake from food to the estimated average requirements shows middle- to upper-income pregnant women lack iron and possibly magnesium. JAm Diet Assoc 2003;103:461-466.
161.	Vaquero MP. Magnesium and trace elements in the elderly: intake, status and recommendations. J Nutr Health Aging 2002;6:147-153.
162.	Gullestad L, Nes M, Ronneberg R, et al. Magnesium status in healthy freelifing elderly Norwegians. J Am Coll Nutr 1994;13:45-50.
163.	Kubena KS, Durlach J. Historical review of the effects of marginal intake of magnesium in chronic experimental magnesium deficiency. Magnes Res 1990;3: 219-226.
164.	Durlach J. Recommended dietary amounts of magnesium: Mg RDA. Magnes Res 1989;2:195-203.
165.	Durlach J, Bac P, Durlach V, Rayssiguier Y, Bara M. Magnesium status and ageing: an update. Magnes Res 1998; 11:25-42.
166.	Abbott RD, Ando F, Masaki KH, et al. Dietary magnesium intake and future risk of coronary heart disease (the Honolulu Heart Program). Am J Cardiol 2003; 92:655-659.

167.	Nair RR, Nair P. Alteration of myocardial mechanics in marginal magnesium deficiency. <i>Magnes Res</i> 2002;15:287-306.
168.	Chakraborti S, Chakraborti T, Mandal M, et al. Protective role of magnesium in cardiovascular diseases: a review. <i>Mol Cell Biochem</i> 2002;238:163-179.
169.	Landon RA, Young EA. Role of magnesium in lung function. <i>J Am Diet Assoc</i> 1993;93:674-677.
170.	Seelig MS, Berger AR, Spielholz N. Latent tetany and anxiety, marginal magnesium deficit and normocalcemia. <i>Dis Nerv Syst</i> 1975;36:461-465.
171.	Altura BM, Altura BT. Tension headaches and muscle tension: is there a role for magnesium? <i>Med Hypoth</i> 2001;57:705-713.
172.	Sarchielli P, Coata G, Firenze V, et al. Serum and salivary magnesium levels in migraine and tension-type headache. Results in a group of adult patients. <i>Cephalalgia</i> 1992;12:21-27.
173.	Held K, Antonijevic IA, Kunzel H, et al. Oral Mg(2+) supplementation reverses age-related neuroendocrine and sleep EEG changes. <i>Pharmacopsychiatry</i> 2002;35:135-143.
174.	Penland JG. Quantitative analysis of EEG effects following experimental marginal magnesium and boron deprivation. <i>Magn Res</i> 1995;8:341-358.
175.	Cox IM, Campbell MJ, Dowson D. Red blood cell magnesium and chronic fatigue syndrome. <i>Lancet</i> 1991;337:757-760.
176.	Manuel y Keenoy B, Moorkens G, Vertommen J, et al. Magnesium status and parameters of the oxidant-antioxidant

	balance in patients with chronic fatigue: effects of supplementation with magnesium. JAm Coll Nutr 2000; 19:374-382.
177.	Clague JE, Edwards RHT, Jackson MJ. Intravenous magnesium loading in chronic fatigue syndrome. Lancet 1992;340:124-125.
178.	Seelig M. Review and hypothesis: might patients with chronic fatigue syndrome have latent tetany of magnesium deficiency. J Chronic Fatigue Syndr 1998; 4(2):77-118.
179.	Kurup RK, Kurup PA. Hypothalamic digoxin, cerebral chemical dominance and myalgic encephalomyelitis. Int J Neurosci 2003;113:445-457.
180.	Russell IJ, Michalek JE, Flechas JD, Abraham GE. Treatment of fibromyalgia syndrome with super malic: a randomized, double blind, placebo controlled crossover pilot study. J RIT.eumatol 1995;22:953-958.
181.	Abraham GE, Flechas JD. Management of fibromyalgia: rationale for the use of magnesium and malic acid. J Nutr Med 1992;3:49-52.
182.	Ho E, Ames BN. Low intracellular zinc induces oxidative DNA damage, disrupts p53, NF-KB and API DNA-binding, and effects DNA repair in a rat glioma cell line. Proc Natl Acad Sci USA 2002;99:16770-16775.
183.	Hennig N, Meerarani P, Toborek M, McClain CJ. Antioxidant-like properties of zinc in activated endothelial cells. JAm Coll Nutr 1999;18:152-158.
184.	Hawk SN, Lanoue L, Keen CL, et al. Copper-deficient rat embryos are characterized by low superoxide dismutase activity and elevated superoxide ions. Biol Reprod

	2003;68:896-903.
185.	Uriu-Adams JY, Keen CL. Copper, oxidative stress, and human health. <i>Mol Aspects Med</i> 2005;26:268-298.
186.	Pucheu S, Coudray C, Tresallet N, Favier A, de Leiris J. Effect of dietary antioxidant trace element supply on cardiac tolerance to ischemia-reperfusion in rat. <i>J Mol Cell Cardiol</i> 1995;27:2303-2314.
187.	Evans P, Halliwell B. Micronutrients: oxidant/antioxidant status. <i>Br J Nutr</i> 2001;85(Supp12):S67-S74.
188.	Johnson F, Giulivi C. Superoxide dismutases and their impact upon human health. <i>Mol Aspects Med</i> 2005;26:340-352.
189.	Graven-Nielsen T, Aspegren Kendall SA, Henriksson KG, et al. Ketamine reduces muscle pain, temporal summation and referred pain in fibromyalgia patients. <i>Pain</i> 2000;85:483-491.
190.	Oye I, Rabben T, Fagerlund TH. Analgesic effect of ketamine in a patient with neuropathic pain. <i>Tidsskr Nor Lægeforen</i> 1996;116:3130-3131.
191.	Sorensen J, Bengtsson A, Backman E, et al. Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine and ketamine. <i>Scand J Rheumatol</i> 1995;24:360-365.
192.	Bennett R. Fibromyalgia, chronic fatigue syndrome and myofascial pain. <i>Curr Opin Rheumatol</i> 1998;2:95-103.
193.	Nicolodi M, Volpe AR, Sicuderi R. Fibromyalgia and headache: Failure of serotonergic analgesia and N-methyl-D-aspartate-mediated neuronal plasticity: their common clues. <i>Cephalalgia</i> 1998; 18(Suppl 21):41-44.

194.	Graven-Nielsen T, Aspergren Kendall S, Hensiksson KG, et al. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. <i>Pain</i> 200;85:483-491.
195.	Stoll AL. Fibromyalgia symptoms relieved by flupirtine: an open label case series. <i>PsYchosomtics</i> 2000;41:371-372.
196.	Buskila D. Fibromyalgia, chronic fatigue syndrome and myofascial pain syndrome. <i>Curr Opin Rheumatol</i> 2001;13:117-127.
197.	Henriksson KG, Sorensen J. The promise of N-methyl-D-aspartate receptor antagonists in fibromyalgia. <i>Rheum Dis Clin North Am</i> 2002;28:343-351.
198.	Hocking G, Cousins MJ. Ketamine in chronic pain management: an evidence-based review. <i>Anesth Analg</i> 2003;97:1730-1739.
199.	Staud SR, Vierck CJ, Robinson ME, Price DD. Effects of the N-methyl-daspartate receptors antagonist dextromethorphan on temporal summation of pain are similar in fibromyalgia patients and normal control subjects. <i>J Pain</i> 2005;6:323-332.
200.	Goldstein JA. <i>Tuning the Brain: Principles and Practice of Neurosomatic Medicine</i> . Binghamton, NY: Haworth Medical Press;2004.
201.	Dudley DL. MCS: trial by science. In: Matthews BL ed, <i>Defining Multiple Chemical Sensitivity</i> ; Jefferson, NC: McFarland & Company;]998:9-26.
202.	Chuang DM. Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases? <i>Crit Rev Neurobiol</i> 2004; 16:83-90.

203.	Hashimoto R, Fujimaki K, Jeong MR, Christ L, Chuang DM. Lithium-induced inhibition of Src tyrosine kinase in rat cerebral cortical neurons: a role in neuroprotection against N-methyl-D-aspartate receptor-mediated excitotoxicity. <i>FEBS Lett</i> 538:145-148.
204.	McGeer EG, McGeer PL. Pharmacologic approaches to the treatment of amyotrophic lateral sclerosis. <i>BioDrugs</i> 2005;19:31-37.
205.	Bensimon G, Doble A. The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis. <i>Expert Opin Drug Saf</i> 2004;3:525-534.
206.	Snow RJ, Turnbull J, da Silva S, Jiang F, Tarnopolsky MA. Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice. <i>Neuroscience</i> 2003;119:661-667.
207.	Schiefer J, Landswehrmeyer GB, Luesse HG, et al. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease. <i>Mov Disord</i> 2002; 17:748-757.
208.	Seppi K, Mueller K, Bodner T, et al. Riluzole in Huntington's disease (HD): an open label study with one year follow up. <i>J Neurol</i> 2001;248:866-869.
209.	Fernandez-Espejo E. Pathogenesis of Parkinson's disease: prospects of neuroprotective and restorative therapies. <i>Mol Neurobiol</i> 2004;29:15-30.
210.	Shwartz G, Fehlings MG. Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. <i>Prog Brain Res</i> 2002;137:177-190.

211.	Jones MG, Cooper E, Amjad S, et al. Urinary and plasma organic acids and amino acids in chronic fatigue syndrome. Clin Chim Acta 2005;361:150-158.
212.	Ziem GE. Profile of patients with chemical injury and sensitivity, Part II Int J Toxicol 1999;18:401-409.
213.	Larson AA, Giovengo SL, Russell IJ, Michalek JE. Changes in concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways. Pain 2000;87:201-211.
214.	Cozzi R, Ricordi R, Bartolini F, et al. Taurine and ellagic acid: two differently-acting natural antioxidants. Environ Mol Mutagen 1995;26:248-254.
215.	Kim JW, Kim C. Inhibition of LPS-induced NO production by taurine chloramines in macrophages is mediated through Ras-ERK-NF-kappa B. Biochem Pharmacol 2005;70:1352-1360.
216.	Serban V, Liu Y, Quinn MR. Production of nitric oxide by activated microglial cells is inhibited by taurine chloramines. Adv Exp Med Biol 2003;526: 357-364.
217.	Elldrissi A, Trenkner E. Taurine as a modulator of excitatory and inhibitory neurotransmission. Neurochem Res 2004;29:189-197.
218.	Lee NY, Kang YS. The brain-to-blood efflux transport of taurine and changes in the blood-brain barrier transport system by tumor necrosis factor-alpha. Brain Res 2004;1023:141-147.
219.	Kuriyama K, Hashimoto T. Interrelationships between taurine and GABA. Adv Exp Med Biol 1998;442:329-337,

220.	Olive MF. Interactions between taurine and ethanol in the central nervous system. <i>Amino Acids</i> 2002;23:345-357.
221.	Song Z, Hatton GI. Taurine and the control of basal hormone release from rat neurohypophysis. <i>Exp Neurol</i> 2003;183:330-337.
222.	Mori M, Gahwiler BH, Gerber U. Beta-alanine and taurine as endogenous agonists at glycine receptors in rat hippocampus in vitro. <i>J Physiol</i> 2002;539: 191-200.
223.	Belluzzi O, Puopolo M, Benedusi M, Kratskin I. Selective neuroinhibitory effects of taurine in slices of the rat olfactory bulb. <i>Neurosci</i> 2004; 124:929-944.
224.	Hilgier W, Oja SS, Sansaari P, Albrecht J. Taurine prevents ammonia-induced accumulation of cyclic GMP in rat striatum by interaction with GABAA and glycine receptors. <i>Brain Res</i> 2005;1043:242-246.
225.	Oja SS, Sansaari P. Modulation of taurine release by glutamate receptors and nitric oxide. <i>Prog Neurobiol</i> 2000;62:407-425.
226.	Foos TM, Wu JY. The role of taurine in the central nervous system and the modulation of intracellular calcium homeostasis. <i>Neurochem Res</i> 2002;27:21-26.
228.	Bayer K, Ahmadi S, Zeilhofer HU. Gabapentin may inhibit synaptic transmission in the mouse spinal cord dorsal horn through a preferential block of P/Q-type Ca^{2+} channels. <i>Neuropharmacology</i> 2004;46:743-749.
229.	Yoon MH, Choi JI, Jeong SW. Spinal gabapentin and antinociception: mechanisms of action. <i>J Korean Med Sci</i> 2003;18:255-261.
230.	Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid

	provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Nutl Acad Sci USA 1981;78:6858-6862.
231.	Ford E, Hughes MN, Wardman P. Kinetics of the reactions of nitrogen dioxide with glutathione, cysteine, and uric acid at physiological pH. Free Radic Biol Med 2002;32:1314-1323.
232.	Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite with uric acid in the presence of ascorbate and thiols: implications for uncoupling endothelial nitric oxide synthase. Biochem Pharmacol 2005;70:343-345.
233.	Robinson KM, Morre JT, Beckman JS. Triuret: a novel product of peroxynitrite-mediated oxidation of urate. Arch Biochem BioPhy,r 2004;423:213-217.
234.	Teng RJ, Ye YZ, Parks DA, Beckman JS. Urate produced during hypoxia protects heart proteins from peroxynitrite-mediated protein nitration. Free Radic Biol Med 2002;33:1243-1249.
235.	Whiteman M, Ketsawatsakul Halliwell B. A reassessment of the peroxynitrite scavenging activity of uric acid. Ann NYAcad Sci 2002;962:242-259.
236.	Hooper DC, Scott GS, Zborek A, et al. Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis. FASEB J 2000; 14:691-698.
237.	Mattle HP, Lienert C, Greeve I. Uric acid and multiple sclerosis. Ther Urrtsch 2004;61:553-555.
238.	Rentzos M, Nikolaou C, Anagnostouli M, et al. Serum uric

	acid and multiple sclerosis. Clin Neurol Neurosurg 2005;Sep 30 [Epub ahead of print].
239.	Scott GS, Spitsin SV, Kean RB. Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc Nati Acad Sci USA 2002;99:16303-16308.
240.	Spitsin S, Hooper DC, Leist T, et al. Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease. Malt Scler 2001;7:313-319.
241.	Scott GS, Cuzzocrea S, Genovese T, Koprowski H, Hooper DC. Uric acid protects against secondary damage after spinal cord injury. Proc Natl Acad Sci USA 2005; 102:3483-3488.
242.	Hoeldtke RD, Bryner KD, McNeil DR, et al. Nitrosative stress, uric acid, and peripheral nerve function in early type I diabetes. Diabetes 2002;51:2817-2825.
243.	Schneider S, Klein HH. Inosine improves islet xenograft survival in immunocompetant diabetic mice. Ear J Med Res 2005;10:283-286.
244.	Shen H, Chen GJ, Harvey BK, Bickford PC, Wang Y. Inosine reduces ischemic brain injury in rats. Stroke 2005;36:654-659.
245.	Liu Z, Wang D, Xue Q, et al. Determination of fatty acid levels in erythrocyte membranes of patients with chronic fatigue syndrome. Nutr Neurosci 2003; 6:389-392.
246.	Horrobin DE Post-viral fatigue syndrome, viral infections in atopic eczema, and essential fatty acids. Med Hypoth 1990;32:211-217.

247.	Behan PO, Behan WM, Horrobin D. Effect of high doses of essential fatty acids on the postviral fatigue syndrome. <i>Acta Neurol Scand</i> 1990;82:209-216.
248.	Pall ML. Elevated, sustained peroxynitrite levels as the cause of chronic fatigue syndrome. <i>Medical Hypoth</i> 2000;54:115-125.
249.	Puri BK, Holmes J, Hamilton G. Eicosapentaenoic acid-rich essential fatty acid supplementation in chronic fatigue syndrome associated with symptom remission and structural brain changes. <i>Int J Clin Pract</i> 2004;58:297-299.
250.	Puri BK. The use of eicosapentaenoic acid in the treatment of chronic fatigue syndrome. <i>Prostaglandins Leukot Essent Fatty Acids</i> 2004;70:399-401.
251.	Ozgocmen S, Catal SA, Ardicoglu O, Kamanli A. Effect of omega-3 fatty acids in management of fibromyalgia. <i>Int J Clüa Phannacol Ther</i> 2000;38:362-363.
252.	Warren G, McKendrick M, Peet M. The role of essential fatty acids in chronic fatigue syndrome. A case-controlled study of red-cell membrane essential fatty acids (EFA) and a placebo-controlled study with high dose EFA. <i>Acta Neurol Scan</i> 1999;99:112-116.
253.	Komatsu W, Ishihara K, Murata M, et al. Docosahexaenoic acid suppresses nitric oxide production and inducible nitric oxide synthase expression in interferony plus lipopolysaccharide-stimulated murine macrophages by inhibiting oxidative stress. <i>Free Rad Biol Med</i> 2003;34:1006-1016.
254.	Khair-El-Din T, Sicher SC, Vazquez MA, et al. Transcription of the murine iNOS gene is inhibited by docosahexaenoic acid, a major constituent of fetal and

	neonatal sera as well as fish oil. J Exp Med 1996;183:1241-1246.
255.	Ohata T, Fukuda K, Takahashi M, et al. Suppression of nitric oxide production in lipopolysaccharide-stimulated macrophage cells by omega-3 polyunsaturated fatty acids. Jpn J Cancer Res 1997;88:234-237.
256.	Takahashi M, Tsuboyama-Kasaoko N, Nakatani T, et al. Fish oil feeding alters live gene expression to defend against PPAR-activation and ROS production. Am J Physiol Gastrointest Liver Physiol 2002;282:G338-G348. And blocks NFkappa B activation.
257.	Zhao Y, Joshi-Barve S, Barve S, Chen LH. Eicosapentaenoic acid prevents LPS-induced TNF-a expression by preventing NF-KB expression. J Am Coll Nutr 2004;23:71-78.
258.	Yoneda K, Yamamoto T, Ueta E, Osaki T. Suppression by azelastine hydrochloride of NF-kappa B activation involved in generation of cytokines and nitric oxide. Jpn J Pharmacol 1997;73:145-153.
259.	Kempuraj D, Huang M, Kandere-Grzybowska K, et al. Azelastine inhibits secretion of IL-6, TNF-alpha and IL-8 as well as NF-kappa B activation and intracellular calcium ion levels in normal human mast cells. Int Arch Allergy Immunol 2003;132:231-239.
260.	Bork PM, Schmitz ML, Kuhnt M, Escher C, Heinrich M. Sesquiterpene lactone containing Mexican Indian medicinal plants and pure sesquiterpene lactones as potent inhibitors of transcription factor NF-kappa B. FEBS Lett 1997;402:85-90.
261.	Garcia-Pineros AJ, Lindenmayer MT, Merfort L Role of cysteine residues of p65/NF-kappa B on the inhibition by

	the sesquiterpene lactone parthenolide and N-ethyl maleimide, and on its transactivating potential. Life Sci 2004;75:841-856.
262.	Guzman ML, Rossi RM, Karnischky K. et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia and progenitor cells. Blood 2005;105:4163-4169.
263.	Riggins RB, Zwart A, Nehra R, Clarke R. The nuclear factor kappa B inhibitor parthenolide restores ICI 182,780 (Faslodex;fulvestrant)-induced apoptosis in anti estrogen-resistant breast cancer cells. Mol Cancer Ther 2005;4:33-41.
264.	Sandoval-Chacon M, Thompson JH, Zhang XJ, et al. Antünflammatory action of cat's claw: the role of NF-kappa B. Aliment Pharmacol Ther 1998;12: 1279-1289.
265.	Akesson C, Lindgren H, Pero RW, et al. An extract of Uncaria tomentosa inhibiting cell division and NF-kappa B activity without inducing cell death. Int /mmunopharmacol 2003;3:1889-1890.
266.	Foster S, Tyler VE. Tyler's Honest Herbal: A Sensible Guide to the Use of Herbals and Related Remedies. Binghamton, NY: The Haworth Press; 1998.
267.	Biswas SK, McClure D, Jimenez LA, Megson IL, Rahman L Curcumin induces glutathione biosynthesis and inhibits NF-kappa B activation and interleukin-8 release in alveolar epithelial cells: mechanisms of free radical scavenging activity. Antioxid Redox Signal 2005;7:32-41.
268.	Kim JE, Kim AR, Chung HY, et al. In vitro peroxynitrite scavenging activity of diarylheptanoids from Curcuma longa. Phytother Res 2003;17:481-484.

269.	Iwunze MO, McEwan D. Peroxynitrite interaction with curcumin solubilized in ethanolic solution. <i>Cell Mol Biol</i> 2004;50:749-752.
270.	Vajragupta O, Boonchoong P, Berliner LJ. Manganese complexes of curcumin analogues: evaluation of hydroxyl radical scavenging ability, superoxide dismutase activity and stability towards hydrolysis. <i>Free Radic Res</i> 2004;38:303-314.
271.	Barik A, Mishra B, Shen L, et al. Evaluation of a new copper(II)-curcumin complex as superoxide dismutase mimic and its free radical reactions. <i>Free Radic Biol Med</i> 2005;39:811-822.
272.	Sumanont Y, Murakami Y, Tohda M, et al. Prevention of kainic acid-induced changes in nitric oxide level and neuronal cell damage in the rat hippocampus by manganese complexes of curcumin and diacetylcurcumin. <i>Life Sci</i> 2005;(Oct 30).
273.	Merchant RE, Andre CA. A review of recent clinical trials of the nutritional supplement <i>Chlorella pyrenoidosa</i> in the treatment of fibromyalgia, hypertension and ulcerative colitis. <i>Altern Ther Health Med</i> 2001;7:79-91.
274.	Merchant RE, Carmack CA, Wise CM. Nutritional supplementation with <i>Chlorella pyrenoidosa</i> for patients with fibromyalgia syndrome: a pilot study. <i>Phytother Res</i> 2000;14:167-173.
275.	Shibata S, Natori Y, Nishihara T, et al. Antioxidant and anti-cataract effects of <i>Chlorella</i> on rats with streptozotocin-induced diabetes. <i>J Nutr Sci Vitaminol</i> 2003;49:334-339.
276.	Guzman S, Gato A, Calleja JM. Antiinflammatory, analgesic and free radical scavenging activities of the marine

	microalgai, Chlorella Stigmatophora and Phaedactylum Triconutum. Phytother Res 2001;15:22i4-230.
277.	Schubert H, Kroon BM, Matthijs HC. In vivo manipulation of the xanthophylls cycle and the role of zeaxanthin in the protection against photodamage in the green alga Chlorella pyrenoidosa. J Biol Chem 1994;269:7267-7272.
278.	Pratt R, Johnson E. Vitamin C and choline content of Chlorella vulgaris and C. pyrenoidosa. J Pharm Sci 1967;56:536-537.
279.	Wu LC, Ho JA, Shieh MC, Lu IW. Antioxidant and antiproliferative activities of Spirulina and Chlorella water extracts. J Agric Food Chem 2005;53:4207-4212.
280.	Benedetti S, Benvenuti F, Pagliarani S, et al. Antioxidant properties of a novel phycocyanin extract from the blue-green alga Aphanizomenon flow-aquae. Life Sci 2004;75:2353-2362.
281.	Halfen LN, Francis GW. The influence of culture temperature on the carotenoid composition of the blue-gree alga Anacystis nidulans. Arch Mikrobiol 1972;81:25-35
282.	Bhat VB, Madyastha KM. Scavenging of peroxynitrite by phycocyanin and phycocyanobilin from Spirulina platensis: protection against oxidative damage to DNA. Biochem Biophys Res Commun 2001;285:262-266.
283.	Hanninen O, Kaartinen K, Rauma A, et al. Antioxidants in vegan diet and rheumatic disorders. Toxicology 2000; 155:45-53.
284.	Yildiz S, Kiralp MZ, Akin A, et al. A new treatment modality for fibromyalgia syndrome: hyperbaric oxygen. J Int Med Res 2004;32:263-267.

285.	Van Hoof E, Coomans D, De Becker P, et al. Hyperbaric therapy in chronic fatigue syndrome. J Chronic Fatigue S.yndr 2003;1 1:37-49.
286.	Piantadosi CA, Tatro LG. Regional H2O, concentration in rat brain after hyperoxic convulsions. JAppl Physiol 1990;69:1761-1766.
287.	Rothfuss A, Dennog C, Speit G. Adaptive protection against the induction of oxidative DNA damage after hyperbaric oxygen treatment. Carcinogenesis 1998; 19:1913-1917.
288.	Hink J, Jansen E. Are superoxide and/or hydrogen peroxide responsible for some of the beneficial effects of hyperbaric oxygen therapy? Med Hypoth 2001; 57:764-769.
289.	Weinberg JM. The anti -inflammatory effects of tetracyclines. Cutis 2005; 75(4 Suppl):6-1 1.
290.	Miyachi T, Yoshioka A, Imamura S, Niwa Y. Effect of antibiotics on the generation of reactive oxygen species. J Invest Dermatol 1986;86:449-453.
291.	Whiteman M, Kaur H, Halliwell B. Protection against peroxynitrite dependent tyrosine nitration and alpha-lantiproteinase inactivation by some anti-inflammatory drugs and by the antibiotic tetracycline. Ann Rheum Dis 1996;55:383-387.
292.	Kraus RL, Pasieczny R, Lariosa-Willingham K, et al. Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical scavenging activity. J Neurochem 2005;94:819-827.
293.	Zhu S, Stavrovskaya IG, Drozda M, et al. Minocycline inhibits cytochrome C release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002;417:74-

	78.
294.	Kriz J, Nguyen MD, Julien JP. 2002 Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis.
295.	Lee SM, Yune TY, Kim SJ, et al. Minocycline inhibits apoptotic cell death via attenuation of TNF- α expression following iNOS/NO induction by lipopolysaccharide in neuron/glia co-cultures. J Neurochem 2004;91:568-578.
296.	Pi, R, Li W, Lee NTK, et al. Minocycline prevents glutamate-induced apoptosis of cerebellar granule neurons by differential regulation of p38 and Akt pathways. JNeurochem 2004;9L1219-1230.
297.	Zhu S, Stavrovskaya IG, Drozda M, et al. Minocycline inhibits cytochrome C release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002;417:74-78.
298.	Zhang W, Narayanan M, Friedlander RM. Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol 2003;53:267-270.
299.	Chem M, Ona VO, Li M, et al. Minocycline inhibits caspase-1 and caspase3 expression and delays mortality in a transgenic mouse model of Huntington's disease. Nat Med 2000;6:797-801.
300.	Pennington JAT. Food Values of Portions Commonly Used. 15th ed. Harper Perennial, 1989.
301.	Andreassen OA, Jenkins BG, Dedeoglu A, et al. Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. J Neurochem 2001;77:383-390.

302.	Malcon C, Kaddurah-Daouk R, Beal ME Neuroprotective effects of creatine administration against NMDA and malonate toxicity. Brain Res 2000;860:195-198.
303.	Royes LF, Figuera MR, Furian AF, et al. Creatine protects against the convulsive behavior and lactate production elicited by the intrastriatal injection of methylmalonate. Neuroscience 2004; 118:1079-1090.
304.	Parnham M, Sies H. Ebselen: prospective therapy for cerebral ischaemia. Expert Opin Investig Drugs 2000;9:607-619.
305.	Fujisawa S, Kadoma Y. Kinetic studies of radical-scavenging activity of ebselen, a seleno-organic compound. Anticancer Res 2005;25:3989-3994.
306.	Nogueira CW, Quinhones EB, Jung EAC, Zeni G, Rocha JBT. Anti-inflammatory and antinociceptive activity of diphenylselenide. Inflamm Res 2003;52:56-63.
307.	Herin GA, Du S, Aizenman E. The neuroprotective agent ebselen modifies NMDA receptor function via the redox modulatory site. J Neurochem 2001;78: 1307-1314.
308.	Kalayci M, Coskun O, Cagavi F, et al. Neuroprotective effects of ebselen on experimental spinal cord injury in rats. Neurochem Res 2005;30:403-410.
309.	Fang J, Zhong L, Zhao R, Holmgren A. Ebselen: a thioredoxin reductasedependent catalyst for alpha-tocopherol quinone reduction. Toxicol Appl Pharmacol 2005;207(2 Suppl): 103-109.
310.	Zhao R, Holmgren A. Ebselen is a dehydroascorbate reductase mimic, facilitating the recycling of ascorbate via mammalian thioredoxin systems. Antioxid Redox Signal

	2004;6:99-104.
311.	Asayama S, Nagaoka S, Kawakami H. Chemical modification of manganese porphyrins with biomolecules for new functional antioxidants. J Biomater Sci Polym Ed 2003;14:1169-1179.
312.	Wu AS, Kiaei M, Aguirre N, et al. Iron porphyrin treatment extends survival in a transgenic animal model of amyotrophic lateral sclerosis. J Neurochem 2003;85:142-150.
313.	Patel MN. Metalloporphyrins improve the survival of Sod2-deficient neurons. Aging Cell 2003;2:219-222.
314.	Okado-Matsumoto A, Batinic-Haberle I, Fridovich L. Complementation of SOD-deficient Escherichia coli by manganese porphyrin mimics of superoxide dismutase. Free Radic Biol Med 2004;37:401-410.
315.	Crow JP, Calingasan NY, Chen J, Hill JL, Beat MF. Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Alan Neurol 2005; 58:258-265.
316.	Helme RD, Littlejohn GO, Weinstein C. Neurogenic flare responses in chronic rheumatic pain syndromes. Clin Exp Neurol 1987;23:91-94.
317.	Morris V, Cruwys S, Kidd B. Increased capsaicin-induced secondary hyperalgesia as a marker of abnormal sensory activity in patients with fibromyalgia. Neurosci Lett 1998;250:205-7.
318.	Staud R, Smitherman ML. Peripheral and central sensitization in fibromyalgia: pathogenetic role. Curr Pain Headache Rep 2002;6:259-266.

319.	Pall ML, Anderson JH. The vanilloid receptor as a putative target of diverse chemicals in multiple chemical sensitivity. Arch Environ Health 2004;59:363-375.
320.	McCarty DJ, Csuka M, McCarthy G, et al. Treatment of pain due to fibromyalgia with topical capsaicin: a pilot study. Semin Arthritis Rheum 1994; 23(Suppl 3):41-47.
321.	Jung S-Y, Choi S, Ko Y-S, et al. Effects of ginsenosides on vanilloid receptor (VRI) channels expressed in <i>Xenopus</i> oocytes. Mol Cells 2001;12:342-346.
322.	Hahn J, Nah SY, Nah J-J, Uhm D-Y, Chung S. Ginsenosides inhibit capsaicin-activated channel in rat sensory neurons. Neurosci Lett 2000;287:45-48.
323.	Bennett RM, De Garmo P, Clark SR. A 1 year double blind placebo controlled study of guaifenesin in fibromyalgia. Arth Rheum 1996;39:S212.
324.	Dicpinigaitis PV, Gayle YE. Effect of guaifenesin on cough reflex sensitivity. Chest 2003;124:2178-2181.
325.	Reddy VP, Garrett MR, Perry G, Smith MA. Carnosine: a versatile antioxidant and antiglycating agent. Sci Aging Knowledge Environ 2005;2005:pe12.
326.	Babishayev MA, Yermakova VN, Sakina NL, et al. N-alpha-acetylcarnosine is a prodrug of L-carnosine in ophthalmic application as an antioxidant. Clin ChimActa 1997;254:1-21.
327.	Fotana M, Pinnen F, Lucente G, Pecci L, Prevention of peroxynitrite-dependent damage by carnosine and related sulphanamido pseudodipeptides. Cell Mol Life Sci 2002;59:546-551.
328.	Cacciatore I, Cocco A, Costa M, et al. Biochemical

	properties of new synthetic carnosine analogues containing the residue of 2,3-diaminopropionic acid: the effect of N-acetylation. Amino Acids 2005;28:77-83.
329.	Chez MG, Buchanan CP, Aimonovitch MC, et al. Double-blind, placebocontrolled study of L-carnosine supplementation in children with autistic spectrum disorders. J Child Neurol 2002;17:833-837.
330.	Pizzi M, Boroni F, Moraitis C, Memo M, Spano P. Neuroprotective effect of thyrotropin-releasing hormone against excitatory amino-acid-induced cell death in hippocampal slices. Eur J Pharmacol 1999;370:133-137.
331.	Kinoshita K, Watanabe Y, Yamamura M, Matsuoka Y. TRH receptor agonists ameliorate 3-acetylpyridine-induced ataxia through NMDA receptors in rats. Eur J Pharmacol 1998;343:129-133.
332.	Nakayama T, Hashimoto T, Nagai Y. Involvement of glutamate and gammaaminobutyrate (GABA)-ergic systems in thyrotropin releasing hormone-induced cerebellar cGMP formation. Eur J Pharmacol 1996;316:157-164.
333.	Koenig ML, Yourick DL, Meyerhoff JL. Thyrotropin-releasing hormone (TRH) attenuates glutamate-stimulated increases in calcium in primary neuronal cultures. Brain Res 1996;730:143-149.
334.	http://virtualhometown.com/dfwcfids/medical/cheney.html#basic
335.	Teitelbaum JE, Bird B, Greenfield RM, Weiss A, Muenz L, Gould L. Effective treatment of chronic fatigue syndrome and fibromyalgia: a randomized, double-blind, placebo-controlled, intent to treat study. J Chronic Fatigue Syndr 2002; 8(2):3-28.

336.	Ellithorpe RR, Settinery RA, Nicolson GL. Pilot study: reduction of fatigue by use of a supplement containing dietary glycopospholipids. JAm Nutraceutical Assoc 2003;6:23-28.
337.	Agadjanyan M, Vasilevko V, Ghochikyan A, et al. Nutritional supplement (NT Factor) restores mitochondrial function and reduces moderately severe fatigue in aged subjects. J Chronic Fatigue Syndr 2003;1 l(4):1-12.
339.	http://www.cfidshealth.com/
340.	http://home.earthlink.net/~stompinangel/recovering.html#petrovic
341.	Calderon C, Huang ZH, Gage DA, Sotomayor EM, Lopez DM. Isolation of a nitric oxide inhibitor from mammary tumor cells and its characterization as phosphatidyl serine. JExp Med 1994;180:945-958.
342.	DiNapoli MR, Calderon CL, Lopez DM. Phosphatidyl serine is involved in the reduced rate of transcription of the inducible nitric oxide synthase gene in macrophages from tumor-bearing mice. Jlrnmunol 1997;158:1810-1817.
343.	http://www.chemicalinjury.net/
344.	Sackett DL. Evidence-based medicine: what it is and what it isn't. BMJ 1996;312:71-72.

HOOFDSTUK – 16

1.	Kuhn, TS. The Structure of Scientific Revolutions, 3rd ed. Chicago: University of Chicago Press; 1996.
----	---

▲ 01 / 02 / 03 / 04 / 05 / 06 / 07 / 08 / 09 / 10 / 11 / 12 / 13 / 14 / 15 / 16